Page last updated: 2024-08-02 08:25:22
g(m3) ganglioside
Description
G(M3) Ganglioside: A ganglioside present in abnormally large amounts in the brain and liver due to a deficient biosynthetic enzyme, G(M3):UDP-N-acetylgalactosaminyltransferase. Deficiency of this enzyme prevents the formation of G(M2) ganglioside from G(M3) ganglioside and is the cause of an anabolic sphingolipidosis. [MeSH]
alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:1(15Z)) : A sialotriaosylceramide consisting of beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of ceramide(d18:1/24:1(15Z)). [CHeBI]
Cross-References
Synonyms (12)
Synonym |
monosialoganglioside gm3 |
monosialodihexosylganglioside |
g(m3) ganglioside |
CHEBI:84989 |
alpha-neu5ac-(2->3)-beta-d-gal-(1->4)-beta-d-glc-(1<->1')-cer(d18:1/24:1(15z)) |
gm3-d18:1/24:1(15z) |
(2s,3r,4e)-3-hydroxy-2-[(15z)-tetracos-15-enoylamino]octadec-4-en-1-yl (6r)-5-(acetylamino)-3,5-dideoxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]-beta-lthreo--hex-2-ulopyranonosyl-(2->3)-beta-d-galactopyranosyl-(1->4)-beta-d-glucopyranoside |
alpha-neu5ac-(2->3)-beta-d-gal-(1->4)-beta-d-glc-(1<->1)-n-cis-tetracos-15-enoylsphingosine |
(2s,3r,4e)-3-hydroxy-2-[(15z)-tetracos-15-enoylamino]octadec-4-en-1-yl 5-acetamido-3,5-dideoxy-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-beta-d-galactopyranosyl-(1->4)-beta-d-glucopyranoside |
nana-gal-glc-ceramide |
CHEBI:84118 |
alpha-neu5ac-(2->3)-beta-d-gal-(1->4)-beta-d-glc-(1<->1)-n-(15z)-tetracos-15-enoylsphingosine |
Roles (1)
Role | Description |
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
Drug Classes (3)
Research
Studies (982)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 194 (19.76) | 18.7374 |
1990's | 282 (28.72) | 18.2507 |
2000's | 261 (26.58) | 29.6817 |
2010's | 199 (20.26) | 24.3611 |
2020's | 46 (4.68) | 2.80 |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 17 (1.68%) | 5.53% |
Reviews | 48 (4.75%) | 6.00% |
Case Studies | 13 (1.29%) | 4.05% |
Observational | 1 (0.10%) | 0.25% |
Other | 931 (92.18%) | 84.16% |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
alpha-hydroxyglutarate | | 2-hydroxydicarboxylic acid; dicarboxylic fatty acid | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-ketoadipic acid | | oxo dicarboxylic acid | human urinary metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-hydroxyanthranilic acid | | aminobenzoic acid; monohydroxybenzoic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-mercaptopyruvic acid | | 2-oxo monocarboxylic acid; thiol | antidote to cyanide poisoning; Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-carbamoyl-beta-alanine | | beta-alanine derivative | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-aminobutyraldehyde | | aminobutanal; omega-aminoaldehyde | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-hydroxybenzaldehyde | | hydroxybenzaldehyde | EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-hydroxyphenylacetic acid | | monocarboxylic acid; phenols | fungal metabolite; human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isocaproaldehyde | | alpha-CH2-containing aldehyde | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aminolevulinic acid | | 4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid | antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ethylene glycol | | ethanediol; glycol | metabolite; mouse metabolite; solvent; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetaldehyde | | aldehyde | carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetyl phosphate | | acyl monophosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
adenine | | 6-aminopurines; purine nucleobase | Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
agmatine | | guanidines; primary amino compound | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
allantoic acid | | ureas | mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aminoacetone | | methyl ketone; propanones | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ammonium hydroxide | | azane; gas molecular entity; mononuclear parent hydride | EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
anthranilic acid | | aminobenzoic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
betaine aldehyde | | quaternary ammonium ion | Aspergillus metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydrobromic acid | | gas molecular entity; hydrogen halide; mononuclear parent hydride | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
butyraldehyde | | butanals | biomarker; Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-butanol | | alkyl alcohol; primary alcohol; short-chain primary fatty alcohol | human metabolite; mouse metabolite; protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cadaverine | | alkane-alpha,omega-diamine | Daphnia magna metabolite; Escherichia coli metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbamyl phosphate | | acyl monophosphate; one-carbon compound | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbon monoxide | | carbon oxide; gas molecular entity; one-carbon compound | biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carnitine | | amino-acid betaine | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
choline | | cholines | allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydrochloric acid | | chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
coproporphyrinogen iii | | coproporphyrinogen | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aminoethylphosphonic acid | | phosphonic acids; primary amino compound; zwitterion | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,2-dihydroxy-1,2-dihydronaphthalene | | dihydronaphthalenes; naphthalenediols | bacterial xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-nitrophenylphosphate | | aryl phosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trimethylenediamine | | alkane-alpha,omega-diamine | human metabolite; mouse metabolite; reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n(1)-methylnicotinamide | | pyridinium ion | algal metabolite; anti-inflammatory agent; human urinary metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphonoacetaldehyde | | phosphonic acids | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gamma-guanidinobutyric acid | | guanidines; monocarboxylic acid; zwitterion | fungal metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphoglycolate | | carboxyalkyl phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydrogen selenide | | mononuclear parent hydride; selenium hydride | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-keto-delta-guanidinovaleric acid | | 2-oxo monocarboxylic acid; zwitterion | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
creatine | | glycine derivative; guanidines; zwitterion | geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytosine | | aminopyrimidine; pyrimidine nucleobase; pyrimidone | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,3-dimethylallyl pyrophosphate | | prenol phosphate | epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydrouracil | | pyrimidone | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diethyl phosphate | | dialkyl phosphate | human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
o,o-diethyl phosphorothionate | | organic thiophosphate | human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydrolipoamide | | dithiol; monocarboxylic acid amide | cofactor; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroxyacetone phosphate | | glycerone phosphates; primary alpha-hydroxy ketone | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroxyacetone | | ketotriose; primary alpha-hydroxy ketone | antifungal agent; Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dimethylglycine | | amino acid zwitterion; N-methyl-amino acid; N-methylglycines | Daphnia magna metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ethanolamine | | ethanolamines; primary alcohol; primary amine | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
formaldehyde | | aldehyde; one-carbon compound | allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glycerol | | alditol; triol | algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glyoxylic acid | | 2-oxo monocarboxylic acid; aldehydic acid | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glycocyamine | | guanidinoacetic acids; zwitterion | bacterial metabolite; human metabolite; mouse metabolite; nutraceutical; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbonic acid | | carbon oxoacid; chalcocarbonic acid | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydrogen carbonate | | carbon oxoanion | cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
histamine | | aralkylamino compound; imidazoles | human metabolite; mouse metabolite; neurotransmitter | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydantoin-5-propionic acid | | imidazolidine-2,4-dione; monocarboxylic acid | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroquinone | | benzenediol; hydroquinones | antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroxymethylbilane | | bilanes | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
indole-3-acetaldehyde | | indoleacetaldehyde | bacterial metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
indoleacetic acid | | indole-3-acetic acids; monocarboxylic acid | auxin; human metabolite; mouse metabolite; plant hormone; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lactaldehyde | | hydroxyaldehyde; propanals | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lipoamide | | dithiolanes; monocarboxylic acid amide | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyruvaldehyde | | 2-oxo aldehyde; propanals | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
methanol | | alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound | amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite | 1999 | 2009 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
melatonin | | acetamides; tryptamines | anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-acetylserotonin | | acetamides; N-acylserotonin; phenols | antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
naphthalene | | naphthalenes; ortho-fused bicyclic arene | apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
niacinamide | | pyridine alkaloid; pyridinecarboxamide; vitamin B3 | anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
niacin | | pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3 | antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroxide ion | | oxygen hydride | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
orotic acid | | pyrimidinemonocarboxylic acid | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-nitrophenol | | 4-nitrophenols | human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hexadecanal | | 2,3-saturated fatty aldehyde; long-chain fatty aldehyde | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
parathion | | C-nitro compound; organic thiophosphate; organothiophosphate insecticide | acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenanthrene | | ortho-fused polycyclic arene; ortho-fused tricyclic hydrocarbon; phenanthrenes | environmental contaminant; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenol | | phenols | antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylacetaldehyde | | alpha-CH2-containing aldehyde; phenylacetaldehydes | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenethylamine | | alkaloid; aralkylamine; phenylethylamine | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphorylcholine | | phosphocholines | allergen; epitope; hapten; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphorylethanolamine | | phosphoethanolamine; primary amino compound | algal metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
porphobilinogen | | aralkylamino compound; dicarboxylic acid; pyrroles | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
propylene glycol | | glycol; propane-1,2-diols | allergen; human xenobiotic metabolite; mouse metabolite; protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxal | | hydroxymethylpyridine; methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 | cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxal phosphate | | methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 phosphate | coenzyme; cofactor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxamine | | aminoalkylpyridine; hydroxymethylpyridine; monohydroxypyridine; vitamin B6 | Escherichia coli metabolite; human metabolite; iron chelator; mouse metabolite; nephroprotective agent; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxamine phosphate | | aminoalkylpyridine; methylpyridines; monohydroxypyridine; vitamin B6 phosphate | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxine | | hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6 | cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxine 5-phosphate | | vitamin B6 phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
quinolinic acid | | pyridinedicarboxylic acid | Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
sarcosine | | N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines | Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
succinic semialdehyde | | aldehydic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tartronate semialdehyde | | 2-hydroxy monocarboxylic acid; 3-oxo monocarboxylic acid; aldehyde | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
taurine | | amino sulfonic acid; zwitterion | antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thiamine | | primary alcohol; vitamin B1 | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thymine | | pyrimidine nucleobase; pyrimidone | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tryptamine | | aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines | human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uracil | | pyrimidine nucleobase; pyrimidone | allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uric acid | | uric acid | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
urea | | isourea; monocarboxylic acid amide; one-carbon compound | Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uroporphyrinogen iii | | uroporphyrinogen | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isopentenyl pyrophosphate | | prenol phosphate | antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
perillic acid | | alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid | antineoplastic agent; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
homovanillic acid | | guaiacols; monocarboxylic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroxyindoleacetic acid | | indole-3-acetic acids | drug metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-methoxytryptamine | | aromatic ether; primary amino compound; tryptamines | 5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-hydroxymelatonin | | acetamides; tryptamines | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
adrenic acid | | docosatetraenoic acid | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzo(a)pyrene | | ortho- and peri-fused polycyclic arene | carcinogenic agent; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
caffeine | | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chloral hydrate | | aldehyde hydrate; ethanediol; organochlorine compound | general anaesthetic; mouse metabolite; sedative; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,5-dihydroxybenzoic acid | | dihydroxybenzoic acid | EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; fungal metabolite; human metabolite; MALDI matrix material; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tele-methylhistamine | | imidazoles; primary amino compound | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
quinone | | 1,4-benzoquinones | cofactor; human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,7-dimethylxanthine | | dimethylxanthine | central nervous system stimulant; human blood serum metabolite; human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
theobromine | | dimethylxanthine | adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tyramine | | monoamine molecular messenger; primary amino compound; tyramines | EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
corticosterone | | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
estriol | | 16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid | estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sorbitol | | glucitol | cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite | 1984 | 1997 | 31.4 | low | 0 | 1 | 4 | 0 | 0 | 0 |
hydroxyproline | | 4-hydroxyproline; L-alpha-amino acid zwitterion | human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thyroxine | | 2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine | antithyroid drug; human metabolite; mouse metabolite; thyroid hormone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aldosterone | | 11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
estrone | | 17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols | antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androsterone | | 17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid | androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
etiocholanolone | | 17-oxo steroid; 3alpha-hydroxy steroid; androstanoid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dehydroepiandrosterone | | 17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid | androgen; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
triiodothyronine | | 2-halophenol; amino acid zwitterion; iodophenol; iodothyronine | human metabolite; mouse metabolite; thyroid hormone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
serine | | L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 1978 | 2006 | 29.7 | low | 0 | 2 | 2 | 2 | 0 | 0 |
aspartic acid | | aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; mouse metabolite; neurotransmitter | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glutamine | | amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lysine | | aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid | algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 1994 | 2007 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
sucrose | | glycosyl glycoside | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uridine monophosphate | | pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uridine diphosphate | | pyrimidine ribonucleoside 5'-diphosphate; uridine 5'-phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
galactose | | D-galactose; galactopyranose | Escherichia coli metabolite; mouse metabolite | 1964 | 2008 | 33.2 | low | 0 | 6 | 11 | 2 | 0 | 0 |
levodopa | | amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cysteamine | | amine; thiol | geroprotector; human metabolite; mouse metabolite; radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
leucine | | amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androstenedione | | 17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid | androgen; Daphnia magna metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine monophosphate | | cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-monophosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine diphosphate | | cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-diphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uridine triphosphate | | pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methionine | | aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid | antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
phenylalanine | | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid | algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
desoxycorticosterone | | 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine | | cytidines | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine triphosphate | | cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-triphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-naphthaldehyde | | naphthaldehyde | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-naphthaldehyde | | naphthaldehyde | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
17-alpha-hydroxyprogesterone | | 17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone | human metabolite; metabolite; mouse metabolite; progestin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ornithine | | non-proteinogenic L-alpha-amino acid; ornithine | algal metabolite; hepatoprotective agent; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
asparagine | | amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
histidine | | amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
valine | | L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
threonine | | amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan | antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
isoleucine | | aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
arginine | | arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methylamine | | methylamines; one-carbon compound; primary aliphatic amine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ethylene oxide | | gas molecular entity; oxacycle; saturated organic heteromonocyclic parent | allergen; mouse metabolite; mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
vinylidene chloride | | chloroethenes | carcinogenic agent; mouse metabolite; mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trichloroacetaldehyde | | aldehyde; organochlorine compound | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trichloroacetic acid | | monocarboxylic acid; organochlorine compound | carcinogenic agent; metabolite; mouse metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gibberellic acid | | C19-gibberellin; gibberellin monocarboxylic acid; lactone; organic heteropentacyclic compound | mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trichloroethylene | | chloroethenes | inhalation anaesthetic; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxic acid | | hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6 | human urinary metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-nitronaphthalene | | mononitronaphthalene | environmental contaminant; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
beta-glucono-1,5-lactone | | aldono-1,5-lactone; gluconolactone | animal metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-naphthoic acid | | naphthoic acid | mouse metabolite; xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphoribosyl pyrophosphate | | 5-O-phosphono-D-ribofuranosyl diphosphate | Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methylphenyl carbinol | | aromatic alcohol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trehalose | | trehalose | Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-hydroxyacetophenone | | monohydroxyacetophenone | fungal metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
styrene | | styrenes; vinylarene; volatile organic compound | mouse metabolite; mutagen; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-phenylacetamide | | monocarboxylic acid amide | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-bromophenol | | bromophenol | human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ethylene dibromide | | bromoalkane; bromohydrocarbon | algal metabolite; carcinogenic agent; fumigant; marine metabolite; mouse metabolite; mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bromobenzene | | bromoarene; bromobenzenes; volatile organic compound | hepatotoxic agent; mouse metabolite; non-polar solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-heptanone | | dialkyl ketone; methyl ketone | mouse metabolite; pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,2,2-trichloroethanol | | chloroethanol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetol | | methyl ketone; primary alcohol; primary alpha-hydroxy ketone; propanones | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-naphthol | | naphthol | antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pregnenolone | | 20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
20-alpha-dihydroprogesterone | | 20-hydroxypregn-4-en-3-one | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
D-proline | | D-alpha-amino acid zwitterion; D-alpha-amino acid; proline | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diiodotyrosine | | diiodotyrosine; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
paraoxon | | aryl dialkyl phosphate; organophosphate insecticide | EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aminoimidazole carboxamide | | aminoimidazole; monocarboxylic acid amide | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methyl-4-tyramine | | tyramines | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
citrulline | | amino acid zwitterion; citrulline | Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lithocholic acid | | bile acid; C24-steroid; monohydroxy-5beta-cholanic acid | geroprotector; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chenodeoxycholic acid | | bile acid; C24-steroid; dihydroxy-5beta-cholanic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphoadenosine phosphosulfate | | acyl sulfate; adenosine bisphosphate; purine ribonucleoside bisphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
adenosine phosphosulfate | | acyl monophosphate; acyl sulfate; adenosine 5'-phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fructose-1,6-diphosphate | | D-fructofuranose 1,6-bisphosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androstenediol | | 17beta-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid | androgen; human metabolite; mouse metabolite; radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydrotestosterone | | 17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid | androgen; Daphnia magna metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyridoxamine dihydrochloride | | hydrochloride; vitamin B6 | Escherichia coli metabolite; human metabolite; iron chelator; mouse metabolite; nephroprotective agent; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroxyhydroquinone | | benzenetriol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
18-hydroxycorticosterone | | 11beta-hydroxy steroid; 18-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo steroid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,2-dihydroxynaphthalene | | naphthalenediol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
galactitol | | hexitol | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-hydroxyphenylacetic acid | | hydroxy monocarboxylic acid; phenols | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
propiolaldehyde | | terminal acetylenic compound; ynal | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dehydroepiandrosterone sulfate | | 17-oxo steroid; steroid sulfate | EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylphosphate | | aryl phosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-cyclohexylformamide | | alicyclic compound; formamides | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxycytidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyuridine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxyadenosine | | purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine diphosphate choline | | nucleotide-(amino alcohol)s; phosphocholines | human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite | 1981 | 2002 | 32.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
deoxycytidine monophosphate | | 2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nicotinamide mononucleotide | | nicotinamide mononucleotide | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroferulic acid | | guaiacols; monocarboxylic acid; phenylpropanoid | antioxidant; human xenobiotic metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxyadenosine triphosphate | | 2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
perillaldehyde | | aldehyde; olefinic compound | human metabolite; mouse metabolite; volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fucose | | fucopyranose; L-fucose | Escherichia coli metabolite; mouse metabolite | 1977 | 2017 | 32.2 | low | 0 | 2 | 1 | 0 | 1 | 0 |
uridine diphosphate glucuronic acid | | UDP-D-glucuronic acid | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
uridine diphosphate galactose | | UDP-D-galactose | mouse metabolite | 1979 | 1996 | 36.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
1-naphthalenemethanol | | naphthylmethanol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diadenosine tetraphosphate | | diadenosyl tetraphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
d-glutamate | | D-alpha-amino acid; glutamic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroiodic acid | | gas molecular entity; hydrogen halide; mononuclear parent hydride | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
iron | | divalent metal cation; iron cation; monoatomic dication | cofactor; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trichloroepoxyethane | | epoxide | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ursodeoxycholic acid | | bile acid; C24-steroid; dihydroxy-5beta-cholanic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glutamic acid | | glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical | 2006 | 2007 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
adenosine diphosphate ribose | | ADP-sugar | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetylgalactosamine | | N-acetyl-D-hexosamine; N-acetylgalactosamine | Escherichia coli metabolite; human metabolite; mouse metabolite | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
phosphopantothenic acid | | amidoalkyl phosphate | Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyromazine | | triamino-1,3,5-triazine | mouse metabolite; triazine insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glucose, (beta-d)-isomer | | D-glucopyranose | epitope; mouse metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
xanthosine | | purines D-ribonucleoside; xanthosines | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thymidine 5'-triphosphate | | pyrimidine 2'-deoxyribonucleoside 5'-triphosphate; thymidine phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxyuridylic acid | | deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-acetylaspartic acid | | N-acetyl-L-amino acid; N-acyl-L-aspartic acid | antioxidant; human metabolite; mouse metabolite; nutraceutical; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyuridine triphosphate | | deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-triphosphate | Arabidopsis thaliana metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
homocitrulline | | amino acid zwitterion; L-lysine derivative; non-proteinogenic L-alpha-amino acid; ureas | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxycytidine 5'-triphosphate | | 2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-triphosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aica ribonucleotide | | 1-(phosphoribosyl)imidazolecarboxamide; aminoimidazole | cardiovascular drug; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
obtusifoliol | | 14alpha-methyl steroid; 3beta-sterol | mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glutathione disulfide | | glutathione derivative; organic disulfide | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lathosterol | | 3beta-sterol; C27-steroid; cholestanoid; Delta(7)-sterol | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-methoxyestradiol | | 17beta-hydroxy steroid; 3-hydroxy steroid | angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3'-cmp | | cytidine 3'-phosphate; pyrimidine ribonucleoside 3'-monophosphate | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cystine | | cystine zwitterion; cystine; L-cysteine derivative; non-proteinogenic L-alpha-amino acid | EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitor; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylacetylglycine | | monocarboxylic acid amide; monocarboxylic acid; N-acylglycine | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hordenine | | phenethylamine alkaloid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
7-methylxanthine | | oxopurine; purine alkaloid | human xenobiotic metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glutaurine | | dipeptide zwitterion; dipeptide; L-glutamine derivative; sulfonic acid | anticonvulsant; anxiolytic drug; hormone; human metabolite; mammalian metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
plasmenylserine | | O-phosphoserine | EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor; EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cifostodine | | 2',3'-cyclic pyrimidine nucleotide | Escherichia coli metabolite; mouse metabolite; Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n'-methyl-2-pyridone-5-carboxamide | | methylpyridines; pyridinecarboxamide; pyridone | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-methyluric acid | | oxopurine | human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclopropylamine | | primary aliphatic amine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxymethylcytosine | | aminopyrimidine; aromatic primary alcohol; nucleobase analogue; pyrimidone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,5-dihydroxybenzaldehyde | | dihydroxybenzaldehyde | human metabolite; mouse metabolite; Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-hydroxynicotinic acid | | monohydroxypyridine | Arabidopsis thaliana metabolite; human urinary metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
xanthosine 5'-triphosphate | | purine ribonucleoside 5'-monophosphate; xanthosine 5'-phosphate | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-naphthalenemethanol | | naphthylmethanol | mouse metabolite; xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydroxyindoleacetaldehyde | | hydroxyindoles; indoleacetaldehyde | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
xanthurenic acid 8-methyl ether | | aromatic ether; monohydroxyquinoline; quinolinemonocarboxylic acid | carcinogenic agent; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glucose | | D-glucopyranose | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,3,7-trimethylurate | | oxopurine | human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-methylxanthine | | 1-methylxanthine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,7-dimethyluric acid | | oxopurine | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
biocytin | | azabicycloalkane; L-alpha-amino acid zwitterion; L-lysine derivative; monocarboxylic acid amide; non-proteinogenic L-alpha-amino acid; thiabicycloalkane; ureas | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
d-aspartic acid | | aspartic acid; D-alpha-amino acid | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,4-dihydroxymandelic acid | | 2-hydroxy monocarboxylic acid; catechols | antioxidant; drug metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
coenzyme a | | adenosine 3',5'-bisphosphate | coenzyme; Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
17-alpha-hydroxypregnenolone | | 17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; hydroxypregnenolone; tertiary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mephentermine | | 2-aminooctadecane-1,3-diol | EC 2.7.11.13 (protein kinase C) inhibitor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,4-dihydroxyphenylglycol | | catechols; tetrol | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
homocysteine | | amino acid zwitterion; homocysteine; serine family amino acid | fundamental metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,7-dimethyluric acid | | oxopurine | human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
24-methylenecholesterol | | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
succinyl-coenzyme a | | omega-carboxyacyl-CoA | Escherichia coli metabolite; inhibitor; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetoacetyl coa | | 3-oxo-fatty acyl-CoA | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,8-dihydroxyadenine | | 6-aminopurines; diol; heteroaryl hydroxy compound; oxopurine | human urinary metabolite; mammalian metabolite; mouse metabolite; nephrotoxic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5beta-pregnane-3,20-dione | | 20-oxo steroid; 3-oxo-5beta-steroid; C21-steroid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
zymosterol | | 3beta-sterol; cholestanoid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
propionyl-coenzyme a | | acyl-CoA | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
21-deoxycortisol | | 11beta-hydroxy steroid; 17alpha-hydroxy-C21-steroid; deoxycortisol; tertiary alpha-hydroxy ketone | human blood serum metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5,6-dihydrothymine | | pyrimidone | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
stearoyl-coenzyme a | | 11,12-saturated fatty acyl-CoA; long-chain fatty acyl-CoA | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
imidazoleacetic acid | | imidazoles; monocarboxylic acid | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-hydroxyphenanthrene | | phenanthrol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,5-dihydroxypyridine | | dihydroxypyridine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cerium | | cholesteryl ester | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
zymostenol | | 3beta-sterol; cholestanoid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
16-hydroxydehydroepiandrosterone | | 16alpha-hydroxy steroid; 17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid; secondary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6,6-dimethyl-2-methylenebicyclo(3.1.1)heptan-3-ol | | carbobicyclic compound; pinane monoterpenoid; secondary alcohol | GABA modulator; mouse metabolite; plant metabolite; volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydrogen sulfite | | sulfur oxoanion | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ecgonine methyl ester | | methyl ester; tertiary amino compound; tropane alkaloid | analgesic; central nervous system depressant; metabolite; mouse metabolite; opioid analgesic; peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine | | hydroxylamine; imidazopyridine | carcinogenic agent; genotoxin; human xenobiotic metabolite; mouse metabolite; mutagen; neurotoxin; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fructose 2,6-diphosphate | | D-fructofuranose 2,6-bisphosphate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cholest-5-en-3 beta,7 alpha-diol | | 3beta-hydroxy-Delta(5)-steroid; 7alpha-hydroxy steroid; oxysterol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hypotaurine | | aminosulfinic acid; zwitterion | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
s-chloromethylglutathione | | organochlorine compound; S-substituted glutathione | alkylating agent; bacterial xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-acetylamino-6-formylamino-3-methyluracil | | formamidopyrimidine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
anserine | | beta-alanine derivative; dipeptide; zwitterion | animal metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5,6-dihydroxyindole | | dihydroxyindole | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androsterone glucuronide | | beta-D-glucosiduronic acid; steroid glucosiduronic acid | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
estrone-3-glucuronide | | 17-oxo steroid; beta-D-glucosiduronic acid; steroid glucosiduronic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,4-dihydroxyphenylacetaldehyde | | alpha-CH2-containing aldehyde; catechols; phenylacetaldehydes | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5,6-dihydroxy-2-indolylcarboxylic acid | | dihydroxyindole | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
protoporphyrinogen | | porphyrinogens | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inositol-3,4,5,6-tetrakisphosphate | | myo-inositol tetrakisphosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
(20s)-20-hydroxycholesterol | | 20-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; oxysterol | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
24-hydroxycholesterol | | 24-hydroxycholesterol | biomarker; human blood serum metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phytosphingosine | | amino alcohol; sphingoid; triol | mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
butyryl-coenzyme a | | butanoyl-CoAs | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-acetylputrescine | | N-monoacetylalkane-alpha,omega-diamine; N-substituted putrescine | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
erythrose 4-phosphate | | erythrose phosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cdp ethanolamine | | nucleotide-(amino alcohol)s; phosphoethanolamine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
7 alpha-hydroxy-4-cholesten-3-one | | 3-oxo-Delta(4) steroid; 7alpha-hydroxy steroid; cholestanoid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
galactose-1-phosphate | | alpha-D-hexose 1-phosphate; D-galactopyranose 1-phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gamma-glutamylcysteine | | gamma-glutamylcysteine | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
27-hydroxycholesterol | | 26-hydroxycholesterol | apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dehydroalanine | | 2,3-dehydroamino acid; alpha,beta-unsaturated monocarboxylic acid; amino acid zwitterion; enamine; non-proteinogenic alpha-amino acid | alkylating agent; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine | | 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 30:0; tetradecanoate ester | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
proline | | amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid | algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
d-glutamine | | amino acid zwitterion; D-alpha-amino acid; glutamine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diquafosol | | pyrimidine ribonucleoside 5'-tetraphosphate; uridine 5'-phosphate | mouse metabolite; P2Y2 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxycytidine diphosphate | | 2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-diphosphate | Escherichia coli metabolite; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
19-hydroxytestosterone | | 17beta-hydroxy steroid; 19-hydroxy steroid; 3-oxo-Delta(4) steroid | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-hydroxy-1,4-benzoquinone | | monohydroxy-1,4-benzoquinones | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,4-dihydroxyphenylglycolaldehyde | | catechols; hydroxyaldehyde | human metabolite; mouse metabolite; neurotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sorbitol 6-phosphate | | alditol 6-phosphate; glucitol phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
adenosine 3'-phosphate-5'-phosphate | | adenosine bisphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androsterone sulfate | | 17-oxo steroid; androstanoid; steroid sulfate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-ribazole | | 1-ribosylbenzimidazole; dimethylbenzimidazole | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,7,12-trihydroxycoprostane | | 12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
saccharopine | | amino acid opine; L-lysine derivative | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
allysine | | allysine; amino acid zwitterion; aminoadipate semialdehyde; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
orotidylic acid | | pyrimidine ribonucleoside 5'-monophosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
beta-ureidoisobutyric acid | | ureidocarboxylic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
saicar | | 1-(phosphoribosyl)imidazolecarboxamide | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
kynurenine | | amino acid zwitterion; kynurenine; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thymidine 5'-diphosphate | | pyrimidine 2'-deoxyribonucleoside 5'-diphosphate; thymidine phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydromethylthionine | | aromatic amine; phenothiazines; tertiary amino compound | bacterial xenobiotic metabolite; fluorochrome; mouse metabolite; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxykynuramine | | hydroxykynurenamine; primary amino compound | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sedoheptulose 1,7-bisphosphate | | ketoheptose phosphate; sedoheptulose derivative | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sedoheptulose 7-phosphate | | ketoheptose phosphate; sedoheptulose derivative | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thiocysteine | | amino acid zwitterion; S-substituted L-cysteine | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diadenosine triphosphate | | diadenosyl triphosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carboxyaminoimidazole ribotide | | 1-(phosphoribosyl)imidazole; aminoimidazole; imidazole-4-carboxylic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isovaleryl-coenzyme a | | methylbutanoyl-CoA; short-chain fatty acyl-CoA | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lauroyl-coenzyme a | | medium-chain fatty acyl-CoA | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nicotinic acid adenine dinucleotide | | nicotinic acid dinucleotide | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4,4-dimethyl-5-alpha-cholesta-(8,24)-dien-3-beta-ol | | 3beta-sterol | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylacetyl-coenzyme a | | acyl-CoA | Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-formamidoimidazole-4-carboxamide ribotide | | 1-(phosphoribosyl)imidazolecarboxamide | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
biotin | | biotins; vitamin B7 | coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite | 1989 | 2010 | 27.8 | low | 0 | 1 | 2 | 1 | 0 | 0 |
campesterol | | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C28-steroid; phytosterols | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxyadenosine triphosphate | | 2'-deoxyadenosine 5'-phosphate; purine 2'-deoxyribonucleoside 5'-diphosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cholestane-3,7,12,26-tetrol | | 12alpha-hydroxy steroid; 26-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gamma-glutamyl phosphate | | gamma-glutamyl phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione | | aminouracil; hydroxypyrimidine | Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cholic acid | | 12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid | human metabolite; mouse metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
sitosterol, (3beta)-isomer | | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol | anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cortisone | | 11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androstane-3,17-dione, (5alpha)-isomer | | 3-oxo-5alpha-steroid; androstane-3,17-dione | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cholesteryl palmitate | | cholesteryl ester | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lanosterol | | 14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid | bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
21-hydroxypregnenolone | | 21-hydroxy steroid; hydroxypregnenolone; primary alpha-hydroxy ketone | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-hydroxyestradiol | | 17beta-hydroxy steroid; 2-hydroxy steroid | carcinogenic agent; human metabolite; metabolite; mouse metabolite; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
epietiocholanolone | | 17-oxo steroid; 3beta-hydroxy steroid; androstanoid | androgen; animal metabolite; human blood serum metabolite; mouse metabolite; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxyisourate | | oxopurine | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
19-hydroxy-4-androstene-3,17-dione | | 17-oxo steroid; 19-hydroxy steroid; 3-oxo steroid; androstanoid | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
taurochenodeoxycholic acid | | bile acid taurine conjugate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glyceraldehyde 3-phosphate | | glyceraldehyde 3-phosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5'-methylthioadenosine | | thioadenosine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5'-deoxyadenosine | | 5'-deoxyribonucleoside; adenosines | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ribulose 5-phosphate | | ribulose 5-phosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
xylulose-5-phosphate, (d)-isomer | | xylulose 5-phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glycerate 1,3-biphosphate | | 2,3-bisphosphoglyceric acid; acyl monophosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isomaltose | | glycosylglucose | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
arabinose | | L-arabinose | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-acetylneuraminic acid | | N-acetylneuraminic acids | antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite | 1984 | 2023 | 22.5 | low | 1 | 8 | 24 | 17 | 8 | 3 |
glucosamine | | D-glucosamine | Escherichia coli metabolite; geroprotector; mouse metabolite | 1977 | 2000 | 35.6 | low | 0 | 2 | 3 | 0 | 0 | 0 |
carnosine | | amino acid zwitterion; dipeptide | anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
raffinose | | raffinose family oligosaccharide; trisaccharide | mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxytryptophan | | 5-hydroxytryptophan; amino acid zwitterion; hydroxy-L-tryptophan; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
xanthosine 5'-triphosphate | | purine ribonucleoside 5'-triphosphate; xanthosine 5'-phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dopaquinone | | 1,2-benzoquinones; amino acid zwitterion; L-phenylalanine derivative | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pantetheine | | pantetheines; thiol | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
galactose | | D-galactopyranose | epitope; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
galactose | | D-galactopyranose | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
s-adenosyl-3-methylthiopropylamine | | adenosines; sulfonium compound | Escherichia coli metabolite; human urinary metabolite; mouse metabolite; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-diphosphomevalonic acid | | carboxyalkyl phosphate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
7-dehydrocholesterol | | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; cholestanoid; Delta(5),Delta(7)-sterol | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-phosphonoglucono-delta-lactone | | aldonolactone phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inositol 1,4,5-trisphosphate | | myo-inositol trisphosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
stachyose | | raffinose family oligosaccharide; tetrasaccharide | mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
desmosterol | | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C27-steroid; cholestanoid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
monoiodotyrosine | | amino acid zwitterion; L-tyrosine derivative; monoiodotyrosine; non-proteinogenic L-alpha-amino acid | EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n'-formylkynurenine | | amino acid zwitterion; N-formylkynurenine; non-proteinogenic amino acid derivative; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ketodihydrosphingosine | | 2-amino-1-hydroxyoctadecan-3-one | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nicotinamide-beta-riboside | | N-glycosylnicotinamide; pyridine nucleoside | geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-hydroxyphenylacetaldehyde | | alpha-CH2-containing aldehyde; phenylacetaldehydes | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
androstane-3,17-dione, (5beta)-isomer | | 3-oxo-5beta-steroid; androstane-3,17-dione | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trimethyllysine | | alpha-amino-acid cation | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inositol 3,4-bisphosphate | | myo-inositol bisphosphate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-acetylglucosamine-1-phosphate | | N-acetyl-D-glucosamine 1-phosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pantothenylcysteine 4'-phosphate | | L-cysteine derivative | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
24,25-dihydrolanosterol | | 3beta-sterol; tetracyclic triterpenoid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-methoxyestrone | | 17-oxo steroid; 3-hydroxy steroid; alicyclic ketone; aromatic ether; phenolic steroid; phenols | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dehydroascorbic acid | | dehydroascorbic acid; vitamin C | coenzyme; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cortodoxone | | deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
estradiol-3-glucuronide | | 17beta-hydroxy steroid; beta-D-glucosiduronic acid; steroid glucosiduronic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
beta-sulfopyruvic acid | | carboxyalkanesulfonic acid | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetyl adenylate | | 5'-acylphosphoadenosin | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-hydroxypropylphosphonic acid | | phosphonic acids; secondary alcohol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4,4-dimethylcholesta-8,14,24-trienol | | 3beta-sterol; Delta(14) steroid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inositol-1,4,5,6-tetrakisphosphate | | myo-inositol tetrakisphosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
maleic acid | | butenedioic acid | algal metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dephosphocoenzyme a | | adenosine 5'-phosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
arachidonic acid | | icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid | Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite | 1988 | 1994 | 32.7 | low | 0 | 1 | 2 | 0 | 0 | 0 |
n(1)-(5-phosphoribosyl)-5,6-dimethylbenzimidazole | | 1-ribosylbenzimidazole; dimethylbenzimidazole; ribose monophosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
prostaglandin h2 | | olefinic compound; oxylipin; prostaglandins H; secondary alcohol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-hydroxy-3-methylglutaryl-coenzyme a | | 3-hydroxy-3-methylglutaryl-CoA; 3-hydroxy fatty acyl-CoA | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
retinol | | retinol; vitamin A | human metabolite; mouse metabolite; plant metabolite | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
docosahexaenoate | | docosahexaenoic acid; omega-3 fatty acid | algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
oleic acid | | octadec-9-enoic acid | antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
farnesyl pyrophosphate | | farnesyl diphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
geranyl pyrophosphate | | polyprenyl diphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,5-dihydro-fad | | flavin adenine dinucleotide | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cocaine | | benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid | adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
eicosapentaenoic acid | | icosapentaenoic acid; omega-3 fatty acid | anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
s-hydroxymethylglutathione | | S-substituted glutathione | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
geranylgeranyl pyrophosphate | | geranylgeranyl diphosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine monophosphate n-acetylneuraminic acid | | CMP-N-acyl-beta-neuraminic acid | mouse metabolite | 1977 | 1989 | 41.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
prostaglandin d2 | | prostaglandins D | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hexanoyl-coenzyme a | | medium-chain fatty acyl-CoA | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-phosphoerythronate | | 4-phosphoerythronic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
colfosceril palmitate | | 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 32:0 | mouse metabolite; surfactant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lyso-pc | | 1-O-acyl-sn-glycero-3-phosphocholine; lysophosphatidylcholine 16:0 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
riboflavin | | flavin; vitamin B2 | anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trans-4-coumaric acid | | 4-coumaric acid | food component; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
retinaldehyde | | retinal; vitamin A | gap junctional intercellular communication inhibitor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
squalene | | triterpene | human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
flavin-adenine dinucleotide | | flavin adenine dinucleotide; vitamin B2 | cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
flavin mononucleotide | | flavin mononucleotide; vitamin B2 | bacterial metabolite; coenzyme; cofactor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-hydroxybutyryl-coenzyme a | | 3-hydroxyacyl-CoA; hydroxybutanoyl-CoA | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
malonyl coenzyme a | | malonyl-CoAs | EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor; Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
palmitoyl coenzyme a | | 11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydrosphingosine 1-phosphate | | sphingoid 1-phosphate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glycerylphosphorylcholine | | phosphocholines; sn-glycerol 3-phosphates | Escherichia coli metabolite; human metabolite; mouse metabolite; neuroprotective agent; parasympatholytic; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
caffeic acid | | caffeic acid | geroprotector; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
coniferyl alcohol | | guaiacols; phenylpropanoid | animal metabolite; monolignol; mouse metabolite; pheromone; plant metabolite; volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cysteine sulfinic acid | | organosulfinic acid; S-substituted L-cysteine | Escherichia coli metabolite; human metabolite; metabotropic glutamate receptor agonist; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
estrone sulfate | | 17-oxo steroid; steroid sulfate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
raphanusamic acid | | thiazolidinemonocarboxylic acid | Arabidopsis thaliana metabolite; mouse metabolite; xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isobutyryl-coenzyme a | | methyl-branched fatty acyl-CoA; short-chain fatty acyl-CoA | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroxycoprostane | | 3alpha-hydroxy steroid; 7alpha-hydroxy steroid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glutaryl-coenzyme a | | glutaryl-CoAs | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sphingosine | | sphing-4-enine | human metabolite; mouse metabolite | 1977 | 2021 | 25.5 | low | 0 | 3 | 7 | 3 | 1 | 1 |
bilirubin | | biladienes; dicarboxylic acid | antioxidant; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dinoprostone | | prostaglandins E | human metabolite; mouse metabolite; oxytocic | 1993 | 2003 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
dinoprost | | monocarboxylic acid; prostaglandins Falpha | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
leukotriene a4 | | epoxy fatty acid; leukotriene; long-chain fatty acid; oxylipin; polyunsaturated fatty acid | human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
calcitriol | | D3 vitamins; hydroxycalciol; triol | antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical | 1986 | 1989 | 36.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
beta carotene | | carotenoid beta-end derivative; cyclic carotene | antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
11-cis-retinal | | retinal | chromophore; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
leukotriene b4 | | dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid | human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
leukotriene c4 | | leukotriene | bronchoconstrictor agent; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thromboxane a2 | | epoxy monocarboxylic acid; thromboxanes A | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
15-hydroxy-5,8,11,13-eicosatetraenoic acid | | (5Z,8Z,11Z,13E)-15-HETE | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxy-6,8,11,14-eicosatetraenoic acid | | HETE | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
arachidonic acid 5-hydroperoxide | | 5-HPETE | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
leukotriene d4 | | dipeptide; leukotriene; organic sulfide | bronchoconstrictor agent; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
prostaglandin g2 | | prostaglandins G | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-ketoprostaglandin f1 alpha | | prostaglandins Falpha | human metabolite; mouse metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
arachidonic acid omega-9 hydroperoxide | | HPETE | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, (s)-(e,z,z,z)-isomer | | 15-HPETE | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gamma-linolenic acid | | linolenic acid; omega-6 fatty acid | human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-linolenic acid | | linolenic acid; omega-3 fatty acid | micronutrient; mouse metabolite; nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-palmitoyl-2-oleoyl-sn-glycerol | | 1,2-diacyl-sn-glycerol; 1-palmitoyl-2-oleoylglycerol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
epoprostenol | | prostaglandins I | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
9-hydroxy-10,12-octadecadienoic acid | | HODE; octadecadienoic acid | human metabolite; metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thromboxane b2 | | thromboxanes B | human metabolite; mouse metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
thromboxane b3 | | thromboxanes B | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
11,12-dihydroxyeicosatrienoic acid | | DHET | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
14,15-dihydroxyeicosatrienoic acid | | DHET; diol; secondary allylic alcohol | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
20-hydroxy-5,8,11,14-eicosatetraenoic acid | | HETE; hydroxy monocarboxylic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-oxo-6,8,11,14-eicosatetraenoic acid | | oxoicosatetraenoic acid | human metabolite; immunomodulator; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5,6-epoxy-8,11,14-eicosatrienoic acid | | EET | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
8,9-epoxyeicosatrienoic acid | | EET | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-palmitoyl-2-oleoylphosphatidylethanolamine, (z & r)-isomer | | 1,2-diacyl-sn-glycero-3-phosphoethanolamine; phosphatidylethanolamine 34:1 zwitterion; phosphatidylethanolamine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sphingosine 1-phosphate | | sphingoid 1-phosphate | mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cholesteryl oleate | | CE(18:1); cholesteryl octadec-9-enoate | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
calcifediol | | D3 vitamins; diol; hydroxycalciol | bone density conservation agent; human metabolite; metabolite; mouse metabolite; nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hyodeoxycholic acid | | 5beta-cholanic acids; 6alpha,20xi-murideoxycholic acid; bile acid; C24-steroid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cerium | | CE(18:2); cholesteryl octadeca-9,12-dienoate | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
xylulose | | xylulose | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
11-dehydrocorticosterone | | 11-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
stearidonic acid | | long-chain fatty acid; octadecatetraenoic acid; omega-3 fatty acid | Daphnia galeata metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trilinolein | | 1,2-diacyl-3-linoleoylglycerol; 1,3-diacyl-2-linoleoylglycerol; linoleoyl containing 1,2,3-triacyl-sn-glycerol; TG(18:2/18:2/18:2); triglyceride | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dimyristoylphosphatidylcholine | | 1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester | antigen; mouse metabolite | 1993 | 2011 | 25.2 | low | 0 | 0 | 3 | 0 | 1 | 0 |
2,3-oxidosqualene | | 2,3-epoxysqualene | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyribose | | deoxypentose | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
monodehydroascorbate | | organic radical | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
oleoyl-coenzyme a | | octadecenoyl-CoA | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
vitamin a2 | | retinoid; vitamin A | human xenobiotic metabolite; marine xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,2-dioleoylphosphatidylserine | | phosphatidylserine(18:1/18:1) | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxy-6,8,11,14,17-eicosapentaenoic acid | | HEPE | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-stearoyl-2-linoleoylphosphatidylcholine | | phosphatidylcholine 36:2 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-stearoyl-2-linoleoyl-sn-glycerol | | 1,2-diacyl-sn-glycerol; diacylglycerol 36:2 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine | | phosphatidylcholine 38:6 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
13(S)-HODE | | HODE | antineoplastic agent; human xenobiotic metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-stearoyl-2-oleoyl-sn-glycerol | | 1,2-diacyl-sn-glycerol; 1-stearoyl-2-oleoylglycerol; diacylglycerol 36:1 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine | | 1-acyl-2-palmitoleoyl-sn-glycero-3-phosphocholine; phosphatidylcholine 32:1 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
13-oxo-9,11-octadecadienoic acid | | 13-oxo-9,11-octadecadienoic acid | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-stearoylsphingomyelin | | sphingomyelin 36:1; sphingomyelin d18:1 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
20,22-dihydroxycholesterol | | 20-hydroxy steroid; 22-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; cholestanoid; oxysterol | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cholesteryl arachidonate | | cholesteryl icosatetraenoate | antibacterial agent; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acryloyl-coenzyme a | | 2-enoyl-CoA; monounsaturated fatty acyl-CoA | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphocreatine | | phosphagen; phosphoamino acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
samarium | | sphingomyelin d18:1/16:0 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-palmitoylgalactosylsphingosine | | HexCer(d18:1/16:0); N-acyl-beta-D-galactosylsphingosine | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cytidine diphosphate choline | | nucleotide-(amino alcohol)s; phosphocholines | human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
palmitoylcarnitine | | O-palmitoylcarnitine; saturated fatty acyl-L-carnitine | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
s-tetradecanoyl-coenzyme a | | 11,12-saturated fatty acyl-CoA; long-chain fatty acyl-CoA | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
prosomatostatin | | heterodetic cyclic peptide; peptide hormone | fungal metabolite; mouse metabolite; rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphatidylcholines | | phosphatidylcholine 40:6 | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-ketoarginine | | 2-oxo monocarboxylic acid; zwitterion | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclosporine | | keto-disaccharide | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclic gmp | | 3',5'-cyclic purine nucleotide; guanyl ribonucleotide | Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diguanosine tetraphosphate | | guanosine 5'-phosphate; purine ribonucleoside 5'-tetraphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyguanosine | | purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyinosine | | purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxyguanosine 5'-phosphate | | deoxyguanosine phosphate; guanyl deoxyribonucleotide; purine 2'-deoxyribonucleoside 5'-monophosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyguanosine triphosphate | | deoxyguanosine phosphate; guanyl deoxyribonucleotide; purine 2'-deoxyribonucleoside 5'-triphosphate | Arabidopsis thaliana metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
7,8-dihydroneopterin | | dihydropterin; neopterins | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydrofolate | | dihydrofolic acids | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroneopterin triphosphate | | dihydropterin; neopterins; pterin phosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deoxyinosine monophosphate | | deoxyinosine phosphate; purine 2'-deoxyribonucleoside 5'-monophosphate | Escherichia coli metabolite; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-deoxyinosine triphosphate | | deoxyinosine phosphate; purine 2'-deoxyribonucleoside 5'-triphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
guanosine diphosphate | | guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate | Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
gdp-4-keto-6-deoxymannose | | GDP-sugar | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
guanosine diphosphate mannose | | GDP-D-mannose | Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
guanosine pentaphosphate | | guanosine 5'-phosphate; guanosine bisphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
guanosine monophosphate | | guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate | biomarker; Escherichia coli metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
guanosine triphosphate | | guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor | 1990 | 1998 | 30.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
guanine | | 2-aminopurines; oxopurine; purine nucleobase | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
guanosine tetraphosphate | | guanosine bisphosphate | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inosinic acid | | inosine phosphate; purine ribonucleoside 5'-monophosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inosine | | inosines; purines D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
inosine triphosphate | | inosine phosphate; purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite; human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
folic acid | | folic acids; N-acyl-amino acid | human metabolite; mouse metabolite; nutrient | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dyspropterin | | biopterins; tetrahydropterin | human metabolite; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
leucovorin | | formyltetrahydrofolic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5,10-methenyltetrahydrofolate | | methylenetetrahydrofolic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
10-formyltetrahydrofolate | | formyltetrahydrofolic acid | Escherichia coli metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
phosphoserine | | non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative | human metabolite | 1994 | 2015 | 19.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
acetic acid | | monocarboxylic acid | antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent | 1989 | 2013 | 23.0 | low | 0 | 1 | 0 | 0 | 1 | 0 |
formic acid | | monocarboxylic acid | antibacterial agent; astringent; metabolite; protic solvent; solvent | 1993 | 1996 | 29.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
methane | | alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound | bacterial metabolite; fossil fuel; greenhouse gas | 1994 | 2018 | 18.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
chlorine | | halide anion; monoatomic chlorine | cofactor; Escherichia coli metabolite; human metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
glycerol | | alditol; triol | algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
kynurenine | | aromatic ketone; non-proteinogenic alpha-amino acid; substituted aniline | human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
pyruvaldehyde | | 2-oxo aldehyde; propanals | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
methanol | | alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound | amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite | 1999 | 2009 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
nickel | | metal allergen; nickel group element atom | epitope; micronutrient | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
palmitic acid | | long-chain fatty acid; straight-chain saturated fatty acid | algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite | 1992 | 2006 | 26.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
picolinic acid | | pyridinemonocarboxylic acid | human metabolite; MALDI matrix material | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
pyruvic acid | | 2-oxo monocarboxylic acid | cofactor; fundamental metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
quinolinic acid | | pyridinedicarboxylic acid | Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
1-anilino-8-naphthalenesulfonate | | aminonaphthalene; naphthalenesulfonic acid | fluorescent probe | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
3-methylcholanthrene | | ortho- and peri-fused polycyclic arene | aryl hydrocarbon receptor agonist; carcinogenic agent | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
theophylline | | dimethylxanthine | adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
aspirin | | benzoic acids; phenyl acetates; salicylates | anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent | 1992 | 1995 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
bay-k-8644 | | (trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
propiolactone | | propan-3-olide | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
chlorpromazine | | organochlorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ciprofibrate | | cyclopropanes; monocarboxylic acid; organochlorine compound | antilipemic drug | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
clofibric acid | | aromatic ether; monocarboxylic acid; monochlorobenzenes | anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
valproic acid | | branched-chain fatty acid; branched-chain saturated fatty acid | anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol | | benzyl alcohols; fatty amide; morpholines; secondary alcohol; tertiary amino compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
erythrosine | | | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ether | | ether; volatile organic compound | inhalation anaesthetic; non-polar solvent; refrigerant | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
gentamicin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
leflunomide | | (trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide | antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
ly 303511 | | N-arylpiperazine | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nocodazole | | aromatic ketone; benzimidazoles; carbamate ester; thiophenes | antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
methylphenidate | | beta-amino acid ester; methyl ester; piperidines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
ethylmaleimide | | maleimides | anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
nicardipine | | benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
oxidopamine | | benzenetriol; catecholamine; primary amino compound | drug metabolite; human metabolite; neurotoxin | 1985 | 2008 | 27.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
potassium iodide | | potassium salt | expectorant; radical scavenger | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
propantheline | | xanthenes | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
resorcinol | | benzenediol; phenolic donor; resorcinols | erythropoietin inhibitor; sensitiser | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
w 7 | | | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
zinc chloride | | inorganic chloride; zinc molecular entity | astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
prednisolone | | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic | 1995 | 2013 | 20.0 | low | 1 | 0 | 1 | 0 | 1 | 0 |
thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite | 1984 | 1997 | 31.4 | low | 0 | 1 | 4 | 0 | 0 | 0 |
dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
2-acetylaminofluorene | | 2-acetamidofluorenes | antimitotic; carcinogenic agent; epitope; mutagen | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
serine | | L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 1978 | 2006 | 29.7 | low | 0 | 2 | 2 | 2 | 0 | 0 |
aspartic acid | | aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; mouse metabolite; neurotransmitter | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lysine | | aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid | algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 1994 | 2007 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
ethinyl estradiol | | 17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound | xenoestrogen | 1987 | 1988 | 36.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
9,10-dimethyl-1,2-benzanthracene | | ortho-fused polycyclic arene; tetraphenes | carcinogenic agent | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
apomorphine | | aporphine alkaloid | alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
bromodeoxyuridine | | pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent | 1977 | 1992 | 39.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
galactose | | D-galactose; galactopyranose | Escherichia coli metabolite; mouse metabolite | 1964 | 2008 | 33.2 | low | 0 | 6 | 11 | 2 | 0 | 0 |
phenylethyl alcohol | | benzenes; primary alcohol | Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
tyrosine | | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical | 1986 | 2020 | 22.8 | low | 0 | 1 | 1 | 3 | 1 | 0 |
lactose | | lactose | | 1981 | 2018 | 21.0 | low | 0 | 2 | 4 | 5 | 3 | 0 |
methionine | | aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid | antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
1,2-dipalmitoylphosphatidylcholine | | | | 1995 | 2016 | 19.2 | low | 0 | 0 | 1 | 3 | 1 | 0 |
cycloheximide | | antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol | anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
egtazic acid | | diether; tertiary amino compound; tetracarboxylic acid | chelator | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
chloroform | | chloromethanes; one-carbon compound | carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
mannitol | | mannitol | allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent | 2008 | 2017 | 11.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
histidine | | amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
n-pentanol | | pentanol; short-chain primary fatty alcohol | human metabolite; plant metabolite | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan | antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
trichloroacetic acid | | monocarboxylic acid; organochlorine compound | carcinogenic agent; metabolite; mouse metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
taurocholic acid | | amino sulfonic acid; bile acid taurine conjugate | human metabolite | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
methylprednisolone | | 6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic | 2015 | 2019 | 7.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
xanthenes | | xanthene | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
4-bromophenacyl bromide | | | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
uridine diphosphate glucose | | UDP-D-glucose | fundamental metabolite | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
perylene | | ortho- and peri-fused polycyclic arene; perylenes | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
quinazolines | | azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines | | 1997 | 2008 | 20.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
cyclopentane | | cycloalkane; cyclopentanes; volatile organic compound | non-polar solvent | 1993 | 1995 | 30.2 | low | 0 | 0 | 4 | 0 | 0 | 0 |
isoxazoles | | isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
nitroblue tetrazolium | | organic cation | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
triphenyltetrazolium | | organic cation | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydrazine | | azane; hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
evans blue | | organic sodium salt | fluorochrome; histological dye; sodium channel blocker; teratogenic agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
diazomethane | | diazo compound | alkylating agent; antineoplastic agent; carcinogenic agent; poison | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methochlorpromazine | | | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
orcinol | | 5-alkylresorcinol; dihydroxytoluene | Aspergillus metabolite | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
alpha-aminopyridine | | | | 2009 | 2010 | 14.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cellobiose | | cellobiose | epitope | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
malondialdehyde | | dialdehyde | biomarker | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
cytidine diphosphate choline | | nucleotide-(amino alcohol)s; phosphocholines | human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite | 1981 | 2002 | 32.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
potassium hydroxide | | alkali metal hydroxide | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dodecyldimethylamine oxide | | tertiary amine oxide | detergent; plant metabolite | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
tricosanoic acid | | straight-chain saturated fatty acid; very long-chain fatty acid | Daphnia magna metabolite; human metabolite; plant metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fucose | | fucopyranose; L-fucose | Escherichia coli metabolite; mouse metabolite | 1977 | 2017 | 32.2 | low | 0 | 2 | 1 | 0 | 1 | 0 |
uridine diphosphate galactose | | UDP-D-galactose | mouse metabolite | 1979 | 1996 | 36.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
fluorescein-5-isothiocyanate | | fluorescein isothiocyanate | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
mannose | | D-aldohexose; D-mannose; mannopyranose | metabolite | 1977 | 2017 | 27.7 | low | 0 | 1 | 1 | 0 | 1 | 0 |
manganese | | elemental manganese; manganese group element atom | Escherichia coli metabolite; micronutrient | 1982 | 1995 | 33.7 | low | 0 | 1 | 2 | 0 | 0 | 0 |
technetium | | manganese group element atom | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
gold | | copper group element atom; elemental gold | | 2013 | 2018 | 8.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
aluminum chloride | | aluminium coordination entity | Lewis acid | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cupric chloride | | copper molecular entity; inorganic chloride | EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
acetylglucosamine | | N-acetyl-D-glucosamine | epitope | 1977 | 2011 | 24.6 | low | 0 | 1 | 1 | 2 | 1 | 0 |
ferric chloride | | iron coordination entity | astringent; Lewis acid | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
fluorine | | diatomic fluorine; gas molecular entity | NMR chemical shift reference compound | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
deuterium oxide | | deuterated compound; water | NMR solvent | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
galactose | | | | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
aluminum sulfate | | aluminium sulfate | | 2014 | 2015 | 9.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
tetradecanoylphorbol acetate | | acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester | antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator | 1984 | 2008 | 32.0 | low | 0 | 6 | 4 | 2 | 0 | 0 |
1-deoxynojirimycin | | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
phosphotyrosine | | L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine | Escherichia coli metabolite; immunogen | 1986 | 2015 | 19.9 | low | 0 | 1 | 2 | 3 | 3 | 0 |
phenyl acetate | | benzenes; phenyl acetates | | 1989 | 1992 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
8-bromo cyclic adenosine monophosphate | | 3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound | antidepressant; protein kinase agonist | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
tridemorph | | morpholines; tertiary amino compound | antifungal agrochemical | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glutamic acid | | glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical | 2006 | 2007 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
torpedo | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
azides | | pseudohalide anion | mitochondrial respiratory-chain inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
zidovudine | | azide; pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
acetylgalactosamine | | N-acetyl-D-hexosamine; N-acetylgalactosamine | Escherichia coli metabolite; human metabolite; mouse metabolite | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
etoposide | | beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound | antineoplastic agent; DNA synthesis inhibitor | 2006 | 2007 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
n-(2-hydroxypropyl)methacrylamide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
colforsin | | acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol | adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
miglustat | | piperidines; tertiary amino compound | anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
fura-2 | | | | 1992 | 1994 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
trichloroacetamide | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
octyl glucoside | | beta-D-glucoside | plant metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
glucose, (beta-d)-isomer | | D-glucopyranose | epitope; mouse metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
oseltamivir | | acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound | antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
cholesteryl sulfate | | steroid sulfate | human metabolite | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
25-hydroxycholesterol | | 25-hydroxy steroid; oxysterol | human metabolite | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
metaperiodate | | iodine oxoacid | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
2-deoxy-2,3-dehydro-n-acetylneuraminic acid | | N-acetylneuraminic acids | | 1989 | 2008 | 25.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate | | | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
methylumbelliferyl-beta-d-xyloside | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
methyl beta-galactoside | | beta-D-galactoside; methyl D-galactoside; monosaccharide derivative | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
fluo-3 | | xanthene dye | fluorochrome | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
parinaric acid | | octadecatetraenoic acid | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
deoxyglucose | | | | 1978 | 2002 | 34.0 | low | 0 | 1 | 0 | 1 | 0 | 0 |
1-phenyl-2-decanoylamino-3-morpholino-1-propanol | | | | 1989 | 2016 | 20.2 | low | 0 | 1 | 2 | 6 | 3 | 0 |
caprylates | | fatty acid anion 8:0; straight-chain saturated fatty acid anion | human metabolite; Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
4-o-alpha-d-galactopyranosyl-d-galactose | | O-acyl carbohydrate | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
methyl lactoside | | disaccharide derivative; methyl glycoside | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
phytosphingosine | | amino alcohol; sphingoid; triol | mouse metabolite; Saccharomyces cerevisiae metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
chapso | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
carbene | | carbene; methanediyl | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gefitinib | | aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound | antineoplastic agent; epidermal growth factor receptor antagonist | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
3-deoxyglycero-galacto-nonulosonic acid | | L-alpha-D-Hepp-(1->7)-L-alpha-D-Hepp-(1->3)-L-alpha-D-Hepp-(1->5)-alpha-Kdo | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- | | organic molecular entity | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
n-acetylneuraminoyllactose | | | | 1981 | 2012 | 25.0 | low | 0 | 2 | 1 | 2 | 1 | 0 |
9-o-acetyl-n-acetylneuraminic acid | | N-acetyl-O-acetylneuraminic acid | | 1996 | 2020 | 18.7 | low | 0 | 0 | 2 | 0 | 1 | 0 |
glycerophosphoinositol 4,5-bisphosphate | | | | 2016 | 2021 | 5.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
n-acetylneuraminosyl(alpha2-6)lactosamine | | amino trisaccharide; glucosamine oligosaccharide | epitope | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
neuramin lactitol | | | | 1992 | 1996 | 30.0 | high | 0 | 0 | 2 | 0 | 0 | 0 |
phorbols | | diterpene; terpenoid fundamental parent | | 1986 | 1986 | 38.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
2-deoxy-lyxo-hexose | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
uridine diphosphate galactosamine | | UDP-amino sugar | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
udp-glucosamine | | UDP-amino sugar | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
biotin | | biotins; vitamin B7 | coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite | 1989 | 2010 | 27.8 | low | 0 | 1 | 2 | 1 | 0 | 0 |
angiotensin ii | | amino acid zwitterion; angiotensin II | human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
erlotinib hydrochloride | | hydrochloride; terminal acetylenic compound | antineoplastic agent; protein kinase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
cholic acid | | 12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid | human metabolite; mouse metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
deoxycholic acid | | bile acid; C24-steroid; dihydroxy-5beta-cholanic acid | human blood serum metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
wortmannin | | acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound | anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dihydropyridines | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
n-acetylneuraminic acid | | N-acetylneuraminic acids | antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite | 1984 | 2023 | 22.5 | low | 1 | 8 | 24 | 17 | 8 | 3 |
glucosamine | | D-glucosamine | Escherichia coli metabolite; geroprotector; mouse metabolite | 1977 | 2000 | 35.6 | low | 0 | 2 | 3 | 0 | 0 | 0 |
elastin | | oligopeptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
n-acetyllactosamine | | beta-D-Galp-(1->4)-D-GlcpNAc | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
puromycin | | puromycins | antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
n-glycolylneuraminic acid | | N-acylneuraminic acid | | 1984 | 2013 | 25.7 | low | 0 | 4 | 4 | 4 | 1 | 0 |
mannosamine | | D-mannosamine | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
monensin | | cyclic hemiketal; monocarboxylic acid; polyether antibiotic; spiroketal | antifungal agent; coccidiostat; ionophore | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
naringin | | (2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside | anti-inflammatory agent; antineoplastic agent; metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
betadex | | cyclodextrin | | 2004 | 2007 | 18.8 | low | 0 | 0 | 0 | 5 | 0 | 0 |
tretinoin | | retinoic acid; vitamin A | anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule | 1978 | 2007 | 31.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
arachidonic acid | | icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid | Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite | 1988 | 1994 | 32.7 | low | 0 | 1 | 2 | 0 | 0 | 0 |
retinol | | retinol; vitamin A | human metabolite; mouse metabolite; plant metabolite | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
oleic acid | | octadec-9-enoic acid | antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
tacrolimus | | macrolide lactam | bacterial metabolite; immunosuppressive agent | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cytidine monophosphate n-acetylneuraminic acid | | CMP-N-acyl-beta-neuraminic acid | mouse metabolite | 1977 | 1989 | 41.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
h 89 | | N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
enkephalin, leucine | | pentapeptide; peptide zwitterion | analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
glycosides | | | | 1993 | 2014 | 23.0 | low | 0 | 0 | 4 | 2 | 1 | 0 |
isomethyleugenol | | isomethyleugenol | | 1977 | 2009 | 28.8 | low | 0 | 2 | 1 | 3 | 0 | 0 |
n-acetylneuraminoyllactose | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
arginine vasopressin | | vasopressin | cardiovascular drug; hematologic agent; mitogen | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
hypocrellin b | | | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
fumonisin b1 | | diester; fumonisin; primary amino compound; triol | carcinogenic agent; metabolite | 1997 | 2013 | 19.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
tamoxifen | | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sodium taurodeoxycholate | | bile acid taurine conjugate | human metabolite | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
krn 7000 | | glycophytoceramide; N-acyl-beta-D-galactosylphytosphingosine | allergen; antigen; antineoplastic agent; epitope; immunological adjuvant | 2008 | 2021 | 9.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
rtki cpd | | | | 1997 | 2008 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
safingol | | amino alcohol | | 1989 | 1997 | 31.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
n-(2,4,6-trinitrophenyl-6-n-aminocaproyl)-1,2-dipalmitoylphosphatidylethanolamine | | | | 1983 | 1983 | 41.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
phosphothreonine | | L-threonine derivative; non-proteinogenic L-alpha-amino acid; O-phosphoamino acid | Escherichia coli metabolite | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
ovalbumin | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chloramine-t | | organic sodium salt | allergen; antifouling biocide; disinfectant | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
myelin basic protein | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
sphingosine | | sphing-4-enine | human metabolite; mouse metabolite | 1977 | 2021 | 25.5 | low | 0 | 3 | 7 | 3 | 1 | 1 |
dinoprostone | | prostaglandins E | human metabolite; mouse metabolite; oxytocic | 1993 | 2003 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
arachidonyltrifluoromethane | | fatty acid derivative; ketone; olefinic compound; organofluorine compound | EC 3.1.1.4 (phospholipase A2) inhibitor | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
calcitriol | | D3 vitamins; hydroxycalciol; triol | antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical | 1986 | 1989 | 36.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
psychosine | | glycosylsphingoid | human metabolite | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
hymecromone | | hydroxycoumarin | antineoplastic agent; hyaluronic acid synthesis inhibitor | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
alprostadil | | prostaglandins E | anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent | 1989 | 1992 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
6-ketoprostaglandin f1 alpha | | prostaglandins Falpha | human metabolite; mouse metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
genistein | | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
caffeic acid phenethyl ester | | alkyl caffeate ester | anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
thromboxane b2 | | thromboxanes B | human metabolite; mouse metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
sphingosine 1-phosphate | | sphingoid 1-phosphate | mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
brefeldin a | | macrolide antibiotic | Penicillium metabolite | 1993 | 2002 | 27.1 | low | 0 | 0 | 5 | 2 | 0 | 0 |
fenretinide | | monocarboxylic acid amide; retinoid | antineoplastic agent; antioxidant | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
morphine | | morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound | anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
herbimycin | | 1,4-benzoquinones; lactam; macrocycle | antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor | 1995 | 1999 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
lysophosphatidylcholines | | 1-O-acyl-sn-glycero-3-phosphocholine | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cytochalasin b | | cytochalasin; lactam; lactone; organic heterotricyclic compound | actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
1,2-oleoylphosphatidylcholine | | phosphatidylcholine(1+) | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
aluminum | | boron group element atom; elemental aluminium; metal atom | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
dimyristoylphosphatidylcholine | | 1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester | antigen; mouse metabolite | 1993 | 2011 | 25.2 | low | 0 | 0 | 3 | 0 | 1 | 0 |
cysteine | | cysteinium | fundamental metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
phosphorus | | monoatomic phosphorus; nonmetal atom; pnictogen | macronutrient | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dizocilpine maleate | | maleate salt; tetracyclic antidepressant | anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
1,2-dioleoylphosphatidylserine | | phosphatidylserine(18:1/18:1) | mouse metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
ganglioside gm3 lactone | | | | 1985 | 2018 | 24.8 | high | 0 | 3 | 5 | 3 | 2 | 0 |
cdw17 antigen | | | | 1987 | 2012 | 25.4 | medium | 0 | 4 | 13 | 6 | 3 | 0 |
ganglioside, gd1b | | | | 1982 | 2019 | 25.2 | low | 0 | 4 | 7 | 6 | 3 | 0 |
trisialoganglioside gt1 | | | | 1982 | 2009 | 29.5 | medium | 0 | 12 | 14 | 10 | 0 | 0 |
ganglioside, gd2 | | | | 1988 | 2014 | 26.2 | low | 0 | 2 | 7 | 3 | 1 | 0 |
asialo gm1 ganglioside | | | | 1995 | 2007 | 22.2 | low | 0 | 0 | 2 | 2 | 0 | 0 |
sialosylparagloboside | | | | 1982 | 1994 | 35.3 | high | 0 | 1 | 2 | 0 | 0 | 0 |
i(3)so3-galactosylceramide | | galactosylceramide sulfate; N-acyl-beta-D-galactosylsphingosine | | 1979 | 2021 | 28.0 | low | 0 | 3 | 5 | 1 | 0 | 1 |
beta-escin | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sq-23377 | | cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid | calcium ionophore; metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
enkephalin, leucine-2-alanine | | | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
dexniguldipine | | diarylmethane | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
staurosporine | | ammonium ion derivative | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
lipid a | | dodecanoate ester; lipid A; tetradecanoate ester | Escherichia coli metabolite | 1994 | 2012 | 18.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
g(m2) ganglioside | | N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine; sialotriaosylceramide | antigen | 1976 | 2023 | 26.0 | medium | 0 | 24 | 31 | 23 | 14 | 1 |
tetramethylrhodamine | | xanthene dye | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
g(m1) ganglioside | | alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine; sialotetraosylceramide | | 1976 | 2023 | 27.1 | medium | 0 | 42 | 49 | 38 | 13 | 2 |
alpha-synuclein | | | | 2007 | 2023 | 10.3 | low | 0 | 0 | 0 | 2 | 3 | 1 |
tamiphosphor | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
ki 8751 | | aromatic ether | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc | | amino tetrasaccharide; glucosamine oligosaccharide | epitope | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
n-acetylmannosamine | | | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
calcimycin | | benzoxazole | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
pituitrin | | | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
melitten | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
glucagon | | peptide hormone | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
prosaptide | | | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
endothelin-1 | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
phosphatidylcholines | | 1,2-diacyl-sn-glycero-3-phosphocholine | | 1990 | 2020 | 19.7 | low | 0 | 0 | 2 | 2 | 2 | 0 |
calpain | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lucifer yellow | | organic lithium salt | fluorochrome | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
eliglustat | | benzodioxine; carboxamide; N-alkylpyrrolidine; secondary alcohol | EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
bucladesine | | 3',5'-cyclic purine nucleotide | | 1977 | 1992 | 38.0 | low | 0 | 2 | 1 | 0 | 0 | 0 |
ganglioside, gd1a | | | | 1981 | 2015 | 29.0 | medium | 0 | 18 | 16 | 15 | 2 | 0 |
glycolipids | | | | 1977 | 2023 | 28.5 | low | 0 | 22 | 23 | 13 | 8 | 1 |
piperidines | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
uridine diphosphate n-acetylgalactosamine | | nucleotide-sugar oxoanion | human metabolite | 1981 | 2000 | 36.3 | low | 0 | 2 | 1 | 0 | 0 | 0 |
diphthamide | | quaternary ammonium ion | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
heparitin sulfate | | | | 1977 | 2021 | 19.3 | low | 0 | 1 | 0 | 0 | 1 | 1 |
epidermal growth factor | | | | 1984 | 2021 | 23.4 | low | 0 | 4 | 7 | 9 | 3 | 1 |
transforming growth factor beta | | | | 1994 | 2020 | 17.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
okadaic acid | | ketal | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
globotriaosylceramide | | | | 1988 | 1998 | 30.0 | low | 0 | 1 | 3 | 0 | 0 | 0 |
bgp 15 | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
ganglioside gm1alpha | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
lewis x antigen | | | | 1994 | 2000 | 26.2 | low | 0 | 0 | 4 | 0 | 0 | 0 |
humulin s | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
cyclosporine | | | | 1994 | 1999 | 27.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
o-acetyl sialic acid | | | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
amyloid beta-peptides | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chondroitin sulfates | | | | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ganglio-n-triaosylceramide | | | | 1994 | 2007 | 25.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
fucosyl gm1 ganglioside | | | | 1997 | 2018 | 16.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
guanosine diphosphate | | guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate | Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
guanosine triphosphate | | guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor | 1990 | 1998 | 30.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
guanosine 5'-o-(3-thiotriphosphate) | | nucleoside triphosphate analogue | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
n-glycolylneuraminyllactosylceramide | | sialotriaosylceramide | tumour antigen | 1985 | 2019 | 17.8 | high | 4 | 2 | 9 | 10 | 17 | 0 |
concanavalin a | | | | 1986 | 1991 | 35.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
ganglioside, gm4 | | | | 1981 | 2001 | 34.9 | high | 0 | 6 | 3 | 1 | 0 | 0 |
gq1b ganglioside | | | | 1988 | 2019 | 23.8 | low | 0 | 1 | 2 | 2 | 1 | 0 |
leptin | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
filipin | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
(pPNET) Peripheral Primitive Neuroectodermal Tumors | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
2019 Novel Coronavirus Disease | 0 | | 2020 | 2023 | 2.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
Abnormal Deep Tendon Reflex | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Abortion, Habitual | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Abortion, Recurrent | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Absence Seizure | 0 | | 2001 | 2022 | 12.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
Acetyl-CoA:alpha-Glucosaminide N-Acetyltransferase Deficiency | 0 | | 1980 | 2021 | 15.0 | low | 0 | 1 | 0 | 2 | 5 | 1 |
Ache | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Acid beta-Glucosidase Deficiency | 0 | | 1984 | 2014 | 19.2 | low | 1 | 1 | 0 | 3 | 1 | 0 |
Acquired Immune Deficiency Syndrome | 0 | | 1993 | 1994 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
Acquired Immunodeficiency Syndrome | 0 | | 1993 | 1994 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
Acrania | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Actinobacillus Infections | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Action Tremor | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Acute Autoimmune Neuropathy | 0 | | 2001 | 2019 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Acute Confusional Senile Dementia | 0 | | 2009 | 2022 | 10.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
Acute Disease | 0 | | 2006 | 2015 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
Acute Myelogenous Leukemia | 0 | | 1985 | 1988 | 38.0 | low | 0 | 5 | 0 | 0 | 0 | 0 |
Acute Promyelocytic Leukemia | 0 | | 1989 | 1993 | 33.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Acute Relapsing Multiple Sclerosis | 0 | | 2001 | 2003 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ADDH | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Adenocarcinoma | 0 | | 1979 | 2011 | 24.6 | low | 0 | 1 | 4 | 4 | 2 | 0 |
Adenocarcinoma Of Kidney | 0 | | 2000 | 2004 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Adenocarcinoma of Lung | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Adenocarcinoma, Basal Cell | 0 | | 1979 | 2011 | 24.6 | low | 0 | 1 | 4 | 4 | 2 | 0 |
Adjuvant Arthritis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Adrenoleukodystrophy, Autosomal Neonatal Form | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Adult GM1 Gangliosidosis | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Adult Neuronal Ceroid Lipofuscinosis | 0 | | 2014 | 2018 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Adult Refsum Disease | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
African Lymphoma | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Aging | 0 | | 1978 | 2021 | 23.5 | low | 0 | 2 | 3 | 3 | 1 | 1 |
Alcohol Abuse | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Alcoholism | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Alloxan Diabetes | 0 | | 2003 | 2018 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
alpha-L-Iduronidase Deficiency | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ALS - Amyotrophic Lateral Sclerosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Alzheimer Disease | 0 | | 2009 | 2022 | 10.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
Amaurosis | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Amaurotic Familial Idiocy | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Amyloid Angiopathy, Cerebral | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Amyloid Deposits | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Amyotrophic Lateral Sclerosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Anaplastic Astrocytoma | 0 | | 1980 | 1994 | 36.2 | low | 0 | 3 | 1 | 0 | 0 | 0 |
Anemia, Hemolytic | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Anemia, Hemolytic, Acquired | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Angioblastic Meningioma | 0 | | 1989 | 2021 | 24.0 | low | 0 | 1 | 1 | 0 | 0 | 1 |
Angiogenesis, Pathologic | 0 | | 1992 | 2021 | 18.4 | low | 0 | 0 | 2 | 2 | 0 | 1 |
Animal Mammary Carcinoma | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Anochlesia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Anxiety | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Aortic Diseases | 0 | | 1999 | 2009 | 21.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
Arachnoidal Cerebellar Sarcoma, Circumscribed | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Argentaffinoma | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ARSA Deficiency | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
ARSB Deficiency | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Arteriosclerosis | 0 | | 1977 | 2001 | 30.6 | low | 0 | 3 | 6 | 1 | 0 | 0 |
Arteriosclerosis, Coronary | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Arthritis, Degenerative | 0 | | 1995 | 2017 | 16.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
Arthritis, Rheumatoid | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Ascites | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Astheno Teratozoospermia | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Astrocytoma | 0 | | 1980 | 1994 | 36.2 | low | 0 | 3 | 1 | 0 | 0 | 0 |
Astrocytoma, Grade IV | 0 | | 1988 | 2001 | 29.7 | low | 0 | 1 | 1 | 1 | 0 | 0 |
Asymmetric Diabetic Proximal Motor Neuropathy | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Ataxia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Atherogenesis | 0 | | 2009 | 2021 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
Atheroma | 0 | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
Atherosclerosis | 0 | | 2009 | 2021 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
Atrial Fibrillation | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Attention Deficit Disorder with Hyperactivity | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Aura | 0 | | 2004 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
Auricular Fibrillation | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Autoimmune Diabetes | 0 | | 2005 | 2018 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Autoimmune Disease | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Autoimmune Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
B16 Melanoma | 0 | | 1987 | 2020 | 25.8 | low | 0 | 8 | 16 | 8 | 2 | 0 |
Basophilic Leukemia, Acute | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Benign Cerebellar Neoplasms | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Benign Meningeal Neoplasms | 0 | | 1989 | 1990 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Benign Neoplasms | 0 | | 1980 | 2020 | 15.8 | low | 0 | 1 | 5 | 6 | 13 | 0 |
Benign Neoplasms, Brain | 0 | | 1979 | 2019 | 27.1 | low | 0 | 2 | 4 | 2 | 1 | 0 |
Berger Disease | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Besnier-Boeck Disease | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Birth Weight | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Bladder Cancer | 0 | | 2001 | 2013 | 19.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
Blindness | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Blood Pressure, High | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Body Weight | 0 | | 2002 | 2016 | 15.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
Bovine Diseases | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Bowel Diseases, Inflammatory | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Brain Diseases | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Brain Disorders | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Brain Ischemia | 0 | | 2005 | 2015 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
Brain Neoplasms | 0 | | 1979 | 2019 | 27.1 | low | 0 | 2 | 4 | 2 | 1 | 0 |
Breast Cancer | 0 | | 1991 | 2023 | 21.1 | low | 4 | 0 | 7 | 5 | 3 | 1 |
Breast Neoplasms | 0 | | 1991 | 2023 | 21.1 | low | 4 | 0 | 7 | 5 | 3 | 1 |
Bronchial Neoplasms | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Bulbar Palsy | 0 | | 2006 | 2018 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
Burkitt Lymphoma | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Calcification, Pathologic | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Calcinosis | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Campylobacter Infection | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cancer of Colon | 0 | | 1983 | 2020 | 25.2 | low | 0 | 2 | 3 | 5 | 1 | 0 |
Cancer of Esophagus | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cancer of Eye | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
Cancer of Head | 0 | | 1989 | 2018 | 20.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
Cancer of Kidney | 0 | | 1983 | 2004 | 27.5 | low | 0 | 1 | 2 | 1 | 0 | 0 |
Cancer of Liver | 0 | | 1978 | 2013 | 32.3 | low | 0 | 2 | 3 | 0 | 1 | 0 |
Cancer of Lung | 0 | | 1979 | 2018 | 20.4 | low | 2 | 2 | 6 | 8 | 7 | 0 |
Cancer of Mouth | 0 | | 1986 | 2012 | 25.0 | low | 0 | 1 | 0 | 0 | 1 | 0 |
Cancer of Ovary | 0 | | 1986 | 2022 | 19.0 | low | 0 | 1 | 1 | 1 | 1 | 1 |
Cancer of Pancreas | 0 | | 1983 | 1991 | 37.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Cancer of Rectum | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Cancer of Skin | 0 | | 1988 | 2020 | 23.9 | low | 1 | 2 | 5 | 6 | 1 | 0 |
Cancer of Stomach | 0 | | 1991 | 2001 | 30.0 | low | 0 | 0 | 3 | 1 | 0 | 0 |
Cancer of the Retina | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Cancer of the Thyroid | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cancer of the Uterus | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Carbohydrate Metabolism, Inborn Error | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Carbohydrate-Deficient Glycoprotein Syndrome | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Carcinogenesis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Carcinoid Tumor | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Carcinoma | 0 | | 1990 | 2019 | 20.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
Carcinoma, Anaplastic | 0 | | 1990 | 2019 | 20.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
Carcinoma, Basal Cell | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
Carcinoma, Basal Cell, Pigmented | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
Carcinoma, Ductal, Breast | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
Carcinoma, Epidermoid | 0 | | 1979 | 2007 | 28.4 | low | 0 | 3 | 4 | 3 | 0 | 0 |
Carcinoma, Hepatocellular | 0 | | 1978 | 2015 | 22.2 | low | 0 | 1 | 1 | 0 | 3 | 0 |
Carcinoma, Large Cell | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Carcinoma, Lewis Lung | 0 | | 2006 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
Carcinoma, Non-Small Cell Lung | 0 | | 1997 | 2018 | 13.0 | low | 1 | 0 | 1 | 4 | 7 | 0 |
Carcinoma, Non-Small-Cell Lung | 0 | | 1997 | 2018 | 13.0 | low | 1 | 0 | 1 | 4 | 7 | 0 |
Carcinoma, Oat Cell | 0 | | 1979 | 2007 | 31.0 | low | 1 | 1 | 0 | 1 | 0 | 0 |
Carcinoma, Papillary | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Carcinoma, Renal Cell | 0 | | 2000 | 2004 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Carcinoma, Small Cell | 0 | | 1979 | 2007 | 31.0 | low | 1 | 1 | 0 | 1 | 0 | 0 |
Carcinoma, Squamous Cell | 0 | | 1979 | 2007 | 28.4 | low | 0 | 3 | 4 | 3 | 0 | 0 |
Carcinoma, Transitional Cell | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cardiac Failure | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Cardiometabolic Syndrome | 0 | | 2011 | 2015 | 10.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
Cataract | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Cataract, Membranous | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Cell Transformation, Neoplastic | 0 | | 1977 | 2005 | 33.2 | low | 0 | 5 | 0 | 4 | 0 | 0 |
Cell Transformation, Viral | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cerebral Amyloid Angiopathy | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cerebral Infarction, Middle Cerebral Artery | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cerebral Ischemia | 0 | | 2005 | 2015 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
Cerebro-Hepato-Renal Syndrome | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Chancroid | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cherry Red Spot Myoclonus Syndrome | 0 | | 1980 | 1989 | 39.8 | low | 0 | 5 | 0 | 0 | 0 | 0 |
Child Development Deviations | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cholelithiasis | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Choriocarcinoma | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Chromosome Deletion | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Chronic Progressive Multiple Sclerosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Cirrhosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Cirrhosis, Liver | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Clinically Isolated CNS Demyelinating Syndrome | 0 | | 1994 | 2001 | 25.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
Colitis Gravis | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Colitis, Granulomatous | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Colitis, Ulcerative | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Colonic Neoplasms | 0 | | 1983 | 2020 | 25.2 | low | 0 | 2 | 3 | 5 | 1 | 0 |
Colorectal Cancer | 0 | | 1999 | 2021 | 15.3 | low | 0 | 0 | 1 | 1 | 0 | 1 |
Colorectal Neoplasms | 0 | | 1999 | 2021 | 15.3 | low | 0 | 0 | 1 | 1 | 0 | 1 |
Condition, Preneoplastic | 0 | | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Congenital Disorders of Glycosylation | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Corneal Diseases | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Coronary Artery Disease | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Coronavirus Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Cranial Nerve II Diseases | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Crohn Disease | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Cytomegalovirus | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Deafness, Transitory | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Deficiency, Vitamin D | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Degenerative Disease, Nervous System, Hereditary | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Degenerative Diseases, Central Nervous System | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Dementia Praecox | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Demyelinating Diseases | 0 | | 1994 | 2001 | 25.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
Dental Granuloma | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Dermatoses | 0 | | 1989 | 2008 | 25.5 | low | 1 | 1 | 0 | 1 | 0 | 0 |
Developmental Disabilities | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Diabetes Mellitus | 0 | | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Diabetes Mellitus, Adult-Onset | 0 | | 1999 | 2020 | 13.2 | low | 0 | 0 | 1 | 4 | 8 | 0 |
Diabetes Mellitus, Type 1 | 0 | | 2005 | 2018 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Diabetes Mellitus, Type 2 | 0 | | 1999 | 2020 | 13.2 | low | 0 | 0 | 1 | 4 | 8 | 0 |
Diabetic Feet | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Diabetic Foot | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Diabetic Glomerulosclerosis | 0 | | 2003 | 2015 | 15.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
Diabetic Nephropathies | 0 | | 2003 | 2015 | 15.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
Diabetic Neuropathies | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Diabetic Retinopathy | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Diarrhea | 0 | | 2003 | 2011 | 17.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
Diffuse Parenchymal Lung Disease | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Disease Exacerbation | 0 | | 1997 | 2016 | 17.8 | low | 0 | 0 | 3 | 2 | 3 | 0 |
Disease Models, Animal | 0 | | 2000 | 2022 | 12.0 | low | 0 | 0 | 1 | 10 | 17 | 2 |
Diseases, Metabolic | 0 | | 2010 | 2022 | 7.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
Dysembryoma | 0 | | 1981 | 2000 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Dyskinesia, Drug-Induced | 0 | | 1989 | 1989 | 35.0 | low | 1 | 1 | 0 | 0 | 0 | 0 |
Dyskinesia, Medication-Induced | 0 | | 1989 | 1989 | 35.0 | low | 1 | 1 | 0 | 0 | 0 | 0 |
Dysplastic Nevus Syndrome, Hereditary | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
E coli Infections | 0 | | 1993 | 2003 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Eccentro-Osteochondrodysplasia | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
EHS Tumor | 0 | | 1982 | 2011 | 27.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
Elevated Cholesterol | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Epilepsy | 0 | | 2004 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
ER-Negative PR-Negative HER2-Negative Breast Cancer | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Escherichia coli Infections | 0 | | 1993 | 2003 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Esophageal Neoplasms | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Experimental Hepatoma | 0 | | 1979 | 1990 | 38.3 | low | 0 | 2 | 1 | 0 | 0 | 0 |
Experimental Leukemia | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Experimental Mammary Neoplasms | 0 | | 1992 | 2021 | 22.3 | low | 0 | 0 | 3 | 2 | 0 | 1 |
Experimental Neoplasms | 0 | | 1977 | 2015 | 36.2 | low | 0 | 3 | 0 | 0 | 1 | 0 |
Extravascular Hemolysis | 0 | | 1985 | 1996 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Eye Cancer, Retinoblastoma | 0 | | 1988 | 2015 | 22.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
Familial Waldenstrom's Macroglobulinaemia | 0 | | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Fibrosarcoma | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Fibrosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Fisher Syndrome | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Fowl Paralysis | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
G(M2) Gangliosidoses | 0 | | 2007 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Gallstone Disease | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Ganglioside Storage Diseases | 0 | | 1978 | 2001 | 38.2 | low | 0 | 4 | 0 | 1 | 0 | 0 |
Gangliosidoses | 0 | | 1978 | 2001 | 38.2 | low | 0 | 4 | 0 | 1 | 0 | 0 |
Gangliosidoses, GM2 | 0 | | 2007 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Gangliosidosis, GM1 | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Gargoylism, Hunter Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Gastric Ulcer | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Gaucher Disease | 0 | | 1984 | 2014 | 19.2 | low | 1 | 1 | 0 | 3 | 1 | 0 |
Gelineau Syndrome | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Genetic Predisposition | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Germinoblastoma | 0 | | 1991 | 2019 | 17.0 | low | 1 | 0 | 1 | 0 | 2 | 0 |
Glial Cell Tumors | 0 | | 1984 | 2005 | 29.8 | low | 0 | 4 | 5 | 3 | 0 | 0 |
Glioblastoma | 0 | | 1988 | 2001 | 29.7 | low | 0 | 1 | 1 | 1 | 0 | 0 |
Glioma | 0 | | 1984 | 2005 | 29.8 | low | 0 | 4 | 5 | 3 | 0 | 0 |
Glomerulonephritis, IGA | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Glomerulonephritis, Lupus | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Granulocytic Leukemia | 0 | | 1985 | 1989 | 37.0 | low | 0 | 4 | 0 | 0 | 0 | 0 |
Granulocytic Leukemia, Chronic | 0 | | 1991 | 2009 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Grippe | 0 | | 2007 | 2019 | 10.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Guillain-Barre Syndrome | 0 | | 2001 | 2019 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Hansen Disease | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Head and Neck Neoplasms | 0 | | 1989 | 2018 | 20.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
Hearing Loss | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Heart Failure | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Helicobacter Infections | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Hematologic Malignancies | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
Hematologic Neoplasms | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
Hematoma | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Hemolysis | 0 | | 1985 | 1996 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Hepatocellular Carcinoma | 0 | | 1978 | 2015 | 22.2 | low | 0 | 1 | 1 | 0 | 3 | 0 |
HIV Coinfection | 0 | | 1996 | 2013 | 21.7 | low | 0 | 0 | 2 | 0 | 1 | 0 |
HIV Infections | 0 | | 1996 | 2013 | 21.7 | low | 0 | 0 | 2 | 0 | 1 | 0 |
Hymenolepiasis | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Hyperactivity, Motor | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Hypercholesterolemia | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Hyperplasia | 0 | | 1978 | 1989 | 40.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
Hypertension | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Hypertrophy | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Hypokalemia | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Idiopathic Parkinson Disease | 0 | | 2010 | 2023 | 6.4 | low | 0 | 0 | 0 | 1 | 2 | 2 |
Inclusion Body Myopathy, Sporadic | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Infarction, Middle Cerebral Artery | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Infections, Coronavirus | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Infections, Helicobacter | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Infections, Orthomyxoviridae | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Infections, Pasteurella | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Infections, Reoviridae | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Inflammation | 0 | | 1996 | 2022 | 10.2 | low | 0 | 0 | 1 | 0 | 2 | 2 |
Inflammatory Bowel Diseases | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Influenza, Human | 0 | | 2007 | 2019 | 10.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
Injuries, Spinal | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
Injury, Ischemia-Reperfusion | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Innate Inflammatory Response | 0 | | 1996 | 2022 | 10.2 | low | 0 | 0 | 1 | 0 | 2 | 2 |
Insulin Resistance | 0 | | 2002 | 2023 | 13.3 | low | 1 | 0 | 0 | 10 | 8 | 2 |
Insulin Sensitivity | 0 | | 2002 | 2023 | 13.3 | low | 1 | 0 | 0 | 10 | 8 | 2 |
Interstitial Cell Tumor | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Intestinal Diseases | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Invasiveness, Neoplasm | 0 | | 1997 | 2013 | 19.8 | low | 0 | 0 | 1 | 7 | 1 | 0 |
Ischemia | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Kahler Disease | 0 | | 1994 | 2006 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Kidney Diseases | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Kidney Neoplasms | 0 | | 1983 | 2004 | 27.5 | low | 0 | 1 | 2 | 1 | 0 | 0 |
Kidney, Polycystic | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Leprosy | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Leucocythaemia | 0 | | 2002 | 2012 | 17.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
Leukemia | 0 | | 2002 | 2012 | 17.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
Leukemia L 1210 | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Leukemia L5178 | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Leukemia, Basophilic, Acute | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Leukemia, Lymphoblastic, Acute, T Cell | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Leukemia, Lymphocytic | 0 | | 1986 | 2013 | 28.7 | low | 0 | 2 | 0 | 0 | 1 | 0 |
Leukemia, Lymphoid | 0 | | 1986 | 2013 | 28.7 | low | 0 | 2 | 0 | 0 | 1 | 0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 0 | | 1991 | 2009 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Leukemia, Myeloid | 0 | | 1985 | 1989 | 37.0 | low | 0 | 4 | 0 | 0 | 0 | 0 |
Leukemia, Myeloid, Acute | 0 | | 1985 | 1988 | 38.0 | low | 0 | 5 | 0 | 0 | 0 | 0 |
Leukemia, Pre-B-Cell | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Leukemia, Promyelocytic, Acute | 0 | | 1989 | 1993 | 33.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Leukemic Infiltration | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Leukodystrophy, Metachromatic | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Lipidoses | 0 | | 1977 | 1980 | 46.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
Liver Cirrhosis | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Liver Neoplasms | 0 | | 1978 | 2013 | 32.3 | low | 0 | 2 | 3 | 0 | 1 | 0 |
Local Neoplasm Recurrence | 0 | | 2012 | 2022 | 6.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
Lung Adenocarcinoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Lung Diseases, Interstitial | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Lung Neoplasms | 0 | | 1979 | 2018 | 20.4 | low | 2 | 2 | 6 | 8 | 7 | 0 |
Lupus Nephritis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Lymph Node Metastasis | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Lymphocytopenia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Lymphoma | 0 | | 1991 | 2019 | 17.0 | low | 1 | 0 | 1 | 0 | 2 | 0 |
Lymphoma, T-Cell | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Lymphopenia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Lysosomal Enzyme Disorders | 0 | | 1992 | 2010 | 24.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
Lysosomal Enzyme Disorders, Nervous System | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Malignant Melanoma | 0 | | 1984 | 2023 | 25.8 | low | 3 | 13 | 22 | 13 | 6 | 1 |
Medulloblastoma | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Melanoma | 0 | | 1984 | 2023 | 25.8 | low | 3 | 13 | 22 | 13 | 6 | 1 |
Meningeal Neoplasms | 0 | | 1989 | 1990 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Meningioma | 0 | | 1989 | 2021 | 24.0 | low | 0 | 1 | 1 | 0 | 0 | 1 |
Metabolic Diseases | 0 | | 2010 | 2022 | 7.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
Metabolic Syndrome | 0 | | 2011 | 2015 | 10.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
Metastase | 0 | | 1993 | 2019 | 19.2 | low | 0 | 0 | 7 | 2 | 4 | 0 |
Mole, Skin | 0 | | 1988 | 2002 | 29.0 | low | 0 | 1 | 0 | 1 | 0 | 0 |
Monosomy | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Mouth Neoplasms | 0 | | 1986 | 2012 | 25.0 | low | 0 | 1 | 0 | 0 | 1 | 0 |
MS (Multiple Sclerosis) | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Mucopolysaccharidoses | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Mucopolysaccharidosis | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Mucopolysaccharidosis I | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Mucopolysaccharidosis II | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Mucopolysaccharidosis III | 0 | | 1980 | 2021 | 15.0 | low | 0 | 1 | 0 | 2 | 5 | 1 |
Mucopolysaccharidosis IV | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Mucopolysaccharidosis VI | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Multiple Myeloma | 0 | | 1994 | 2006 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Multiple Sclerosis | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Multiple Sclerosis, Chronic Progressive | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Multiple Sclerosis, Relapsing-Remitting | 0 | | 2001 | 2003 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
Muscle Contraction | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Myositis, Inclusion Body | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Narcolepsy | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Necrosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Neoplasm Metastasis | 0 | | 1993 | 2019 | 19.2 | low | 0 | 0 | 7 | 2 | 4 | 0 |
Neoplasms | 0 | | 1980 | 2020 | 15.8 | low | 0 | 1 | 5 | 6 | 13 | 0 |
Neoplasms, Bronchial | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Neoplasms, Nervous System | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Neoplasms, Otorhinolaryngologic | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Nervous System Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Nervous System Disorders | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Neural Tube Defects | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Neuroblastoma | 0 | | 1976 | 2005 | 32.8 | low | 0 | 8 | 8 | 3 | 0 | 0 |
Neurocutaneous Disorders | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Neurodegenerative Diseases | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Neuroectodermal Tumors | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Neuroectodermal Tumors, Primitive, Peripheral | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Neuronal Ceroid-Lipofuscinoses | 0 | | 2014 | 2018 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia | 0 | | 2008 | 2017 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
Nevi, Melanocytic | 0 | | 1992 | 2012 | 22.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
Nevus, Pigmented | 0 | | 1992 | 2012 | 22.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
Niemann-Pick Disease | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Niemann-Pick Disease, Type C | 0 | | 2008 | 2017 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
Niemann-Pick Diseases | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Obesity | 0 | | 2009 | 2022 | 8.1 | low | 0 | 0 | 0 | 1 | 5 | 1 |
Optic Nerve Diseases | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Orthomyxoviridae Infections | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Osteoarthritis | 0 | | 1995 | 2017 | 16.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
Ovarian Neoplasms | 0 | | 1986 | 2022 | 19.0 | low | 0 | 1 | 1 | 1 | 1 | 1 |
Pain | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Pancreatic Neoplasms | 0 | | 1983 | 1991 | 37.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Parkinson Disease | 0 | | 2010 | 2023 | 6.4 | low | 0 | 0 | 0 | 1 | 2 | 2 |
Periapical Cyst | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Periapical Diseases | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Peripheral Nerve Diseases | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Peripheral Nervous System Diseases | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Peroxisomal Disorders | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Plasma Cell Tumor | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Plasmacytoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Pneumonia, Viral | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Polycystic Kidney Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Potassium Deficiency | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Poultry Diseases | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Precancerous Conditions | 0 | | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Pregnancy | 0 | | 1979 | 2012 | 29.6 | low | 0 | 5 | 8 | 1 | 2 | 0 |
Proteinuria | 0 | | 2003 | 2020 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
Recrudescence | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Rectal Neoplasms | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Reflex, Abnormal | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Reperfusion Injury | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Retinoblastoma | 0 | | 1988 | 2015 | 22.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
Rheumatoid Arthritis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Rotavirus Infections | 0 | | 1998 | 2011 | 19.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
Salmonella Infections, Animal | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Sarcoidosis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Sarcoma | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Sarcoma, Epithelioid | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Schizophrenia | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Seizures | 0 | | 2001 | 2022 | 12.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
Sensitivity and Specificity | 0 | | 1990 | 2014 | 19.8 | low | 0 | 0 | 2 | 1 | 2 | 0 |
Skin Diseases | 0 | | 1989 | 2008 | 25.5 | low | 1 | 1 | 0 | 1 | 0 | 0 |
Skin Neoplasms | 0 | | 1988 | 2020 | 23.9 | low | 1 | 2 | 5 | 6 | 1 | 0 |
Small Fiber Neuropathy | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Sphingolipid Storage Diseases | 0 | | 1992 | 1995 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
Stomach Neoplasms | 0 | | 1991 | 2001 | 30.0 | low | 0 | 0 | 3 | 1 | 0 | 0 |
Stomach Ulcer | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Swine Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Symptom Cluster | 0 | | 2003 | 2004 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
Syndrome | 0 | | 2003 | 2004 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
T-Cell Lymphoma | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Tauopathies | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Tay-Sachs Disease | 0 | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Teratoma | 0 | | 1981 | 2000 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
Tetraploid | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Thyroid Neoplasms | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Tremor | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Triple Negative Breast Neoplasms | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Urinary Bladder Neoplasms | 0 | | 2001 | 2013 | 19.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
Uterine Neoplasms | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Uveal Neoplasms | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Vitamin D Deficiency | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Vitiligo | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
Waldenstrom Macroglobulinemia | 0 | | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
Wallerian Degeneration | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Weight Loss | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Weight Reduction | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Zellweger Syndrome | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
[Effects of GM3 on proliferation, apoptosis and VEGF expression in human lung adenocarcinoma cell line A549 cells].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 33, Issue:4, 2011
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.Immunobiology, , Volume: 216, Issue:12, 2011
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer science, , Volume: 98, Issue:10, 2007
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.International journal of cancer, , Jan-10, Volume: 97, Issue:2, 2002
Glycosylation defining cancer malignancy: new wine in an old bottle.Proceedings of the National Academy of Sciences of the United States of America, , Aug-06, Volume: 99, Issue:16, 2002
Glycotherapy for cancer: remodeling of ganglioside pattern as an effective approach for cancer therapy.Cancer detection and prevention, , Volume: 26, Issue:2, 2002
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).British journal of cancer, , Volume: 75, Issue:2, 1997
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Gangliosides and phospholipids in human thyroids responsive and unresponsive to thyrotropin.Journal of endocrinological investigation, , Volume: 13, Issue:10, 1990
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
GM3 Ganglioside Linked to Neurofibrillary Pathology in a Transgenic Rat Model for Tauopathy.International journal of molecular sciences, , Nov-22, Volume: 22, Issue:22, 2021
Age-dependent and regional heterogeneity in the long-chain base of A-series gangliosides observed in the rat brain using MALDI Imaging.Scientific reports, , 11-23, Volume: 7, Issue:1, 2017
Reduced motor and sensory functions and emotional response in GM3-only mice: emergence from early stage of life and exacerbation with aging.Behavioural brain research, , Mar-02, Volume: 198, Issue:1, 2009
Gangliosides determine the amyloid pathology of Alzheimer's disease.Neuroreport, , Aug-05, Volume: 20, Issue:12, 2009
Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B.Molecular genetics and metabolism, , Volume: 90, Issue:4, 2007
Ferret pyramidal cell dendritogenesis: changes in morphology and ganglioside expression during cortical development.The Journal of comparative neurology, , Oct-25, Volume: 413, Issue:3, 1999
Changes of the human liver GM3 ganglioside molecular species during aging.European journal of biochemistry, , Jan-15, Volume: 203, Issue:1-2, 1992
Glycosphingolipids of human myometrium and endometrium and their changes during the menstrual cycle, pregnancy and ageing.Journal of reproduction and fertility, , Volume: 88, Issue:1, 1990
Developmental changes of hematoside of rat small intestine. Postnatal hydroxylation of fatty acids and sialic acid.The Journal of biological chemistry, , Jan-10, Volume: 258, Issue:1, 1983
Sequential synthesis of ganglioside precursors and haematosides in chicken retina.Biochemical Society transactions, , Volume: 6, Issue:1, 1978
Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer's disease.Alzheimer's research & therapy, , 02-01, Volume: 14, Issue:1, 2022
Increased Expression of Simple Ganglioside Species GM2 and GM3 Detected by MALDI Imaging Mass Spectrometry in a Combined Rat Model of Aβ Toxicity and Stroke.PloS one, , Volume: 10, Issue:6, 2015
How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40).PloS one, , Feb-05, Volume: 5, Issue:2, 2010
Gangliosides determine the amyloid pathology of Alzheimer's disease.Neuroreport, , Aug-05, Volume: 20, Issue:12, 2009
Enhancing of GM3 synthase expression during differentiation of human blood monocytes into macrophages as in vitro model of GM3 accumulation in atherosclerotic lesion.Molecular and cellular biochemistry, , Volume: 330, Issue:1-2, 2009
Phenotype determination of anti-GM3 positive cells in atherosclerotic lesions of the human aorta. Hypothetical role of ganglioside GM3 in foam cell formation.Biochimica et biophysica acta, , Feb-14, Volume: 1535, Issue:2, 2001
Atherosclerotic aortic gangliosides enhance integrin-mediated platelet adhesion to collagen.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 19, Issue:3, 1999
Phenotype determination of anti-GM3 positive cells in atherosclerotic lesions of the human aorta. Hypothetical role of ganglioside GM3 in foam cell formation.Biochimica et biophysica acta, , Feb-14, Volume: 1535, Issue:2, 2001
Atherosclerotic aortic gangliosides enhance integrin-mediated platelet adhesion to collagen.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 19, Issue:3, 1999
Autoantibodies to gangliosides in sera of atherosclerotic patients.Clinica chimica acta; international journal of clinical chemistry, , Apr-27, Volume: 272, Issue:2, 1998
Incorporation and localisation of ganglioside GM3 in human intimal atherosclerotic lesions.Biochimica et biophysica acta, , Oct-24, Volume: 1361, Issue:3, 1997
Effects of exogenous gangliosides on intracellular Ca2+ mobilization and functional responses in human platelets.Glycobiology, , Volume: 6, Issue:3, 1996
[Autoantibodies to ganglioside GM3 and serotonin in blood serum in atherosclerosis].Biokhimiia (Moscow, Russia), , Volume: 60, Issue:5, 1995
TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify.The Journal of clinical investigation, , Volume: 93, Issue:5, 1994
Ganglioside content and composition of cells from normal and atherosclerotic human aorta.Atherosclerosis, , Volume: 78, Issue:1, 1989
Sialylated lactosylceramides. Possible inducers of non-specific immunosuppression and atherosclerotic lesions.European journal of biochemistry, , Feb-15, Volume: 172, Issue:1, 1988
Structural characterization of gangliosides from normal and atherosclerotic human thoracic aortas.Advances in experimental medicine and biology, , Volume: 82, 1977
Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.Cancer, , Dec-01, Volume: 74, Issue:11, 1994
The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.Journal of immunology (Baltimore, Md. : 1950), , Feb-01, Volume: 142, Issue:3, 1989
Ganglioside content and composition in human gliomas.Acta neurochirurgica. Supplementum, , Volume: 43, 1988
Serum gangliosides in cerebral astrocytoma.Annals of neurology, , Volume: 8, Issue:5, 1980
Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model.Urology, , Volume: 81, Issue:1, 2013
Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway.Proceedings of the National Academy of Sciences of the United States of America, , Feb-12, Volume: 105, Issue:6, 2008
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.The Journal of biological chemistry, , Oct-21, Volume: 280, Issue:42, 2005
Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer.Cancer research, , Jul-01, Volume: 62, Issue:13, 2002
Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells.International journal of oncology, , Volume: 19, Issue:4, 2001
Glycolipid composition in bladder tumor: a crucial role of GM3 ganglioside in tumor invasion.International journal of cancer, , Nov-01, Volume: 94, Issue:3, 2001
Sialic acid and GM3 ganglioside expression in papillomavirus-associated urinary bladder tumours of cattle with chronic enzootic haematuria.Journal of comparative pathology, , Volume: 137, Issue:2-3
GM2-GM3 gangliosides ratio is dependent on GRP94 through down-regulation of GM2-AP cofactor in brain metastasis cells.Scientific reports, , 10-02, Volume: 9, Issue:1, 2019
Ganglioside GM3 inhibits proliferation and invasion of glioma.Journal of neuro-oncology, , Volume: 71, Issue:2, 2005
GM3 as a novel growth regulator for human gliomas.Experimental neurology, , Volume: 168, Issue:2, 2001
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors.Journal of lipid research, , Volume: 39, Issue:11, 1998
Influence of ganglioside GM3 and high density lipoprotein on the cohesion of mouse brain tumor cells.Journal of lipid research, , Volume: 38, Issue:1, 1997
Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.Cancer, , Dec-01, Volume: 74, Issue:11, 1994
Serum gangliosides in cerebral astrocytoma.Annals of neurology, , Volume: 8, Issue:5, 1980
[Study of a correlation between glycolipids and tumorigenesis in 6 cell lines derived from human brain tumors].Comptes rendus des seances de l'Academie des sciences. Serie D, Sciences naturelles, , Mar-05, Volume: 288, Issue:9, 1979
T7 phage display reveals NOLC1 as a GM3 binding partner in human breast cancer MCF-7 cells.Archives of biochemistry and biophysics, , Volume: 750, 2023
Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.Glycoconjugate journal, , Volume: 36, Issue:5, 2019
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 40, Issue:8, 2017
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.Immunobiology, , Volume: 216, Issue:12, 2011
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc.Breast cancer research and treatment, , Volume: 96, Issue:2, 2006
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-15, Volume: 21, Issue:6, 2003
Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides.Clinical immunology (Orlando, Fla.), , Volume: 107, Issue:2, 2003
Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer.The Kurume medical journal, , Volume: 49, Issue:1-2, 2002
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.Hybridoma, , Volume: 17, Issue:6, 1998
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside.Human antibodies and hybridomas, , Volume: 6, Issue:3, 1995
[Ganglioside lactones in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 58, Issue:10, 1993
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
[Gangliosides GM3 and GD3 in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 56, Issue:3, 1991
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
GM2-GM3 gangliosides ratio is dependent on GRP94 through down-regulation of GM2-AP cofactor in brain metastasis cells.Scientific reports, , 10-02, Volume: 9, Issue:1, 2019
Inhibition of EGF-mediated receptor activity and cell proliferation by HK1-ceramide, a stable analog of the ganglioside GM3-lactone.Glycobiology, , Volume: 12, Issue:8, 2002
Gangliosides and phospholipids in human thyroids responsive and unresponsive to thyrotropin.Journal of endocrinological investigation, , Volume: 13, Issue:10, 1990
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.Expert review of vaccines, , Volume: 14, Issue:1, 2015
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody.Cancer science, , Volume: 104, Issue:1, 2013
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.Glycoconjugate journal, , Volume: 27, Issue:5, 2010
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.BMC cancer, , Jun-11, Volume: 9, 2009
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer science, , Volume: 98, Issue:10, 2007
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).British journal of cancer, , Volume: 75, Issue:2, 1997
Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of beta 1,4GalNAc transferase.FEBS letters, , Jun-04, Volume: 567, Issue:2-3, 2004
Inverse relationship of expression between GM3 and globo-series ganglioside in human renal cell carcinoma.The Tohoku journal of experimental medicine, , Volume: 190, Issue:4, 2000
Suppression of epidermal growth factor receptor signaling by protein kinase C-alpha activation requires CD82, caveolin-1, and ganglioside.Cancer research, , Oct-15, Volume: 67, Issue:20, 2007
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.The Journal of investigative dermatology, , Volume: 126, Issue:12, 2006
Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.The Journal of investigative dermatology, , Volume: 124, Issue:4, 2005
Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431.Experimental cell research, , Apr-10, Volume: 256, Issue:1, 2000
The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells.Oncogene, , Jul-15, Volume: 18, Issue:28, 1999
GM3 directly inhibits tyrosine phosphorylation and de-N-acetyl-GM3 directly enhances serine phosphorylation of epidermal growth factor receptor, independently of receptor-receptor interaction.The Journal of biological chemistry, , Jan-21, Volume: 269, Issue:3, 1994
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.Japanese journal of clinical oncology, , Volume: 22, Issue:5, 1992
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 and lyso-GM3 in tyrosine phosphorylation of the epidermal growth factor receptor.The Journal of biological chemistry, , Aug-05, Volume: 263, Issue:22, 1988
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor.The Journal of biological chemistry, , Feb-15, Volume: 261, Issue:5, 1986
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Gangliosides and CD82 inhibit the motility of colon cancer by downregulating the phosphorylation of EGFR at different tyrosine sites and signaling pathways.Molecular medicine reports, , Volume: 22, Issue:5, 2020
The AP-2alpha transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene.Glycobiology, , Volume: 18, Issue:5, 2008
Glycosylation defining cancer malignancy: new wine in an old bottle.Proceedings of the National Academy of Sciences of the United States of America, , Aug-06, Volume: 99, Issue:16, 2002
Glycotherapy for cancer: remodeling of ganglioside pattern as an effective approach for cancer therapy.Cancer detection and prevention, , Volume: 26, Issue:2, 2002
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.International journal of cancer, , Jan-10, Volume: 97, Issue:2, 2002
GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy.Biochemistry, , May-29, Volume: 40, Issue:21, 2001
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Detection of 4-O-acetyl-N-glycolylneuraminyl lactosylceramide as one of tumor-associated antigens in human colon cancer tissues by specific antibody.Molecular immunology, , Volume: 23, Issue:6, 1986
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
Sensorimotor demyelinating neuropathy with IgM antibody against gangliosides GD1a, GT1b and GM3.Journal of the neurological sciences, , Jul-15, Volume: 188, Issue:1-2, 2001
A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice.Experimental neurology, , Volume: 166, Issue:2, 2000
Glycosphingolipid antigens in cultured bovine brain microvascular endothelial cells: sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy [corrected].The Journal of cell biology, , Volume: 126, Issue:1, 1994
Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: Implications of glycosphingolipid metabolism in pathophysiology of diabetes.Journal of diabetes, , Volume: 10, Issue:2, 2018
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy?Diabetes, , Volume: 54, Issue:1, 2005
Assay Development and Screening for the Identification of Ganglioside GM3 Synthase Inhibitors.Biochemistry, , 03-31, Volume: 59, Issue:12, 2020
Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: Implications of glycosphingolipid metabolism in pathophysiology of diabetes.Journal of diabetes, , Volume: 10, Issue:2, 2018
Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice.Molecular pain, , Volume: 12, 2016
siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Proceedings of the National Academy of Sciences of the United States of America, , May-05, Volume: 112, Issue:18, 2015
Ganglioside GM3 depletion reverses impaired wound healing in diabetic mice by activating IGF-1 and insulin receptors.The Journal of investigative dermatology, , Volume: 134, Issue:5, 2014
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
Physiopathological function of hematoside (GM3 ganglioside).Proceedings of the Japan Academy. Series B, Physical and biological sciences, , Volume: 87, Issue:4, 2011
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.Handbook of experimental pharmacology, , Issue:203, 2011
Obesity causes a shift in metabolic flow of gangliosides in adipose tissues.Biochemical and biophysical research communications, , Feb-06, Volume: 379, Issue:2, 2009
[Regulation of insulin receptor function in microdomains].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 53, Issue:12 Suppl, 2008
[Insulin resistance in type 2 diabetes as a microdomain syndrome].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 48, Issue:8 Suppl, 2003
Expressional changes of ganglioside GM3 during ovarian maturation and early embryonic development in db/db mice.Development, growth & differentiation, , Volume: 45, Issue:1, 2003
Autoimmune markers and neurological complications in non-insulin-dependent diabetes mellitus.Human immunology, , Volume: 60, Issue:9, 1999
Glycosphingolipids and insulin resistance.Progress in lipid research, , Volume: 48, Issue:3-4
The missing link - likely pathogenetic role of GM3 and other gangliosides in the development of diabetic nephropathy.Kidney & blood pressure research, , Volume: 40, Issue:3, 2015
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy?Diabetes, , Volume: 54, Issue:1, 2005
Decreases of ganglioside GM3 in streptozotocin-induced diabetic glomeruli of rats.Life sciences, , Mar-14, Volume: 72, Issue:17, 2003
Early growth and development impairments in patients with ganglioside GM3 synthase deficiency.Clinical genetics, , Volume: 89, Issue:5, 2016
Ganglioside GM3 is essential for the structural integrity and function of cochlear hair cells.Human molecular genetics, , May-15, Volume: 24, Issue:10, 2015
A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma.Analytical biochemistry, , Jun-15, Volume: 455, 2014
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.Nature genetics, , Volume: 36, Issue:11, 2004
Guillain-Barré syndrome complicated with hemolytic anemia in association with antiganglioside GM3 antibody.The American journal of medicine, , Apr-01, Volume: 110, Issue:5, 2001
Internalization of exogenous gangliosides in cultured skin fibroblasts for the diagnosis of mucolipidosis IV.Clinica chimica acta; international journal of clinical chemistry, , Jun-15, Volume: 157, Issue:2, 1986
Congenital ascites as a presenting sign of lysosomal storage disease.The Journal of pediatrics, , Volume: 104, Issue:2, 1984
[Factors of phenotypic polymorphism and genetic consultation in thesaurismoses (review)].Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), , Volume: 80, Issue:10, 1980
GM1-gangliosidosis: accumulation of ganglioside GM1 in cultured skin fibroblasts and correlation with clinical types.Human genetics, , Aug-31, Volume: 43, Issue:2, 1978
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.Blood cells, molecules & diseases, , Volume: 53, Issue:4, 2014
Common and uncommon pathogenic cascades in lysosomal storage diseases.The Journal of biological chemistry, , Jul-02, Volume: 285, Issue:27, 2010
Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.Clinica chimica acta; international journal of clinical chemistry, , Volume: 389, Issue:1-2, 2008
Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:3, 2008
Congenital ascites as a presenting sign of lysosomal storage disease.The Journal of pediatrics, , Volume: 104, Issue:2, 1984
GM3 as a novel growth regulator for human gliomas.Experimental neurology, , Volume: 168, Issue:2, 2001
Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.Cancer, , Dec-01, Volume: 74, Issue:11, 1994
Ganglioside content and composition in human gliomas.Acta neurochirurgica. Supplementum, , Volume: 43, 1988
Ganglioside GM3 inhibits proliferation and invasion of glioma.Journal of neuro-oncology, , Volume: 71, Issue:2, 2005
GM3 ganglioside inhibits endothelin-1-mediated signal transduction in C6 glioma cells.FEBS letters, , Oct-19, Volume: 507, Issue:1, 2001
GM3 as a novel growth regulator for human gliomas.Experimental neurology, , Volume: 168, Issue:2, 2001
Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice.Journal of neurochemistry, , Volume: 73, Issue:1, 1999
Cell density regulates crypticity of GM3 ganglioside on human glioma cells.Experimental cell research, , May-25, Volume: 233, Issue:1, 1997
Synthesis of a glioma-related ganglioside, O-Ac GM3 having 3-O-Ac ceramide and its substrate property toward hydrolases.Journal of lipid research, , Volume: 37, Issue:10, 1996
Novel modification of ceramide: rat glioma ganglioside GM3 having 3-O-acetylated sphingenine.FEBS letters, , Mar-20, Volume: 361, Issue:2-3, 1995
Nerve growth factor mediates monosialoganglioside-induced release of fibronectin and J1/tenascin from C6 glioma cells.Journal of neurochemistry, , Volume: 56, Issue:1, 1991
Coordinate regulation of ganglioside glycosyltransferases in differentiating NG108-15 neuroblastoma x glioma cells.Journal of neurochemistry, , Volume: 52, Issue:5, 1989
Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells.Biochimica et biophysica acta, , Dec-16, Volume: 963, Issue:3, 1988
[Effect of GM3 ganglioside on the adenyl and guanyl cyclase activity of cultured cells].Comptes rendus des seances de la Societe de biologie et de ses filiales, , Volume: 178, Issue:6, 1984
Cell-cycle dependence of a ganglioside glycosyltransferase activity and its inhibition by enkephalin in a neurotumor cell line.Journal of neurochemistry, , Volume: 42, Issue:4, 1984
Interaction between complement proteins C5b-7 and erythrocyte membrane sialic acid.The Journal of experimental medicine, , Oct-01, Volume: 184, Issue:4, 1996
N-Acetylneuraminyllactosylceramide, GM3-NeuAc, a new influenza A virus receptor which mediates the adsorption-fusion process of viral infection. Binding specificity of influenza virus A/Aichi/2/68 (H3N2) to membrane-associated GM3 with different molecularThe Journal of biological chemistry, , Feb-10, Volume: 260, Issue:3, 1985
Ganglioside GM3 exerts opposite effects on motility via epidermal growth factor receptor and hepatocyte growth factor receptor-mediated migration signaling.Molecular medicine reports, , Volume: 11, Issue:4, 2015
Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.Molecular and cellular biochemistry, , Volume: 382, Issue:1-2, 2013
Ganglioside GM3 inhibits hepatoma cell motility via down-regulating activity of EGFR and PI3K/AKT signaling pathway.Journal of cellular biochemistry, , Volume: 114, Issue:7, 2013
Accumulation of gangliosides with N-acetylneuraminosyl(alpha 2-6)lactosamine structure in primary human hepatoma.Cancer research, , Feb-15, Volume: 50, Issue:4, 1990
Gangliosides of liver tumors induced by N-2-fluorenylacetamide. I. Ganglioside alterations in liver tumorigenesis and normal development.Journal of the National Cancer Institute, , Volume: 60, Issue:6, 1978
[Homeostatic and Pathophysiological Regulation of Toll-like Receptor 4 Signaling by GM3 Ganglioside Molecular Species].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 142, Issue:3, 2022
Neuronally expressed a-series gangliosides are sufficient to prevent the lethal age-dependent phenotype in GM3-only expressing mice.Journal of neurochemistry, , Volume: 158, Issue:2, 2021
GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women.International journal of obesity (2005), , Volume: 40, Issue:4, 2016
Monosialic ganglioside GM3 specifically suppresses the monocyte adhesion to endothelial cells for inflammation.The international journal of biochemistry & cell biology, , Volume: 46, 2014
Sphingolipid-dependent protein kinases.Advances in pharmacology (San Diego, Calif.), , Volume: 36, 1996
Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor β signalling pathway.The Journal of general virology, , Volume: 100, Issue:4, 2019
Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus.Journal of autoimmunity, , Volume: 63, 2015
Binding kinetics of influenza viruses to sialic acid-containing carbohydrates.Glycoconjugate journal, , Volume: 24, Issue:9, 2007
Ganglioside GM3 prevents high fat diet-induced hepatosteatosis via attenuated insulin signaling pathway.PloS one, , Volume: 18, Issue:2, 2023
Homeostatic and pathogenic roles of the GM3 ganglioside.The FEBS journal, , Volume: 289, Issue:17, 2022
Ganglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptor-Rac1 Activation to Inhibit Keratinocyte Motility.The Journal of investigative dermatology, , Volume: 137, Issue:2, 2017
Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice.Molecular pain, , Volume: 12, 2016
GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women.International journal of obesity (2005), , Volume: 40, Issue:4, 2016
Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: Evidence and mechanisms.FEBS letters, , Oct-24, Volume: 589, Issue:21, 2015
GM3 and diabetes.Glycoconjugate journal, , Volume: 31, Issue:3, 2014
No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoid-induced insulin resistance in healthy men.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:3, 2013
Dissociation of the insulin receptor from caveolae during TNFα-induced insulin resistance and its recovery by D-PDMP.FEBS letters, , Jan-20, Volume: 586, Issue:2, 2012
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.Handbook of experimental pharmacology, , Issue:203, 2011
Membrane microdomains and insulin resistance.FEBS letters, , May-03, Volume: 584, Issue:9, 2010
Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:3, 2008
[Regulation of insulin receptor function in microdomains].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 53, Issue:12 Suppl, 2008
Insulin resistance as a membrane microdomain disorder.Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 127, Issue:4, 2007
Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance.Proceedings of the National Academy of Sciences of the United States of America, , Aug-21, Volume: 104, Issue:34, 2007
TNFalpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3.Glycobiology, , Volume: 15, Issue:1, 2005
Enhanced insulin sensitivity in mice lacking ganglioside GM3.Proceedings of the National Academy of Sciences of the United States of America, , Mar-18, Volume: 100, Issue:6, 2003
[Insulin resistance in type 2 diabetes as a microdomain syndrome].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 48, Issue:8 Suppl, 2003
Ganglioside GM3 participates in the pathological conditions of insulin resistance.The Journal of biological chemistry, , Feb-01, Volume: 277, Issue:5, 2002
[Ganglioside GM3-mediated modulation of insulin resistance in 3T3-L1 adipocytes].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 77, Issue:3, 2002
Glycosphingolipids and insulin resistance.Progress in lipid research, , Volume: 48, Issue:3-4
Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of beta 1,4GalNAc transferase.FEBS letters, , Jun-04, Volume: 567, Issue:2-3, 2004
Inverse relationship of expression between GM3 and globo-series ganglioside in human renal cell carcinoma.The Tohoku journal of experimental medicine, , Volume: 190, Issue:4, 2000
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, , Volume: 13, Issue:1
A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.Glycoconjugate journal, , Volume: 30, Issue:7, 2013
Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies.Cancer research, , Mar-15, Volume: 47, Issue:6, 1987
Alteration in glycosphingolipid pattern during phorbol-12-myristate-13-acetate-induced cell differentiation in human T-lymphoid leukemia cells.Cancer research, , Volume: 46, Issue:6, 1986
Characteristic incorporation of ganglioside GM3, which induces monocytic differentiation in human myelogenous leukemia HL-60 cells.Biochemical and biophysical research communications, , Jun-15, Volume: 161, Issue:2, 1989
Ganglioside GM3 as a modulator of differentiation of mouse myeloid leukemia cells (M1-T22).Cell structure and function, , Volume: 13, Issue:2, 1988
Ganglioside GM3: an acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monocytoid leukemic cell lines HL-60 and U937.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 83, Issue:3, 1986
Differentiation-associated ganglioside changes in chronic myelogenous leukemia cells.Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society, , Volume: 48, Issue:6, 1985
Ceramides and glycosphingolipids in maturation process: leukemic cells as an experimental model.Blood cells, molecules & diseases, , Volume: 33, Issue:1
Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.Molecular and cellular biochemistry, , Volume: 382, Issue:1-2, 2013
Gangliosides in human uveal melanoma metastatic process.International journal of cancer, , Sep-27, Volume: 68, Issue:1, 1996
Accumulation of gangliosides with N-acetylneuraminosyl(alpha 2-6)lactosamine structure in primary human hepatoma.Cancer research, , Feb-15, Volume: 50, Issue:4, 1990
[Spectrum pattern and determination of ganglioside from human primary liver cancer of different origins].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 12, Issue:5, 1990
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
Gangliosides of liver tumors induced by N-2-fluorenylacetamide. I. Ganglioside alterations in liver tumorigenesis and normal development.Journal of the National Cancer Institute, , Volume: 60, Issue:6, 1978
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody.Cancer science, , Volume: 104, Issue:1, 2013
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
[Effects of GM3 on proliferation, apoptosis and VEGF expression in human lung adenocarcinoma cell line A549 cells].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 33, Issue:4, 2011
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.Glycoconjugate journal, , Volume: 27, Issue:5, 2010
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.BMC cancer, , Jun-11, Volume: 9, 2009
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.Cancer biology & therapy, , Volume: 6, Issue:2, 2007
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer science, , Volume: 98, Issue:10, 2007
Gangliosides enhance migration of mouse B16-melanoma cells through artificial basement membrane alone or in presence of laminin or fibronectin.Indian journal of experimental biology, , Volume: 43, Issue:12, 2005
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.International journal of cancer, , Jan-10, Volume: 97, Issue:2, 2002
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.International journal of cancer, , Nov-04, Volume: 73, Issue:3, 1997
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).British journal of cancer, , Volume: 75, Issue:2, 1997
Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.The Journal of dermatology, , Volume: 22, Issue:8, 1995
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line.Clinical & experimental metastasis, , Volume: 11, Issue:1, 1993
Glycosphingolipid expression on murine L1-fibrosarcoma cells: analysis of clonal in vivo and in vitro selected sublines with different lung colonisation potential.British journal of cancer, , Volume: 61, Issue:6, 1990
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.Anticancer research, , Volume: 18, Issue:4C
Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseases.Scientific reports, , 04-19, Volume: 9, Issue:1, 2019
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.Journal of immunology (Baltimore, Md. : 1950), , Jan-01, Volume: 186, Issue:1, 2011
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Cell density-dependent membrane distribution of ganglioside GM3 in melanoma cells.Cellular and molecular life sciences : CMLS, , May-30, Volume: 80, Issue:6, 2023
Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma.Biochimica et biophysica acta. General subjects, , Volume: 1864, Issue:12, 2020
Conjugation of a GM3 lactone mimetic on carbon nanotubes enhances the related inhibition of melanoma-associated metastatic events.Organic & biomolecular chemistry, , 08-22, Volume: 16, Issue:33, 2018
Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.Molecular cancer research : MCR, , Volume: 11, Issue:6, 2013
Multivalent presentation of a hydrolytically stable GM(3) lactone mimetic as modulator of melanoma cells motility and adhesion.Bioorganic & medicinal chemistry, , May-15, Volume: 21, Issue:10, 2013
NGcGM3/VSSP vaccine as treatment for melanoma patients.Human vaccines & immunotherapeutics, , Volume: 9, Issue:6, 2013
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.Oral diseases, , Volume: 18, Issue:8, 2012
Stable GM3 lactone mimetic raises antibodies specific for the antigens expressed on melanoma cells.Bioconjugate chemistry, , Aug-18, Volume: 21, Issue:8, 2010
Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells.Glycobiology, , Volume: 19, Issue:6, 2009
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.Cancer research, , Nov-15, Volume: 69, Issue:22, 2009
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.Cancer biology & therapy, , Volume: 7, Issue:4, 2008
Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.Biochemical and biophysical research communications, , May-04, Volume: 356, Issue:2, 2007
Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 13, Issue:9, 2007
Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis.International immunology, , Volume: 18, Issue:6, 2006
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.Cancer immunology, immunotherapy : CII, , Volume: 53, Issue:2, 2004
Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis.Journal of immunology (Baltimore, Md. : 1950), , Apr-01, Volume: 170, Issue:7, 2003
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
In vitro transformation of human congenital naevus to malignant melanoma.Melanoma research, , Volume: 12, Issue:1, 2002
An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.Journal of immunology (Baltimore, Md. : 1950), , Mar-01, Volume: 168, Issue:5, 2002
Characterization of the acid stability of glycosidically linked neuraminic acid: use in detecting de-N-acetyl-gangliosides in human melanoma.The Journal of biological chemistry, , May-17, Volume: 277, Issue:20, 2002
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
Studies on the specificity and sensitivity of the influenza C virus binding assay for 9-O-acetylated sialic acids and its application to human melanomas.Journal of biochemistry, , Volume: 127, Issue:6, 2000
Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins.The journal of investigative dermatology. Symposium proceedings, , Volume: 4, Issue:2, 1999
Lack of the induction of anti-ganglioside GM3 antibody in the patients with malignant melanoma in Japanese.Pigment cell research, , Volume: 11, Issue:4, 1998
Glycosylation of lactosylceramide analogs in animal cells: amphipathic disaccharide primers for glycosphingolipid synthesis.Biochemical and biophysical research communications, , Dec-29, Volume: 241, Issue:3, 1997
Gangliosides in human uveal melanoma metastatic process.International journal of cancer, , Sep-27, Volume: 68, Issue:1, 1996
Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.The Journal of dermatology, , Volume: 22, Issue:8, 1995
Expression of de-N-acetyl-gangliosides in human melanoma cells is induced by genistein or nocodazole.The Journal of biological chemistry, , Feb-17, Volume: 270, Issue:7, 1995
Optimal conditions to radiolabel (3H or 14C) aminosugar-containing glycosphingolipids by de-N-acetylation and re-N-acetylation.Biochimica et biophysica acta, , Jun-09, Volume: 1244, Issue:2-3, 1995
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside.Human antibodies and hybridomas, , Volume: 6, Issue:3, 1995
Conversion of short-chain ceramides to short-chain ceramide GM3 in B16 melanoma cells.FEBS letters, , Oct-30, Volume: 374, Issue:2, 1995
Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer alpha 2-3 sialyltransferase (GM3 synthase).FEBS letters, , Apr-03, Volume: 362, Issue:2, 1995
Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3 synthase).The Journal of biological chemistry, , Jun-03, Volume: 269, Issue:22, 1994
Both VH and VL regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM3.Cell biophysics, , Volume: 24-25, 1994
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Alpha- and beta-xylosides alter glycolipid synthesis in human melanoma and Chinese hamster ovary cells.The Journal of biological chemistry, , Jan-25, Volume: 268, Issue:3, 1993
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.Japanese journal of clinical oncology, , Volume: 22, Issue:5, 1992
Ganglioside GM3:GD3 ratio as an index for the management of melanoma.Cancer, , Jun-15, Volume: 67, Issue:12, 1991
Induction of mouse anti-melanoma cytotoxic and suppressor T cells in vitro by an artificial antigen, GM3-lactone.Japanese journal of cancer research : Gann, , Volume: 81, Issue:4, 1990
[Induction of anti-melanoma CTL by GM3 (NeuGc)-liposomes].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 48, Issue:2, 1990
Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3.Journal of the National Cancer Institute, , Nov-21, Volume: 82, Issue:22, 1990
Monoclonal antibody MACG1 distinguishes between different molecular species of the ganglioside GM3.Hybridoma, , Volume: 8, Issue:2, 1989
Involvement of the acyl chain of ceramide in carbohydrate recognition by an anti-glycolipid monoclonal antibody: the case of an anti-melanoma antibody, M2590, to GM3-ganglioside.Glycoconjugate journal, , Volume: 6, Issue:4, 1989
[GM3 ganglioside as melanoma specific antigen and its biological function].Human cell, , Volume: 2, Issue:1, 1989
The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.Journal of immunology (Baltimore, Md. : 1950), , Feb-01, Volume: 142, Issue:3, 1989
Ganglioside GD3 shedding by human malignant melanoma cells.International journal of cancer, , Jul-15, Volume: 44, Issue:1, 1989
Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.International journal of cancer, , Mar-15, Volume: 41, Issue:3, 1988
An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.Cancer research, , Oct-15, Volume: 48, Issue:20, 1988
A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth.The Journal of biological chemistry, , May-05, Volume: 263, Issue:13, 1988
Occurrence of tumor-associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas.Japanese journal of cancer research : Gann, , Volume: 78, Issue:6, 1987
Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 27, Issue:6, 1986
[Mouse monoclonal antibodies recognizing melanoma-associated ganglioside antigens].Seikagaku. The Journal of Japanese Biochemical Society, , Volume: 57, Issue:10, 1985
Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.The Journal of biological chemistry, , Oct-25, Volume: 260, Issue:24, 1985
Gangliosides of normal and neoplastic human melanocytes.Biochemical and biophysical research communications, , Apr-30, Volume: 120, Issue:2, 1984
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 27, Issue:6
Glycation Interferes with the Expression of Sialyltransferases in Meningiomas.Cells, , 11-25, Volume: 10, Issue:12, 2021
Expression of the ganglioside GD3 in human meningiomas is associated with monosomy of chromosome 22.Journal of neurochemistry, , Volume: 55, Issue:6, 1990
Ganglioside composition in human meningiomas.Journal of neurochemistry, , Volume: 53, Issue:3, 1989
[Homeostatic and Pathophysiological Regulation of Toll-like Receptor 4 Signaling by GM3 Ganglioside Molecular Species].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 142, Issue:3, 2022
Biology of GM3 Ganglioside.Progress in molecular biology and translational science, , Volume: 156, 2018
Membrane microdomains and insulin resistance.FEBS letters, , May-03, Volume: 584, Issue:9, 2010
Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.Cells, , 04-08, Volume: 10, Issue:4, 2021
A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.Human gene therapy, , Volume: 27, Issue:5, 2016
Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.Experimental neurology, , Volume: 278, 2016
Repeated administrations of human umbilical cord blood cells improve disease outcomes in a mouse model of Sanfilippo syndrome type III B.Cell transplantation, , Volume: 23, Issue:12, 2014
Abnormal gangliosides are localized in lipid rafts in Sanfilippo (MPS3a) mouse brain.Neurochemical research, , Volume: 37, Issue:6, 2012
Blood-brain barrier impairment in an animal model of MPS III B.PloS one, , Mar-07, Volume: 6, Issue:3, 2011
Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B.Molecular genetics and metabolism, , Volume: 90, Issue:4, 2007
Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Nov-10, Volume: 24, Issue:45, 2004
[Factors of phenotypic polymorphism and genetic consultation in thesaurismoses (review)].Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), , Volume: 80, Issue:10, 1980
Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.Molecular genetics and metabolism, , Volume: 131, Issue:1-2
Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.The journal of gene medicine, , Volume: 16, Issue:11-12
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.Cancer immunology, immunotherapy : CII, , Volume: 55, Issue:4, 2006
Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin.Journal of biochemistry, , Volume: 116, Issue:1, 1994
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.BMC cancer, , Jun-10, Volume: 19, Issue:1, 2019
Conjugation of a GM3 lactone mimetic on carbon nanotubes enhances the related inhibition of melanoma-associated metastatic events.Organic & biomolecular chemistry, , 08-22, Volume: 16, Issue:33, 2018
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.Molecular cancer research : MCR, , Volume: 11, Issue:6, 2013
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.The Journal of biological chemistry, , Oct-21, Volume: 280, Issue:42, 2005
Studies on the specificity and sensitivity of the influenza C virus binding assay for 9-O-acetylated sialic acids and its application to human melanomas.Journal of biochemistry, , Volume: 127, Issue:6, 2000
Suppression by ganglioside GD1A of migration capability, adhesion to vitronectin and metastatic potential of highly metastatic FBJ-LL cells.International journal of cancer, , Nov-26, Volume: 83, Issue:5, 1999
Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation.Cancer research, , May-15, Volume: 59, Issue:10, 1999
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Gangliosides in human uveal melanoma metastatic process.International journal of cancer, , Sep-27, Volume: 68, Issue:1, 1996
Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer alpha 2-3 sialyltransferase (GM3 synthase).FEBS letters, , Apr-03, Volume: 362, Issue:2, 1995
Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line.Clinical & experimental metastasis, , Volume: 11, Issue:1, 1993
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
Design, synthesis and biological evaluation of new ganglioside GM3 analogues as potential agents for cancer therapy.European journal of medicinal chemistry, , Mar-01, Volume: 189, 2020
Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.Scientific reports, , 07-09, Volume: 9, Issue:1, 2019
Ganglioside GM3 and Its Role in Cancer.Current medicinal chemistry, , Volume: 26, Issue:16, 2019
Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.Glycoconjugate journal, , Volume: 36, Issue:5, 2019
Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture.Scientific reports, , Jul-18, Volume: 8, Issue:1, 2018
GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.Seminars in oncology, , Volume: 45, Issue:1-2, 2018
Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth.The Journal of biological chemistry, , Oct-07, Volume: 291, Issue:41, 2016
GM3 and cancer.Glycoconjugate journal, , Volume: 32, Issue:1-2, 2015
Synthesis and cytotoxicity assay of four ganglioside GM3 analogues.European journal of medicinal chemistry, , Mar-21, Volume: 75, 2014
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.European journal of immunology, , Volume: 43, Issue:3, 2013
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.Clinical and experimental immunology, , Volume: 167, Issue:2, 2012
Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse.ACS chemical biology, , Jan-20, Volume: 7, Issue:1, 2012
Gangliosides as regulators of cell membrane organization and functions.Advances in experimental medicine and biology, , Volume: 688, 2010
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
NGcGM3 ganglioside: a privileged target for cancer vaccines.Clinical & developmental immunology, , Volume: 2010, 2010
Structural study of liposomes loaded with a GM3 lactone analogue for the targeting of tumor epitopes.Biochimica et biophysica acta, , Volume: 1788, Issue:12, 2009
Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity.Molecular cancer therapeutics, , Volume: 7, Issue:7, 2008
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.Cancer immunology, immunotherapy : CII, , Volume: 55, Issue:4, 2006
Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines.Cancer research, , Nov-15, Volume: 53, Issue:22, 1993
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Murine monoclonal anti-idiotype antibody (alpha) as a probe to detect human monoclonal antibody bound to human tumor tissues.Journal of immunological methods, , Nov-06, Volume: 134, Issue:1, 1990
Serum gangliosides in cerebral astrocytoma.Annals of neurology, , Volume: 8, Issue:5, 1980
Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.mAbs, , Volume: 3, Issue:6
Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression.Journal of pediatric surgery, , Volume: 40, Issue:1, 2005
Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B.Cell proliferation, , Volume: 35, Issue:2, 2002
Desialylation of extracellular GD1a-neoganglioprotein suggests cell surface orientation of the plasma membrane-bound ganglioside sialidase activity in human neuroblastoma cells.FEBS letters, , Mar-02, Volume: 491, Issue:3, 2001
Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides.Cancer research, , Nov-01, Volume: 58, Issue:21, 1998
Angiogenic and angiostatic microenvironment in tumors--role of gangliosides.Acta oncologica (Stockholm, Sweden), , Volume: 36, Issue:4, 1997
Gangliosides inhibit growth factor-stimulated neurite outgrowth in SH-SY5Y human neuroblastoma cells.Journal of neuroscience research, , Mar-15, Volume: 47, Issue:6, 1997
Prosaposin and prosaptide, a peptide from prosaposin, induce an increase in ganglioside content on NS20Y neuroblastoma cells.Glycoconjugate journal, , Volume: 13, Issue:2, 1996
Endogenous ganglioside GM1 modulates L-type calcium channel activity in N18 neuroblastoma cells.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Volume: 14, Issue:4, 1994
Accumulation of high level of pp60c-srcN is an early event during GM3-antibody mediated differentiation of neuro-2a neuroblastoma cells.Brain research, , Oct-22, Volume: 625, Issue:2, 1993
Alpha- and beta-xylosides alter glycolipid synthesis in human melanoma and Chinese hamster ovary cells.The Journal of biological chemistry, , Jan-25, Volume: 268, Issue:3, 1993
Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside.Brain research, , Jun-26, Volume: 583, Issue:1-2, 1992
Coordinate regulation of ganglioside glycosyltransferases in differentiating NG108-15 neuroblastoma x glioma cells.Journal of neurochemistry, , Volume: 52, Issue:5, 1989
Immunosuppressive activity of human neuroblastoma tumor gangliosides.International journal of cancer, , Jan-15, Volume: 43, Issue:1, 1989
Comparison of epi-GM3 with GM3 and GM1 as stimulators of neurite outgrowth.Brain research, , Mar-01, Volume: 467, Issue:1, 1988
Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma.Lancet (London, England), , Jan-19, Volume: 1, Issue:8421, 1985
Cell-cycle dependence of a ganglioside glycosyltransferase activity and its inhibition by enkephalin in a neurotumor cell line.Journal of neurochemistry, , Volume: 42, Issue:4, 1984
Ganglioside composition and biosynthesis in cultred cells derived from CNS.Journal of neurochemistry, , Volume: 28, Issue:6, 1977
Gangliosides of active and inactive neuroblastoma clones.Differentiation; research in biological diversity, , May-26, Volume: 8, Issue:1, 1977
Biosynthesis of glycosphingolipids in cultured mouse neuroblastoma cells. Precursor-product relationships among sialoglycosphingolipids.The Journal of biological chemistry, , Dec-10, Volume: 251, Issue:23, 1976
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
Inhibitory action of ganglioside GM3 on murine neuroblastoma cell proliferation: modulating effect of fetal calf serum.Anticancer research, , Volume: 15, Issue:3
Altered Expression of Ganglioside Metabolizing Enzymes Results in GM3 Ganglioside Accumulation in Cerebellar Cells of a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis.International journal of molecular sciences, , Feb-22, Volume: 19, Issue:2, 2018
Altered levels of α-synuclein and sphingolipids in Batten disease lymphoblast cells.Gene, , Apr-15, Volume: 539, Issue:2, 2014
[Homeostatic and Pathophysiological Regulation of Toll-like Receptor 4 Signaling by GM3 Ganglioside Molecular Species].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 142, Issue:3, 2022
Homeostatic and pathogenic roles of GM3 ganglioside molecular species in TLR4 signaling in obesity.The EMBO journal, , 06-17, Volume: 39, Issue:12, 2020
GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women.International journal of obesity (2005), , Volume: 40, Issue:4, 2016
Control of homeostatic and pathogenic balance in adipose tissue by ganglioside GM3.Glycobiology, , Volume: 25, Issue:3, 2015
Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: Evidence and mechanisms.FEBS letters, , Oct-24, Volume: 589, Issue:21, 2015
Ganglioside GM3 depletion reverses impaired wound healing in diabetic mice by activating IGF-1 and insulin receptors.The Journal of investigative dermatology, , Volume: 134, Issue:5, 2014
Obesity causes a shift in metabolic flow of gangliosides in adipose tissues.Biochemical and biophysical research communications, , Feb-06, Volume: 379, Issue:2, 2009
Glycosphingolipids and insulin resistance.Progress in lipid research, , Volume: 48, Issue:3-4
Depletion of Gangliosides Enhances Articular Cartilage Repair in Mice.Scientific reports, , 03-02, Volume: 7, 2017
Ganglioside GM3 has an essential role in the pathogenesis and progression of rheumatoid arthritis.PloS one, , Volume: 7, Issue:6, 2012
Gangliosides from normal and osteoarthritic joints.The Journal of rheumatology. Supplement, , Volume: 43, 1995
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.Frontiers in immunology, , Volume: 13, 2022
Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing β3Gn-T5 knockout mice.Scientific reports, , 02-07, Volume: 8, Issue:1, 2018
Inhibition of EGF-mediated receptor activity and cell proliferation by HK1-ceramide, a stable analog of the ganglioside GM3-lactone.Glycobiology, , Volume: 12, Issue:8, 2002
Ganglioside shedding and changes in ceramide biosynthesis in human ovarian tumors.Biochemistry. Biokhimiia, , Volume: 62, Issue:5, 1997
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor.The Journal of biological chemistry, , Feb-15, Volume: 261, Issue:5, 1986
Ganglioside GM3 stimulates lipid-protein co-assembly in α-synuclein amyloid formation.Biophysical chemistry, , Volume: 293, 2023
Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis.PloS one, , Volume: 12, Issue:2, 2017
Acceleration of α-synuclein aggregation by exosomes.The Journal of biological chemistry, , Jan-30, Volume: 290, Issue:5, 2015
Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.Journal of molecular biology, , Mar-19, Volume: 397, Issue:1, 2010
Transfer of gangliosides across the human placenta.Placenta, , Volume: 33, Issue:4, 2012
Epigenetic reduction in invariant NKT cells following in utero vitamin D deficiency in mice.Journal of immunology (Baltimore, Md. : 1950), , Feb-01, Volume: 186, Issue:3, 2011
Two active and differently N-glycosylated isoforms of human ST3Gal-V are produced from the placental mRNA variant by a leaky scanning mechanism.FEBS letters, , Apr-16, Volume: 584, Issue:8, 2010
Developmental patterns of mST3GalV mRNA expression in the mouse: in situ hybridization using DIG-labeled RNA probes.Archives of pharmacal research, , Volume: 23, Issue:5, 2000
Chronological changes in the ganglioside composition of human milk during lactation.Early human development, , Volume: 55, Issue:1, 1999
Developmental changes in carbohydrate antigens in embryonic rat lens.Glycobiology, , Volume: 7, Issue:5, 1997
Alteration of acidic lipids in human sera during the course of pregnancy: characteristic increase in the concentration of cholesterol sulfate.Journal of chromatography. B, Biomedical sciences and applications, , Dec-19, Volume: 704, Issue:1-2, 1997
Ganglioside composition of the rat choriocarcinoma cell line, Rcho-1.Glycoconjugate journal, , Volume: 13, Issue:3, 1996
Clinical significance of anti-GM3 antibodies in recurrent pregnancy loss with elevated level of antiphospholipid antibodies.American journal of reproductive immunology (New York, N.Y. : 1989), , Volume: 33, Issue:3, 1995
Gangliosides stimulate synthesis of prostaglandin E2 and prostacyclin in fetal rat brain hemispheres after episodes of global intrauterine ischemia.Journal of neuroscience research, , Nov-01, Volume: 36, Issue:4, 1993
Glycosphingolipids of human myometrium and endometrium and their changes during the menstrual cycle, pregnancy and ageing.Journal of reproduction and fertility, , Volume: 88, Issue:1, 1990
Glycosphingolipid patterns of fetal and adult small intestinal mucosa in the sheep.Biochimica et biophysica acta, , Feb-12, Volume: 875, Issue:2, 1986
Congenital ascites as a presenting sign of lysosomal storage disease.The Journal of pediatrics, , Volume: 104, Issue:2, 1984
GM3 and GD3 are the major gangliosides of rat fetal intestine.Biochimica et biophysica acta, , Nov-12, Volume: 713, Issue:2, 1982
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Effect of pregnancy and lactation on glycosyltransferase activities of rat mammary gland.The International journal of biochemistry, , Volume: 10, Issue:2, 1979
A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma.Analytical biochemistry, , Jun-15, Volume: 455, 2014
Fluorescence-monitored zero dead-volume nanoLC-microESI-QIT-TOF MS for analysis of fluorescently tagged glycosphingolipids.The Analyst, , Mar-07, Volume: 136, Issue:5, 2011
A liquid chromatography/tandem mass spectrometric approach for the determination of gangliosides GD3 and GM3 in bovine milk and infant formulae.Rapid communications in mass spectrometry : RCM, , Volume: 20, Issue:24, 2006
Studies on the specificity and sensitivity of the influenza C virus binding assay for 9-O-acetylated sialic acids and its application to human melanomas.Journal of biochemistry, , Volume: 127, Issue:6, 2000
Murine monoclonal anti-idiotype antibody (alpha) as a probe to detect human monoclonal antibody bound to human tumor tissues.Journal of immunological methods, , Nov-06, Volume: 134, Issue:1, 1990
Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma.Biochimica et biophysica acta. General subjects, , Volume: 1864, Issue:12, 2020
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.Cancer research, , Nov-15, Volume: 69, Issue:22, 2009
Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 13, Issue:9, 2007
Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.Biochemical and biophysical research communications, , May-04, Volume: 356, Issue:2, 2007
Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.The Journal of investigative dermatology, , Volume: 124, Issue:4, 2005
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.Cancer immunology, immunotherapy : CII, , Volume: 53, Issue:2, 2004
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins.The journal of investigative dermatology. Symposium proceedings, , Volume: 4, Issue:2, 1999
Ganglioside profiles of experimental melanomas and of their melanosomal fractions.Melanoma research, , Volume: 5, Issue:2, 1995
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.Japanese journal of clinical oncology, , Volume: 22, Issue:5, 1992
Alteration in keratinocyte ganglioside content in basal cell carcinomas.The Journal of investigative dermatology, , Volume: 98, Issue:2, 1992
Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells.Journal of cellular physiology, , Volume: 141, Issue:3, 1989
Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.International journal of cancer, , Mar-15, Volume: 41, Issue:3, 1988
GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy.Biochemistry, , May-29, Volume: 40, Issue:21, 2001
[Ganglioside lactones in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 58, Issue:10, 1993
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
[Gangliosides GM3 and GD3 in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 56, Issue:3, 1991
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.Nature genetics, , Volume: 36, Issue:11, 2004
[Insulin resistance in type 2 diabetes as a microdomain syndrome].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 48, Issue:8 Suppl, 2003
Polyphenol from millet bran increases the sensitivity of colorectal cancer cells to oxaliplatin by blocking the ganglioside GM3 catabolism.Food & function, , Jan-07, Volume: 12, Issue:1, 2021
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.Glycobiology, , Volume: 16, Issue:7, 2006
Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.Oncology research, , Volume: 11, Issue:1, 1999
Ganglioside GM3 as a modulator of differentiation of mouse myeloid leukemia cells (M1-T22).Cell structure and function, , Volume: 13, Issue:2, 1988
Activation of CMP-N-acetylneuraminic acid:lactosylceramide sialyltransferase during the differentiation of HL-60 cells induced by 12-O-tetradecanoylphorbol-13-acetate.The Journal of biological chemistry, , Dec-05, Volume: 261, Issue:34, 1986
Ganglioside GM3: an acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monocytoid leukemic cell lines HL-60 and U937.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 83, Issue:3, 1986
The differentiation of HL-60 cells in the synthetic medium induced by GM3 ganglioside.Bioscience reports, , Volume: 5, Issue:6, 1985
An acidic glycosphingolipid, monosialo-ganglioside GM3, is a potent physiological inducer for monocytic differentiation of human promyelocytic leukemia cell line HL-60 cells.Biochemical and biophysical research communications, , Oct-15, Volume: 132, Issue:1, 1985
Glycosphingolipid patterns in human promyelocytic HL-60 leukemia cells susceptible or resistant to differentiation induction by phorbol 12-myristate 13-acetate.Biochimica et biophysica acta, , Mar-10, Volume: 1176, Issue:1-2, 1993
Differential effects of long-chain (sphingoid) bases on the monocytic differentiation of human leukemia (HL-60) cells induced by phorbol esters, 1 alpha, 25-dihydroxyvitamin D3, or ganglioside GM3.Cancer research, , Jun-15, Volume: 49, Issue:12, 1989
Effect of a cell differentiation inducer, ganglioside GM3, on the neutral glycosphingolipid composition and cell membrane fluidity of a human promyelocytic leukemia cell line HL-60.In vivo (Athens, Greece), , Volume: 4, Issue:3
Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169.PLoS pathogens, , Volume: 9, Issue:4, 2013
HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection.Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, , Nov-01, Volume: 19, Issue:3, 1998
Overexpression of monosialoganglioside GM3 on lymphocyte plasma membrane in patients with HIV infection.Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, , Jun-01, Volume: 12, Issue:2, 1996
Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion.Glycoconjugate journal, , Volume: 17, Issue:3 -4
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.Cancer biology & therapy, , Volume: 6, Issue:2, 2007
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.Anticancer research, , Volume: 18, Issue:4C
Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.Experimental neurology, , Volume: 278, 2016
A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma.Analytical biochemistry, , Jun-15, Volume: 455, 2014
Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis.Journal of neuropathology and experimental neurology, , Volume: 66, Issue:8, 2007
[Guillain-Barré syndrome with refractory optic neuropathy].Rinsho shinkeigaku = Clinical neurology, , Oct-26, Volume: 59, Issue:10, 2019
Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with predominant bulbar palsy and anti-GM3 IgG antibodies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 39, Issue:7, 2018
Guillain-Barré syndrome complicated with hemolytic anemia in association with antiganglioside GM3 antibody.The American journal of medicine, , Apr-01, Volume: 110, Issue:5, 2001
Identification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic Syndrome.PloS one, , Volume: 10, Issue:6, 2015
GM3 and diabetes.Glycoconjugate journal, , Volume: 31, Issue:3, 2014
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.Handbook of experimental pharmacology, , Issue:203, 2011
Enhanced Anti-Atherosclerotic Efficacy of pH-Responsively Releasable Ganglioside GM3 Delivered by Reconstituted High-Density Lipoprotein.International journal of molecular sciences, , Dec-20, Volume: 22, Issue:24, 2021
Exogenous GM3 ganglioside inhibits atherosclerosis via multiple steps: A potential atheroprotective drug.Pharmacological research, , Volume: 148, 2019
Enhancing of GM3 synthase expression during differentiation of human blood monocytes into macrophages as in vitro model of GM3 accumulation in atherosclerotic lesion.Molecular and cellular biochemistry, , Volume: 330, Issue:1-2, 2009
[Activation of ganglioside GM3 biosynthesis in human blood mononuclear cells in atherosclerosis].Biomeditsinskaia khimiia, , Volume: 59, Issue:4
Diversity of glycosphingolipid GM2 and cholesterol accumulation in NPC1 patient-specific iPSC-derived neurons.Brain research, , 02-15, Volume: 1657, 2017
Inhibition of GM3 synthase attenuates neuropathology of Niemann-Pick disease Type C. by affecting sphingolipid metabolism.Molecules and cells, , Volume: 37, Issue:2, 2014
Morphological alterations of the cornea in the mouse model of niemann-pick disease type c1.Cornea, , Volume: 30, Issue:7, 2011
GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice.Journal of lipid research, , Volume: 49, Issue:8, 2008
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.Cancer biology & therapy, , Volume: 6, Issue:2, 2007
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.Anticancer research, , Volume: 18, Issue:4C
Early growth and development impairments in patients with ganglioside GM3 synthase deficiency.Clinical genetics, , Volume: 89, Issue:5, 2016
Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis.Proceedings of the National Academy of Sciences of the United States of America, , Jun-30, Volume: 112, Issue:26, 2015
Ganglioside GM3 has an essential role in the pathogenesis and progression of rheumatoid arthritis.PloS one, , Volume: 7, Issue:6, 2012
Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis.Journal of neuropathology and experimental neurology, , Volume: 66, Issue:8, 2007
Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells.Cancer biology & therapy, , Volume: 6, Issue:6, 2007
Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.International journal of cancer, , Jan-05, Volume: 75, Issue:1, 1998
Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis.Annals of neurology, , Volume: 44, Issue:6, 1998
Angiogenic and angiostatic microenvironment in tumors--role of gangliosides.Acta oncologica (Stockholm, Sweden), , Volume: 36, Issue:4, 1997
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells.Glycobiology, , Volume: 16, Issue:7, 2006
Glycosphingolipid deficiency affects functional microdomain formation in Lewis lung carcinoma cells.Glycoconjugate journal, , Volume: 17, Issue:3 -4
Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.Experimental neurology, , Volume: 278, 2016
A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma.Analytical biochemistry, , Jun-15, Volume: 455, 2014
Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis.Journal of neuropathology and experimental neurology, , Volume: 66, Issue:8, 2007
[Guillain-Barré syndrome with refractory optic neuropathy].Rinsho shinkeigaku = Clinical neurology, , Oct-26, Volume: 59, Issue:10, 2019
Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with predominant bulbar palsy and anti-GM3 IgG antibodies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 39, Issue:7, 2018
Guillain-Barré syndrome complicated with hemolytic anemia in association with antiganglioside GM3 antibody.The American journal of medicine, , Apr-01, Volume: 110, Issue:5, 2001
Identification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic Syndrome.PloS one, , Volume: 10, Issue:6, 2015
GM3 and diabetes.Glycoconjugate journal, , Volume: 31, Issue:3, 2014
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.Handbook of experimental pharmacology, , Issue:203, 2011
Enhanced Anti-Atherosclerotic Efficacy of pH-Responsively Releasable Ganglioside GM3 Delivered by Reconstituted High-Density Lipoprotein.International journal of molecular sciences, , Dec-20, Volume: 22, Issue:24, 2021
Exogenous GM3 ganglioside inhibits atherosclerosis via multiple steps: A potential atheroprotective drug.Pharmacological research, , Volume: 148, 2019
Enhancing of GM3 synthase expression during differentiation of human blood monocytes into macrophages as in vitro model of GM3 accumulation in atherosclerotic lesion.Molecular and cellular biochemistry, , Volume: 330, Issue:1-2, 2009
[Activation of ganglioside GM3 biosynthesis in human blood mononuclear cells in atherosclerosis].Biomeditsinskaia khimiia, , Volume: 59, Issue:4
Diversity of glycosphingolipid GM2 and cholesterol accumulation in NPC1 patient-specific iPSC-derived neurons.Brain research, , 02-15, Volume: 1657, 2017
Inhibition of GM3 synthase attenuates neuropathology of Niemann-Pick disease Type C. by affecting sphingolipid metabolism.Molecules and cells, , Volume: 37, Issue:2, 2014
Morphological alterations of the cornea in the mouse model of niemann-pick disease type c1.Cornea, , Volume: 30, Issue:7, 2011
GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice.Journal of lipid research, , Volume: 49, Issue:8, 2008
Comparison and Possible Binding Orientations of SARS-CoV-2 Spike N-Terminal Domain for Gangliosides GM3 and GM1.The journal of physical chemistry. B, , 08-10, Volume: 127, Issue:31, 2023
Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis.Cell metabolism, , 08-04, Volume: 32, Issue:2, 2020
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.Immunobiology, , Volume: 216, Issue:12, 2011
[Effects of GM3 on proliferation, apoptosis and VEGF expression in human lung adenocarcinoma cell line A549 cells].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 33, Issue:4, 2011
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer science, , Volume: 98, Issue:10, 2007
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.International journal of cancer, , Jan-10, Volume: 97, Issue:2, 2002
Glycosylation defining cancer malignancy: new wine in an old bottle.Proceedings of the National Academy of Sciences of the United States of America, , Aug-06, Volume: 99, Issue:16, 2002
Glycotherapy for cancer: remodeling of ganglioside pattern as an effective approach for cancer therapy.Cancer detection and prevention, , Volume: 26, Issue:2, 2002
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).British journal of cancer, , Volume: 75, Issue:2, 1997
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Gangliosides and phospholipids in human thyroids responsive and unresponsive to thyrotropin.Journal of endocrinological investigation, , Volume: 13, Issue:10, 1990
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer's disease.Alzheimer's research & therapy, , 02-01, Volume: 14, Issue:1, 2022
Increased Expression of Simple Ganglioside Species GM2 and GM3 Detected by MALDI Imaging Mass Spectrometry in a Combined Rat Model of Aβ Toxicity and Stroke.PloS one, , Volume: 10, Issue:6, 2015
How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40).PloS one, , Feb-05, Volume: 5, Issue:2, 2010
Gangliosides determine the amyloid pathology of Alzheimer's disease.Neuroreport, , Aug-05, Volume: 20, Issue:12, 2009
Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.Cancer, , Dec-01, Volume: 74, Issue:11, 1994
The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.Journal of immunology (Baltimore, Md. : 1950), , Feb-01, Volume: 142, Issue:3, 1989
Ganglioside content and composition in human gliomas.Acta neurochirurgica. Supplementum, , Volume: 43, 1988
Serum gangliosides in cerebral astrocytoma.Annals of neurology, , Volume: 8, Issue:5, 1980
Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model.Urology, , Volume: 81, Issue:1, 2013
Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway.Proceedings of the National Academy of Sciences of the United States of America, , Feb-12, Volume: 105, Issue:6, 2008
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.The Journal of biological chemistry, , Oct-21, Volume: 280, Issue:42, 2005
Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer.Cancer research, , Jul-01, Volume: 62, Issue:13, 2002
Glycolipid composition in bladder tumor: a crucial role of GM3 ganglioside in tumor invasion.International journal of cancer, , Nov-01, Volume: 94, Issue:3, 2001
Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells.International journal of oncology, , Volume: 19, Issue:4, 2001
Sialic acid and GM3 ganglioside expression in papillomavirus-associated urinary bladder tumours of cattle with chronic enzootic haematuria.Journal of comparative pathology, , Volume: 137, Issue:2-3
Early growth and development impairments in patients with ganglioside GM3 synthase deficiency.Clinical genetics, , Volume: 89, Issue:5, 2016
Higher expression of renal sulfoglycolipids in marine mammals.Glycoconjugate journal, , Volume: 25, Issue:8, 2008
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
GM2-GM3 gangliosides ratio is dependent on GRP94 through down-regulation of GM2-AP cofactor in brain metastasis cells.Scientific reports, , 10-02, Volume: 9, Issue:1, 2019
Ganglioside GM3 inhibits proliferation and invasion of glioma.Journal of neuro-oncology, , Volume: 71, Issue:2, 2005
GM3 as a novel growth regulator for human gliomas.Experimental neurology, , Volume: 168, Issue:2, 2001
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors.Journal of lipid research, , Volume: 39, Issue:11, 1998
Influence of ganglioside GM3 and high density lipoprotein on the cohesion of mouse brain tumor cells.Journal of lipid research, , Volume: 38, Issue:1, 1997
Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.Cancer, , Dec-01, Volume: 74, Issue:11, 1994
Serum gangliosides in cerebral astrocytoma.Annals of neurology, , Volume: 8, Issue:5, 1980
[Study of a correlation between glycolipids and tumorigenesis in 6 cell lines derived from human brain tumors].Comptes rendus des seances de l'Academie des sciences. Serie D, Sciences naturelles, , Mar-05, Volume: 288, Issue:9, 1979
T7 phage display reveals NOLC1 as a GM3 binding partner in human breast cancer MCF-7 cells.Archives of biochemistry and biophysics, , Volume: 750, 2023
Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.Glycoconjugate journal, , Volume: 36, Issue:5, 2019
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 40, Issue:8, 2017
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.Immunobiology, , Volume: 216, Issue:12, 2011
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc.Breast cancer research and treatment, , Volume: 96, Issue:2, 2006
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-15, Volume: 21, Issue:6, 2003
Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides.Clinical immunology (Orlando, Fla.), , Volume: 107, Issue:2, 2003
Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer.The Kurume medical journal, , Volume: 49, Issue:1-2, 2002
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.Hybridoma, , Volume: 17, Issue:6, 1998
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside.Human antibodies and hybridomas, , Volume: 6, Issue:3, 1995
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
[Ganglioside lactones in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 58, Issue:10, 1993
[Gangliosides GM3 and GD3 in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 56, Issue:3, 1991
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
GM2-GM3 gangliosides ratio is dependent on GRP94 through down-regulation of GM2-AP cofactor in brain metastasis cells.Scientific reports, , 10-02, Volume: 9, Issue:1, 2019
Inhibition of EGF-mediated receptor activity and cell proliferation by HK1-ceramide, a stable analog of the ganglioside GM3-lactone.Glycobiology, , Volume: 12, Issue:8, 2002
Gangliosides and phospholipids in human thyroids responsive and unresponsive to thyrotropin.Journal of endocrinological investigation, , Volume: 13, Issue:10, 1990
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.Expert review of vaccines, , Volume: 14, Issue:1, 2015
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody.Cancer science, , Volume: 104, Issue:1, 2013
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.Glycoconjugate journal, , Volume: 27, Issue:5, 2010
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.BMC cancer, , Jun-11, Volume: 9, 2009
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer science, , Volume: 98, Issue:10, 2007
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).British journal of cancer, , Volume: 75, Issue:2, 1997
Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of beta 1,4GalNAc transferase.FEBS letters, , Jun-04, Volume: 567, Issue:2-3, 2004
Inverse relationship of expression between GM3 and globo-series ganglioside in human renal cell carcinoma.The Tohoku journal of experimental medicine, , Volume: 190, Issue:4, 2000
Suppression of epidermal growth factor receptor signaling by protein kinase C-alpha activation requires CD82, caveolin-1, and ganglioside.Cancer research, , Oct-15, Volume: 67, Issue:20, 2007
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.The Journal of investigative dermatology, , Volume: 126, Issue:12, 2006
Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.The Journal of investigative dermatology, , Volume: 124, Issue:4, 2005
Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431.Experimental cell research, , Apr-10, Volume: 256, Issue:1, 2000
The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells.Oncogene, , Jul-15, Volume: 18, Issue:28, 1999
GM3 directly inhibits tyrosine phosphorylation and de-N-acetyl-GM3 directly enhances serine phosphorylation of epidermal growth factor receptor, independently of receptor-receptor interaction.The Journal of biological chemistry, , Jan-21, Volume: 269, Issue:3, 1994
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.Japanese journal of clinical oncology, , Volume: 22, Issue:5, 1992
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 and lyso-GM3 in tyrosine phosphorylation of the epidermal growth factor receptor.The Journal of biological chemistry, , Aug-05, Volume: 263, Issue:22, 1988
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor.The Journal of biological chemistry, , Feb-15, Volume: 261, Issue:5, 1986
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.The Journal of biological chemistry, , Oct-21, Volume: 280, Issue:42, 2005
Glycosphingolipids govern gene expression.Glycoconjugate journal, , Volume: 20, Issue:3, 2004
[Biological significance of lactosylceramide branching and domain formation: glycosphingolipids govern gene expression].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 47, Issue:4 Suppl, 2002
GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy.Biochemistry, , May-29, Volume: 40, Issue:21, 2001
Change in the topographical distribution of GM3 during cell spreading and growth: immunostaining with monoclonal antibody against GM3.Cell structure and function, , Volume: 12, Issue:1, 1987
Ganglioside GM3: an acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monocytoid leukemic cell lines HL-60 and U937.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 83, Issue:3, 1986
Gangliosides and their cell density-dependent changes in control and chemically transformed C3H/10T1/2 cells.Experimental cell research, , Mar-15, Volume: 112, Issue:2, 1978
Selective inhibition of cell growth and associated changes in glycolipid metabolism induced by monovalent antibodies to glycolipids.Experimental cell research, , Volume: 108, Issue:2, 1977
Glycolipids of chick embryo fibroblasts infected with temperature-sensitive mutants of avian sarcoma viruses.Virology, , Volume: 76, Issue:2, 1977
Gangliosides and CD82 inhibit the motility of colon cancer by downregulating the phosphorylation of EGFR at different tyrosine sites and signaling pathways.Molecular medicine reports, , Volume: 22, Issue:5, 2020
The AP-2alpha transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene.Glycobiology, , Volume: 18, Issue:5, 2008
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.International journal of cancer, , Jan-10, Volume: 97, Issue:2, 2002
Glycosylation defining cancer malignancy: new wine in an old bottle.Proceedings of the National Academy of Sciences of the United States of America, , Aug-06, Volume: 99, Issue:16, 2002
Glycotherapy for cancer: remodeling of ganglioside pattern as an effective approach for cancer therapy.Cancer detection and prevention, , Volume: 26, Issue:2, 2002
GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy.Biochemistry, , May-29, Volume: 40, Issue:21, 2001
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Detection of 4-O-acetyl-N-glycolylneuraminyl lactosylceramide as one of tumor-associated antigens in human colon cancer tissues by specific antibody.Molecular immunology, , Volume: 23, Issue:6, 1986
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
Sensorimotor demyelinating neuropathy with IgM antibody against gangliosides GD1a, GT1b and GM3.Journal of the neurological sciences, , Jul-15, Volume: 188, Issue:1-2, 2001
A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice.Experimental neurology, , Volume: 166, Issue:2, 2000
Glycosphingolipid antigens in cultured bovine brain microvascular endothelial cells: sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy [corrected].The Journal of cell biology, , Volume: 126, Issue:1, 1994
Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: Implications of glycosphingolipid metabolism in pathophysiology of diabetes.Journal of diabetes, , Volume: 10, Issue:2, 2018
siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Proceedings of the National Academy of Sciences of the United States of America, , May-05, Volume: 112, Issue:18, 2015
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
Decreases of ganglioside GM3 in streptozotocin-induced diabetic glomeruli of rats.Life sciences, , Mar-14, Volume: 72, Issue:17, 2003
Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: Implications of glycosphingolipid metabolism in pathophysiology of diabetes.Journal of diabetes, , Volume: 10, Issue:2, 2018
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy?Diabetes, , Volume: 54, Issue:1, 2005
Assay Development and Screening for the Identification of Ganglioside GM3 Synthase Inhibitors.Biochemistry, , 03-31, Volume: 59, Issue:12, 2020
Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: Implications of glycosphingolipid metabolism in pathophysiology of diabetes.Journal of diabetes, , Volume: 10, Issue:2, 2018
Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice.Molecular pain, , Volume: 12, 2016
siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Proceedings of the National Academy of Sciences of the United States of America, , May-05, Volume: 112, Issue:18, 2015
Ganglioside GM3 depletion reverses impaired wound healing in diabetic mice by activating IGF-1 and insulin receptors.The Journal of investigative dermatology, , Volume: 134, Issue:5, 2014
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
Physiopathological function of hematoside (GM3 ganglioside).Proceedings of the Japan Academy. Series B, Physical and biological sciences, , Volume: 87, Issue:4, 2011
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.Handbook of experimental pharmacology, , Issue:203, 2011
Obesity causes a shift in metabolic flow of gangliosides in adipose tissues.Biochemical and biophysical research communications, , Feb-06, Volume: 379, Issue:2, 2009
[Regulation of insulin receptor function in microdomains].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 53, Issue:12 Suppl, 2008
[Insulin resistance in type 2 diabetes as a microdomain syndrome].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 48, Issue:8 Suppl, 2003
Expressional changes of ganglioside GM3 during ovarian maturation and early embryonic development in db/db mice.Development, growth & differentiation, , Volume: 45, Issue:1, 2003
Autoimmune markers and neurological complications in non-insulin-dependent diabetes mellitus.Human immunology, , Volume: 60, Issue:9, 1999
Glycosphingolipids and insulin resistance.Progress in lipid research, , Volume: 48, Issue:3-4
The missing link - likely pathogenetic role of GM3 and other gangliosides in the development of diabetic nephropathy.Kidney & blood pressure research, , Volume: 40, Issue:3, 2015
Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes.Journal of physiology and biochemistry, , Volume: 69, Issue:4, 2013
a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy?Diabetes, , Volume: 54, Issue:1, 2005
Decreases of ganglioside GM3 in streptozotocin-induced diabetic glomeruli of rats.Life sciences, , Mar-14, Volume: 72, Issue:17, 2003
Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer's disease.Alzheimer's research & therapy, , 02-01, Volume: 14, Issue:1, 2022
GM3 Ganglioside Linked to Neurofibrillary Pathology in a Transgenic Rat Model for Tauopathy.International journal of molecular sciences, , Nov-22, Volume: 22, Issue:22, 2021
GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.Seminars in oncology, , Volume: 45, Issue:1-2, 2018
Altered Expression of Ganglioside Metabolizing Enzymes Results in GM3 Ganglioside Accumulation in Cerebellar Cells of a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis.International journal of molecular sciences, , Feb-22, Volume: 19, Issue:2, 2018
Depletion of Gangliosides Enhances Articular Cartilage Repair in Mice.Scientific reports, , 03-02, Volume: 7, 2017
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice.Molecular pain, , Volume: 12, 2016
Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.Experimental neurology, , Volume: 278, 2016
A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.Human gene therapy, , Volume: 27, Issue:5, 2016
Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis.Proceedings of the National Academy of Sciences of the United States of America, , Jun-30, Volume: 112, Issue:26, 2015
siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.Proceedings of the National Academy of Sciences of the United States of America, , May-05, Volume: 112, Issue:18, 2015
Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside.Immunobiology, , Volume: 220, Issue:12, 2015
The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.Nature communications, , Dec-09, Volume: 5, 2014
Repeated administrations of human umbilical cord blood cells improve disease outcomes in a mouse model of Sanfilippo syndrome type III B.Cell transplantation, , Volume: 23, Issue:12, 2014
Inhibition of GM3 synthase attenuates neuropathology of Niemann-Pick disease Type C. by affecting sphingolipid metabolism.Molecules and cells, , Volume: 37, Issue:2, 2014
Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model.Urology, , Volume: 81, Issue:1, 2013
Attenuation of acetic acid-induced gastric ulcer formation in rats by glucosylceramide synthase inhibitors.Digestive diseases and sciences, , Volume: 58, Issue:2, 2013
Blood-brain barrier impairment in an animal model of MPS III B.PloS one, , Mar-07, Volume: 6, Issue:3, 2011
Morphological alterations of the cornea in the mouse model of niemann-pick disease type c1.Cornea, , Volume: 30, Issue:7, 2011
Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.PloS one, , Apr-07, Volume: 5, Issue:4, 2010
Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models.Nature medicine, , Volume: 16, Issue:7, 2010
Development of a sialic acid-containing hydrogel of poly[N-(2-hydroxypropyl) methacrylamide]: characterization and implantation study.Biomacromolecules, , Volume: 9, Issue:9, 2008
Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B.Molecular genetics and metabolism, , Volume: 90, Issue:4, 2007
Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis.Journal of neuropathology and experimental neurology, , Volume: 66, Issue:8, 2007
GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells.Oncology, , Volume: 73, Issue:5-6, 2007
a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy?Diabetes, , Volume: 54, Issue:1, 2005
Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression.Journal of pediatric surgery, , Volume: 40, Issue:1, 2005
Expressional changes of ganglioside GM3 during ovarian maturation and early embryonic development in db/db mice.Development, growth & differentiation, , Volume: 45, Issue:1, 2003
Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.Journal of cancer research and clinical oncology, , Volume: 128, Issue:12, 2002
A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice.Experimental neurology, , Volume: 166, Issue:2, 2000
Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.Molecular genetics and metabolism, , Volume: 131, Issue:1-2
Early growth and development impairments in patients with ganglioside GM3 synthase deficiency.Clinical genetics, , Volume: 89, Issue:5, 2016
Ganglioside GM3 is essential for the structural integrity and function of cochlear hair cells.Human molecular genetics, , May-15, Volume: 24, Issue:10, 2015
A new liquid chromatography/tandem mass spectrometry method for quantification of gangliosides in human plasma.Analytical biochemistry, , Jun-15, Volume: 455, 2014
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.Nature genetics, , Volume: 36, Issue:11, 2004
Guillain-Barré syndrome complicated with hemolytic anemia in association with antiganglioside GM3 antibody.The American journal of medicine, , Apr-01, Volume: 110, Issue:5, 2001
Internalization of exogenous gangliosides in cultured skin fibroblasts for the diagnosis of mucolipidosis IV.Clinica chimica acta; international journal of clinical chemistry, , Jun-15, Volume: 157, Issue:2, 1986
Congenital ascites as a presenting sign of lysosomal storage disease.The Journal of pediatrics, , Volume: 104, Issue:2, 1984
[Factors of phenotypic polymorphism and genetic consultation in thesaurismoses (review)].Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), , Volume: 80, Issue:10, 1980
GM1-gangliosidosis: accumulation of ganglioside GM1 in cultured skin fibroblasts and correlation with clinical types.Human genetics, , Aug-31, Volume: 43, Issue:2, 1978
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.Blood cells, molecules & diseases, , Volume: 53, Issue:4, 2014
Common and uncommon pathogenic cascades in lysosomal storage diseases.The Journal of biological chemistry, , Jul-02, Volume: 285, Issue:27, 2010
Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.Clinica chimica acta; international journal of clinical chemistry, , Volume: 389, Issue:1-2, 2008
Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:3, 2008
Congenital ascites as a presenting sign of lysosomal storage disease.The Journal of pediatrics, , Volume: 104, Issue:2, 1984
GM3 as a novel growth regulator for human gliomas.Experimental neurology, , Volume: 168, Issue:2, 2001
Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors.Cancer, , Dec-01, Volume: 74, Issue:11, 1994
Ganglioside content and composition in human gliomas.Acta neurochirurgica. Supplementum, , Volume: 43, 1988
Ganglioside GM3 inhibits proliferation and invasion of glioma.Journal of neuro-oncology, , Volume: 71, Issue:2, 2005
GM3 ganglioside inhibits endothelin-1-mediated signal transduction in C6 glioma cells.FEBS letters, , Oct-19, Volume: 507, Issue:1, 2001
GM3 as a novel growth regulator for human gliomas.Experimental neurology, , Volume: 168, Issue:2, 2001
Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice.Journal of neurochemistry, , Volume: 73, Issue:1, 1999
Cell density regulates crypticity of GM3 ganglioside on human glioma cells.Experimental cell research, , May-25, Volume: 233, Issue:1, 1997
Synthesis of a glioma-related ganglioside, O-Ac GM3 having 3-O-Ac ceramide and its substrate property toward hydrolases.Journal of lipid research, , Volume: 37, Issue:10, 1996
Novel modification of ceramide: rat glioma ganglioside GM3 having 3-O-acetylated sphingenine.FEBS letters, , Mar-20, Volume: 361, Issue:2-3, 1995
Nerve growth factor mediates monosialoganglioside-induced release of fibronectin and J1/tenascin from C6 glioma cells.Journal of neurochemistry, , Volume: 56, Issue:1, 1991
Coordinate regulation of ganglioside glycosyltransferases in differentiating NG108-15 neuroblastoma x glioma cells.Journal of neurochemistry, , Volume: 52, Issue:5, 1989
Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells.Biochimica et biophysica acta, , Dec-16, Volume: 963, Issue:3, 1988
Cell-cycle dependence of a ganglioside glycosyltransferase activity and its inhibition by enkephalin in a neurotumor cell line.Journal of neurochemistry, , Volume: 42, Issue:4, 1984
[Effect of GM3 ganglioside on the adenyl and guanyl cyclase activity of cultured cells].Comptes rendus des seances de la Societe de biologie et de ses filiales, , Volume: 178, Issue:6, 1984
Interaction between complement proteins C5b-7 and erythrocyte membrane sialic acid.The Journal of experimental medicine, , Oct-01, Volume: 184, Issue:4, 1996
N-Acetylneuraminyllactosylceramide, GM3-NeuAc, a new influenza A virus receptor which mediates the adsorption-fusion process of viral infection. Binding specificity of influenza virus A/Aichi/2/68 (H3N2) to membrane-associated GM3 with different molecularThe Journal of biological chemistry, , Feb-10, Volume: 260, Issue:3, 1985
Ganglioside GM3 exerts opposite effects on motility via epidermal growth factor receptor and hepatocyte growth factor receptor-mediated migration signaling.Molecular medicine reports, , Volume: 11, Issue:4, 2015
Ganglioside GM3 inhibits hepatoma cell motility via down-regulating activity of EGFR and PI3K/AKT signaling pathway.Journal of cellular biochemistry, , Volume: 114, Issue:7, 2013
Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.Molecular and cellular biochemistry, , Volume: 382, Issue:1-2, 2013
Accumulation of gangliosides with N-acetylneuraminosyl(alpha 2-6)lactosamine structure in primary human hepatoma.Cancer research, , Feb-15, Volume: 50, Issue:4, 1990
Gangliosides of liver tumors induced by N-2-fluorenylacetamide. I. Ganglioside alterations in liver tumorigenesis and normal development.Journal of the National Cancer Institute, , Volume: 60, Issue:6, 1978
[Homeostatic and Pathophysiological Regulation of Toll-like Receptor 4 Signaling by GM3 Ganglioside Molecular Species].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 142, Issue:3, 2022
Neuronally expressed a-series gangliosides are sufficient to prevent the lethal age-dependent phenotype in GM3-only expressing mice.Journal of neurochemistry, , Volume: 158, Issue:2, 2021
GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women.International journal of obesity (2005), , Volume: 40, Issue:4, 2016
Monosialic ganglioside GM3 specifically suppresses the monocyte adhesion to endothelial cells for inflammation.The international journal of biochemistry & cell biology, , Volume: 46, 2014
Sphingolipid-dependent protein kinases.Advances in pharmacology (San Diego, Calif.), , Volume: 36, 1996
Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor β signalling pathway.The Journal of general virology, , Volume: 100, Issue:4, 2019
Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus.Journal of autoimmunity, , Volume: 63, 2015
Binding kinetics of influenza viruses to sialic acid-containing carbohydrates.Glycoconjugate journal, , Volume: 24, Issue:9, 2007
Ganglioside GM3 prevents high fat diet-induced hepatosteatosis via attenuated insulin signaling pathway.PloS one, , Volume: 18, Issue:2, 2023
Homeostatic and pathogenic roles of the GM3 ganglioside.The FEBS journal, , Volume: 289, Issue:17, 2022
Ganglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptor-Rac1 Activation to Inhibit Keratinocyte Motility.The Journal of investigative dermatology, , Volume: 137, Issue:2, 2017
GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women.International journal of obesity (2005), , Volume: 40, Issue:4, 2016
Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice.Molecular pain, , Volume: 12, 2016
Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: Evidence and mechanisms.FEBS letters, , Oct-24, Volume: 589, Issue:21, 2015
GM3 and diabetes.Glycoconjugate journal, , Volume: 31, Issue:3, 2014
No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoid-induced insulin resistance in healthy men.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:3, 2013
Dissociation of the insulin receptor from caveolae during TNFα-induced insulin resistance and its recovery by D-PDMP.FEBS letters, , Jan-20, Volume: 586, Issue:2, 2012
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.Handbook of experimental pharmacology, , Issue:203, 2011
Membrane microdomains and insulin resistance.FEBS letters, , May-03, Volume: 584, Issue:9, 2010
Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:3, 2008
[Regulation of insulin receptor function in microdomains].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 53, Issue:12 Suppl, 2008
Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance.Proceedings of the National Academy of Sciences of the United States of America, , Aug-21, Volume: 104, Issue:34, 2007
Insulin resistance as a membrane microdomain disorder.Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 127, Issue:4, 2007
TNFalpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3.Glycobiology, , Volume: 15, Issue:1, 2005
[Insulin resistance in type 2 diabetes as a microdomain syndrome].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 48, Issue:8 Suppl, 2003
Enhanced insulin sensitivity in mice lacking ganglioside GM3.Proceedings of the National Academy of Sciences of the United States of America, , Mar-18, Volume: 100, Issue:6, 2003
Ganglioside GM3 participates in the pathological conditions of insulin resistance.The Journal of biological chemistry, , Feb-01, Volume: 277, Issue:5, 2002
[Ganglioside GM3-mediated modulation of insulin resistance in 3T3-L1 adipocytes].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 77, Issue:3, 2002
Glycosphingolipids and insulin resistance.Progress in lipid research, , Volume: 48, Issue:3-4
Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of beta 1,4GalNAc transferase.FEBS letters, , Jun-04, Volume: 567, Issue:2-3, 2004
Inverse relationship of expression between GM3 and globo-series ganglioside in human renal cell carcinoma.The Tohoku journal of experimental medicine, , Volume: 190, Issue:4, 2000
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, , Volume: 13, Issue:1
A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.Glycoconjugate journal, , Volume: 30, Issue:7, 2013
Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies.Cancer research, , Mar-15, Volume: 47, Issue:6, 1987
Alteration in glycosphingolipid pattern during phorbol-12-myristate-13-acetate-induced cell differentiation in human T-lymphoid leukemia cells.Cancer research, , Volume: 46, Issue:6, 1986
Characteristic incorporation of ganglioside GM3, which induces monocytic differentiation in human myelogenous leukemia HL-60 cells.Biochemical and biophysical research communications, , Jun-15, Volume: 161, Issue:2, 1989
Ganglioside GM3 as a modulator of differentiation of mouse myeloid leukemia cells (M1-T22).Cell structure and function, , Volume: 13, Issue:2, 1988
Ganglioside GM3: an acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monocytoid leukemic cell lines HL-60 and U937.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 83, Issue:3, 1986
Differentiation-associated ganglioside changes in chronic myelogenous leukemia cells.Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society, , Volume: 48, Issue:6, 1985
Ceramides and glycosphingolipids in maturation process: leukemic cells as an experimental model.Blood cells, molecules & diseases, , Volume: 33, Issue:1
[Factors of phenotypic polymorphism and genetic consultation in thesaurismoses (review)].Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), , Volume: 80, Issue:10, 1980
High-pressure liquid chromatography of glycosphingolipids (with special reference to gangliosides).Journal of chromatography, , Jun-11, Volume: 136, Issue:2, 1977
Glycosphingolipids in fetal Tay-Sachs disease brain and lung cultures.Journal of neurochemistry, , Volume: 29, Issue:3, 1977
Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.Molecular and cellular biochemistry, , Volume: 382, Issue:1-2, 2013
Gangliosides in human uveal melanoma metastatic process.International journal of cancer, , Sep-27, Volume: 68, Issue:1, 1996
[Spectrum pattern and determination of ganglioside from human primary liver cancer of different origins].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 12, Issue:5, 1990
Accumulation of gangliosides with N-acetylneuraminosyl(alpha 2-6)lactosamine structure in primary human hepatoma.Cancer research, , Feb-15, Volume: 50, Issue:4, 1990
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
Gangliosides of liver tumors induced by N-2-fluorenylacetamide. I. Ganglioside alterations in liver tumorigenesis and normal development.Journal of the National Cancer Institute, , Volume: 60, Issue:6, 1978
Gangliosides depleted in plasma membrane are directed to internal membranes of rat hepatomas: evidence for a glycolipid sorting defect in hepatocarcinogenesis.Biochemical and biophysical research communications, , May-31, Volume: 169, Issue:1, 1990
Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells.Biochimica et biophysica acta, , Dec-16, Volume: 963, Issue:3, 1988
Biosynthesis of different gangliosides in two types of rat ascites hepatoma cells with different degrees of cell adhesiveness.Biochimica et biophysica acta, , Jan-29, Volume: 572, Issue:1, 1979
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8, 2018
Racotumomab for treating lung cancer and pediatric refractory malignancies.Expert opinion on biological therapy, , Volume: 16, Issue:4, 2016
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 20, Issue:14, 2014
Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody.Cancer science, , Volume: 104, Issue:1, 2013
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.Journal of immunology (Baltimore, Md. : 1950), , Mar-15, Volume: 186, Issue:6, 2011
[Effects of GM3 on proliferation, apoptosis and VEGF expression in human lung adenocarcinoma cell line A549 cells].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 33, Issue:4, 2011
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.Glycoconjugate journal, , Volume: 27, Issue:5, 2010
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.BMC cancer, , Jun-11, Volume: 9, 2009
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 181, Issue:9, 2008
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.Cancer biology & therapy, , Volume: 6, Issue:2, 2007
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer science, , Volume: 98, Issue:10, 2007
Gangliosides enhance migration of mouse B16-melanoma cells through artificial basement membrane alone or in presence of laminin or fibronectin.Indian journal of experimental biology, , Volume: 43, Issue:12, 2005
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.International journal of cancer, , Jan-10, Volume: 97, Issue:2, 2002
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.International journal of cancer, , Nov-04, Volume: 73, Issue:3, 1997
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).British journal of cancer, , Volume: 75, Issue:2, 1997
Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.The Journal of dermatology, , Volume: 22, Issue:8, 1995
Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line.Clinical & experimental metastasis, , Volume: 11, Issue:1, 1993
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Glycosphingolipid expression on murine L1-fibrosarcoma cells: analysis of clonal in vivo and in vitro selected sublines with different lung colonisation potential.British journal of cancer, , Volume: 61, Issue:6, 1990
Colorectal carcinomas have a characteristic ganglioside pattern.Medical biology, , Volume: 61, Issue:1, 1983
[Study on glycolipids in human lung carcinoma of histologically different types (author's transl)].[Hokkaido igaku zasshi] The Hokkaido journal of medical science, , Volume: 54, Issue:4, 1979
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line.Anticancer research, , Volume: 18, Issue:4C
Serum GM3(d18:1-16:0) and GM3(d18:1-24:1) levels may be associated with lymphoma: An exploratory study with haematological diseases.Scientific reports, , 04-19, Volume: 9, Issue:1, 2019
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.Journal of immunology (Baltimore, Md. : 1950), , Jan-01, Volume: 186, Issue:1, 2011
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Endothelial ganglioside GM3 regulates angiogenesis in solid tumors.Biochemical and biophysical research communications, , 09-10, Volume: 569, 2021
Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.Journal of experimental & clinical cancer research : CR, , Dec-01, Volume: 28, 2009
Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.Journal of cancer research and clinical oncology, , Volume: 128, Issue:12, 2002
Regulatory role of GM3 ganglioside in alpha 5 beta 1 integrin receptor for fibronectin-mediated adhesion of FUA169 cells.The Journal of biological chemistry, , Jan-25, Volume: 268, Issue:3, 1993
Selection of a mutant cell line based on differential expression of glycosphingolipid, utilizing anti-lactosylceramide antibody and complement.The Journal of biological chemistry, , Jan-25, Volume: 268, Issue:3, 1993
Regulatory role of GM3 ganglioside in integrin function, as evidenced by its effect on function of alpha 5 beta 1-liposomes: a preliminary note.Biochemical and biophysical research communications, , Aug-14, Volume: 186, Issue:3, 1992
Cell density-dependent membrane distribution of ganglioside GM3 in melanoma cells.Cellular and molecular life sciences : CMLS, , May-30, Volume: 80, Issue:6, 2023
Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma.Biochimica et biophysica acta. General subjects, , Volume: 1864, Issue:12, 2020
Conjugation of a GM3 lactone mimetic on carbon nanotubes enhances the related inhibition of melanoma-associated metastatic events.Organic & biomolecular chemistry, , 08-22, Volume: 16, Issue:33, 2018
Multivalent presentation of a hydrolytically stable GM(3) lactone mimetic as modulator of melanoma cells motility and adhesion.Bioorganic & medicinal chemistry, , May-15, Volume: 21, Issue:10, 2013
Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.Molecular cancer research : MCR, , Volume: 11, Issue:6, 2013
NGcGM3/VSSP vaccine as treatment for melanoma patients.Human vaccines & immunotherapeutics, , Volume: 9, Issue:6, 2013
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.Oral diseases, , Volume: 18, Issue:8, 2012
Stable GM3 lactone mimetic raises antibodies specific for the antigens expressed on melanoma cells.Bioconjugate chemistry, , Aug-18, Volume: 21, Issue:8, 2010
Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells.Glycobiology, , Volume: 19, Issue:6, 2009
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.Cancer research, , Nov-15, Volume: 69, Issue:22, 2009
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.Cancer biology & therapy, , Volume: 7, Issue:4, 2008
Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.Biochemical and biophysical research communications, , May-04, Volume: 356, Issue:2, 2007
Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 13, Issue:9, 2007
Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis.International immunology, , Volume: 18, Issue:6, 2006
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.Cancer immunology, immunotherapy : CII, , Volume: 53, Issue:2, 2004
Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis.Journal of immunology (Baltimore, Md. : 1950), , Apr-01, Volume: 170, Issue:7, 2003
Characterization of the acid stability of glycosidically linked neuraminic acid: use in detecting de-N-acetyl-gangliosides in human melanoma.The Journal of biological chemistry, , May-17, Volume: 277, Issue:20, 2002
An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.Journal of immunology (Baltimore, Md. : 1950), , Mar-01, Volume: 168, Issue:5, 2002
In vitro transformation of human congenital naevus to malignant melanoma.Melanoma research, , Volume: 12, Issue:1, 2002
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
Studies on the specificity and sensitivity of the influenza C virus binding assay for 9-O-acetylated sialic acids and its application to human melanomas.Journal of biochemistry, , Volume: 127, Issue:6, 2000
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.Hybridoma, , Volume: 19, Issue:3, 2000
Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins.The journal of investigative dermatology. Symposium proceedings, , Volume: 4, Issue:2, 1999
Lack of the induction of anti-ganglioside GM3 antibody in the patients with malignant melanoma in Japanese.Pigment cell research, , Volume: 11, Issue:4, 1998
Glycosylation of lactosylceramide analogs in animal cells: amphipathic disaccharide primers for glycosphingolipid synthesis.Biochemical and biophysical research communications, , Dec-29, Volume: 241, Issue:3, 1997
Gangliosides in human uveal melanoma metastatic process.International journal of cancer, , Sep-27, Volume: 68, Issue:1, 1996
Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.The Journal of dermatology, , Volume: 22, Issue:8, 1995
Conversion of short-chain ceramides to short-chain ceramide GM3 in B16 melanoma cells.FEBS letters, , Oct-30, Volume: 374, Issue:2, 1995
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside.Human antibodies and hybridomas, , Volume: 6, Issue:3, 1995
Expression of de-N-acetyl-gangliosides in human melanoma cells is induced by genistein or nocodazole.The Journal of biological chemistry, , Feb-17, Volume: 270, Issue:7, 1995
Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer alpha 2-3 sialyltransferase (GM3 synthase).FEBS letters, , Apr-03, Volume: 362, Issue:2, 1995
Optimal conditions to radiolabel (3H or 14C) aminosugar-containing glycosphingolipids by de-N-acetylation and re-N-acetylation.Biochimica et biophysica acta, , Jun-09, Volume: 1244, Issue:2-3, 1995
Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3 synthase).The Journal of biological chemistry, , Jun-03, Volume: 269, Issue:22, 1994
Both VH and VL regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM3.Cell biophysics, , Volume: 24-25, 1994
Alpha- and beta-xylosides alter glycolipid synthesis in human melanoma and Chinese hamster ovary cells.The Journal of biological chemistry, , Jan-25, Volume: 268, Issue:3, 1993
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.Japanese journal of clinical oncology, , Volume: 22, Issue:5, 1992
Ganglioside GM3:GD3 ratio as an index for the management of melanoma.Cancer, , Jun-15, Volume: 67, Issue:12, 1991
Induction of mouse anti-melanoma cytotoxic and suppressor T cells in vitro by an artificial antigen, GM3-lactone.Japanese journal of cancer research : Gann, , Volume: 81, Issue:4, 1990
[Induction of anti-melanoma CTL by GM3 (NeuGc)-liposomes].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 48, Issue:2, 1990
Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3.Journal of the National Cancer Institute, , Nov-21, Volume: 82, Issue:22, 1990
Monoclonal antibody MACG1 distinguishes between different molecular species of the ganglioside GM3.Hybridoma, , Volume: 8, Issue:2, 1989
Ganglioside GD3 shedding by human malignant melanoma cells.International journal of cancer, , Jul-15, Volume: 44, Issue:1, 1989
Involvement of the acyl chain of ceramide in carbohydrate recognition by an anti-glycolipid monoclonal antibody: the case of an anti-melanoma antibody, M2590, to GM3-ganglioside.Glycoconjugate journal, , Volume: 6, Issue:4, 1989
The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.Journal of immunology (Baltimore, Md. : 1950), , Feb-01, Volume: 142, Issue:3, 1989
[GM3 ganglioside as melanoma specific antigen and its biological function].Human cell, , Volume: 2, Issue:1, 1989
Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.International journal of cancer, , Mar-15, Volume: 41, Issue:3, 1988
A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth.The Journal of biological chemistry, , May-05, Volume: 263, Issue:13, 1988
An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.Cancer research, , Oct-15, Volume: 48, Issue:20, 1988
Occurrence of tumor-associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas.Japanese journal of cancer research : Gann, , Volume: 78, Issue:6, 1987
Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 27, Issue:6, 1986
[Mouse monoclonal antibodies recognizing melanoma-associated ganglioside antigens].Seikagaku. The Journal of Japanese Biochemical Society, , Volume: 57, Issue:10, 1985
Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.The Journal of biological chemistry, , Oct-25, Volume: 260, Issue:24, 1985
Gangliosides of normal and neoplastic human melanocytes.Biochemical and biophysical research communications, , Apr-30, Volume: 120, Issue:2, 1984
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.Anticancer research, , Volume: 13, Issue:6A
Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 27, Issue:6
Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma.Biochimica et biophysica acta. General subjects, , Volume: 1864, Issue:12, 2020
GM3 suppresses anchorage-independent growth via Rho GDP dissociation inhibitor beta in melanoma B16 cells.Cancer science, , Volume: 102, Issue:8, 2011
Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.Journal of experimental & clinical cancer research : CR, , Dec-01, Volume: 28, 2009
Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.Cancer immunology, immunotherapy : CII, , Volume: 57, Issue:12, 2008
Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell.Bioorganic & medicinal chemistry, , Dec-15, Volume: 15, Issue:24, 2007
GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells.Oncology, , Volume: 73, Issue:5-6, 2007
Gangliosides enhance migration of mouse B16-melanoma cells through artificial basement membrane alone or in presence of laminin or fibronectin.Indian journal of experimental biology, , Volume: 43, Issue:12, 2005
Fluorous-tagged compound: a viable scaffold to prime oligosaccharide synthesis by cellular enzymes.Biochemical and biophysical research communications, , Apr-09, Volume: 316, Issue:3, 2004
Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.Journal of cancer research and clinical oncology, , Volume: 128, Issue:12, 2002
A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.Melanoma research, , Volume: 11, Issue:3, 2001
Effect of synthetic sialyl 2-->1 sphingosine and other glycosylsphingosines on the structure and function of the "glycosphingolipid signaling domain (GSD)" in mouse melanoma B16 cells.Biochemistry, , Mar-14, Volume: 39, Issue:10, 2000
Reconstitution of membranes simulating "glycosignaling domain" and their susceptibility to lyso-GM3.The Journal of biological chemistry, , May-19, Volume: 275, Issue:20, 2000
Azido glycoside primer: a versatile building block for the biocombinatorial synthesis of glycosphingolipid analogues.Carbohydrate research, , Dec-01, Volume: 329, Issue:4, 2000
Separation of glycosphingolipid-enriched microdomains from caveolar membrane characterized by presence of caveolin.Methods in enzymology, , Volume: 312, 2000
Analysis of glycolipid-dependent cell adhesion based on carbohydrate-carbohydrate interaction.Methods in enzymology, , Volume: 312, 2000
A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.International journal of oncology, , Volume: 15, Issue:1, 1999
Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.Oncology research, , Volume: 11, Issue:1, 1999
Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.International journal of cancer, , Jan-05, Volume: 75, Issue:1, 1998
GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells.The Journal of biological chemistry, , Apr-10, Volume: 273, Issue:15, 1998
Anti-tumor effect of internal image bearing anti-idiotypic monoclonal antibody in relation to GM3 ganglioside.International journal of cancer, , May-04, Volume: 76, Issue:3, 1998
A close association of GM3 with c-Src and Rho in GM3-enriched microdomains at the B16 melanoma cell surface membrane: a preliminary note.Biochemical and biophysical research communications, , Jul-09, Volume: 236, Issue:1, 1997
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.International journal of cancer, , Nov-04, Volume: 73, Issue:3, 1997
Ganglioside profiles of experimental melanomas and of their melanosomal fractions.Melanoma research, , Volume: 5, Issue:2, 1995
A mouse B16 melanoma mutant deficient in glycolipids.Proceedings of the National Academy of Sciences of the United States of America, , Mar-29, Volume: 91, Issue:7, 1994
Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.Experientia, , Jul-15, Volume: 50, Issue:7, 1994
Autoreactive T-cell clones which suppress cytotoxic T cell responses.International immunology, , Volume: 3, Issue:4, 1991
Specific interaction between gangliotriaosylceramide (Gg3) and sialosyllactosylceramide (GM3) as a basis for specific cellular recognition between lymphoma and melanoma cells.The Journal of biological chemistry, , Dec-05, Volume: 264, Issue:34, 1989
Density of GM3 with normal primary structure determines mouse melanoma antigenicity; a new concept of tumor antigen.Japanese journal of cancer research : Gann, , Volume: 80, Issue:10, 1989
Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells.Journal of cellular physiology, , Volume: 141, Issue:3, 1989
Analysis of melanoma antigen and its involvement in tumor-escape mechanisms.Princess Takamatsu symposia, , Volume: 19, 1988
Escape mechanisms of melanoma from immune system by soluble melanoma antigen.Journal of immunology (Baltimore, Md. : 1950), , May-01, Volume: 140, Issue:9, 1988
Mouse melanoma antigen recognized by Lyt-2- and L3T4- cytotoxic T-lymphocytes.Cancer research, , May-15, Volume: 48, Issue:10, 1988
Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.Journal of immunology (Baltimore, Md. : 1950), , Nov-01, Volume: 139, Issue:9, 1987
Change in the topographical distribution of GM3 during cell spreading and growth: immunostaining with monoclonal antibody against GM3.Cell structure and function, , Volume: 12, Issue:1, 1987
Glycation Interferes with the Expression of Sialyltransferases in Meningiomas.Cells, , 11-25, Volume: 10, Issue:12, 2021
Expression of the ganglioside GD3 in human meningiomas is associated with monosomy of chromosome 22.Journal of neurochemistry, , Volume: 55, Issue:6, 1990
Ganglioside composition in human meningiomas.Journal of neurochemistry, , Volume: 53, Issue:3, 1989
[Homeostatic and Pathophysiological Regulation of Toll-like Receptor 4 Signaling by GM3 Ganglioside Molecular Species].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 142, Issue:3, 2022
Biology of GM3 Ganglioside.Progress in molecular biology and translational science, , Volume: 156, 2018
Membrane microdomains and insulin resistance.FEBS letters, , May-03, Volume: 584, Issue:9, 2010
Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties.The Biochemical journal, , May-15, Volume: 260, Issue:1, 1989
Internalization of exogenous gangliosides in cultured skin fibroblasts for the diagnosis of mucolipidosis IV.Clinica chimica acta; international journal of clinical chemistry, , Jun-15, Volume: 157, Issue:2, 1986
Congenital ascites as a presenting sign of lysosomal storage disease.The Journal of pediatrics, , Volume: 104, Issue:2, 1984
[Studies on GM3 ganglioside sialidase].No to shinkei = Brain and nerve, , Volume: 34, Issue:7, 1982
Biochemical investigations of cultured amniotic fluid cells in mucolipidosis type IV.Clinica chimica acta; international journal of clinical chemistry, , Sep-25, Volume: 106, Issue:2, 1980
Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.Cells, , 04-08, Volume: 10, Issue:4, 2021
A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.Human gene therapy, , Volume: 27, Issue:5, 2016
Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.Experimental neurology, , Volume: 278, 2016
Repeated administrations of human umbilical cord blood cells improve disease outcomes in a mouse model of Sanfilippo syndrome type III B.Cell transplantation, , Volume: 23, Issue:12, 2014
Abnormal gangliosides are localized in lipid rafts in Sanfilippo (MPS3a) mouse brain.Neurochemical research, , Volume: 37, Issue:6, 2012
Blood-brain barrier impairment in an animal model of MPS III B.PloS one, , Mar-07, Volume: 6, Issue:3, 2011
Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B.Molecular genetics and metabolism, , Volume: 90, Issue:4, 2007
Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Nov-10, Volume: 24, Issue:45, 2004
[Factors of phenotypic polymorphism and genetic consultation in thesaurismoses (review)].Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), , Volume: 80, Issue:10, 1980
Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.The journal of gene medicine, , Volume: 16, Issue:11-12
Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.Molecular genetics and metabolism, , Volume: 131, Issue:1-2
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.Cancer immunology, immunotherapy : CII, , Volume: 55, Issue:4, 2006
Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin.Journal of biochemistry, , Volume: 116, Issue:1, 1994
Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.Molecular cancer research : MCR, , Volume: 11, Issue:6, 2013
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.Cancer research, , Nov-15, Volume: 69, Issue:22, 2009
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.The Journal of biological chemistry, , Oct-21, Volume: 280, Issue:42, 2005
Ganglioside GM3 inhibits proliferation and invasion of glioma.Journal of neuro-oncology, , Volume: 71, Issue:2, 2005
Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of beta 1,4GalNAc transferase.FEBS letters, , Jun-04, Volume: 567, Issue:2-3, 2004
Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin.The Journal of biological chemistry, , Jul-11, Volume: 278, Issue:28, 2003
Glycolipid composition in bladder tumor: a crucial role of GM3 ganglioside in tumor invasion.International journal of cancer, , Nov-01, Volume: 94, Issue:3, 2001
Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells.International journal of oncology, , Volume: 19, Issue:4, 2001
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.International journal of cancer, , Nov-04, Volume: 73, Issue:3, 1997
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.BMC cancer, , Jun-10, Volume: 19, Issue:1, 2019
Conjugation of a GM3 lactone mimetic on carbon nanotubes enhances the related inhibition of melanoma-associated metastatic events.Organic & biomolecular chemistry, , 08-22, Volume: 16, Issue:33, 2018
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.Clinical & experimental metastasis, , Volume: 33, Issue:7, 2016
Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.Molecular cancer research : MCR, , Volume: 11, Issue:6, 2013
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.The Journal of biological chemistry, , Oct-21, Volume: 280, Issue:42, 2005
Studies on the specificity and sensitivity of the influenza C virus binding assay for 9-O-acetylated sialic acids and its application to human melanomas.Journal of biochemistry, , Volume: 127, Issue:6, 2000
Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation.Cancer research, , May-15, Volume: 59, Issue:10, 1999
GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside.Biochimica et biophysica acta, , Jan-29, Volume: 1437, Issue:1, 1999
Suppression by ganglioside GD1A of migration capability, adhesion to vitronectin and metastatic potential of highly metastatic FBJ-LL cells.International journal of cancer, , Nov-26, Volume: 83, Issue:5, 1999
Gangliosides in human uveal melanoma metastatic process.International journal of cancer, , Sep-27, Volume: 68, Issue:1, 1996
Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer alpha 2-3 sialyltransferase (GM3 synthase).FEBS letters, , Apr-03, Volume: 362, Issue:2, 1995
Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line.Clinical & experimental metastasis, , Volume: 11, Issue:1, 1993
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.Journal of immunotherapy (Hagerstown, Md. : 1997), , Volume: 29, Issue:2
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.Frontiers in immunology, , Volume: 13, 2022
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.BMC cancer, , Jun-10, Volume: 19, Issue:1, 2019
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.Oral diseases, , Volume: 18, Issue:8, 2012
Design, synthesis and biological evaluation of new ganglioside GM3 analogues as potential agents for cancer therapy.European journal of medicinal chemistry, , Mar-01, Volume: 189, 2020
Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.Glycoconjugate journal, , Volume: 36, Issue:5, 2019
Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.Scientific reports, , 07-09, Volume: 9, Issue:1, 2019
Ganglioside GM3 and Its Role in Cancer.Current medicinal chemistry, , Volume: 26, Issue:16, 2019
Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture.Scientific reports, , Jul-18, Volume: 8, Issue:1, 2018
GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.Seminars in oncology, , Volume: 45, Issue:1-2, 2018
Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth.The Journal of biological chemistry, , Oct-07, Volume: 291, Issue:41, 2016
GM3 and cancer.Glycoconjugate journal, , Volume: 32, Issue:1-2, 2015
Synthesis and cytotoxicity assay of four ganglioside GM3 analogues.European journal of medicinal chemistry, , Mar-21, Volume: 75, 2014
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:4, 2014
Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.European journal of immunology, , Volume: 43, Issue:3, 2013
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.Clinical and experimental immunology, , Volume: 167, Issue:2, 2012
Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse.ACS chemical biology, , Jan-20, Volume: 7, Issue:1, 2012
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Expert opinion on biological therapy, , Volume: 10, Issue:2, 2010
Gangliosides as regulators of cell membrane organization and functions.Advances in experimental medicine and biology, , Volume: 688, 2010
NGcGM3 ganglioside: a privileged target for cancer vaccines.Clinical & developmental immunology, , Volume: 2010, 2010
Structural study of liposomes loaded with a GM3 lactone analogue for the targeting of tumor epitopes.Biochimica et biophysica acta, , Volume: 1788, Issue:12, 2009
Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity.Molecular cancer therapeutics, , Volume: 7, Issue:7, 2008
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.Cancer immunology, immunotherapy : CII, , Volume: 55, Issue:4, 2006
Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines.Cancer research, , Nov-15, Volume: 53, Issue:22, 1993
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Murine monoclonal anti-idiotype antibody (alpha) as a probe to detect human monoclonal antibody bound to human tumor tissues.Journal of immunological methods, , Nov-06, Volume: 134, Issue:1, 1990
Serum gangliosides in cerebral astrocytoma.Annals of neurology, , Volume: 8, Issue:5, 1980
Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.mAbs, , Volume: 3, Issue:6
Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.Gene therapy, , Volume: 22, Issue:12, 2015
Lipid patterns of embryonal carcinoma cell lines and their derivatives: changes with differentiation.Developmental biology, , Apr-30, Volume: 83, Issue:2, 1981
Gangliosides of liver tumors induced by N-2-fluorenylacetamide. I. Ganglioside alterations in liver tumorigenesis and normal development.Journal of the National Cancer Institute, , Volume: 60, Issue:6, 1978
Gangliosides of active and inactive neuroblastoma clones.Differentiation; research in biological diversity, , May-26, Volume: 8, Issue:1, 1977
Endothelial ganglioside GM3 regulates angiogenesis in solid tumors.Biochemical and biophysical research communications, , 09-10, Volume: 569, 2021
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.BMC cancer, , Jun-11, Volume: 9, 2009
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.Glycobiology, , Volume: 19, Issue:3, 2009
Angiogenic and angiostatic microenvironment in tumors--role of gangliosides.Acta oncologica (Stockholm, Sweden), , Volume: 36, Issue:4, 1997
Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio.Laboratory investigation; a journal of technical methods and pathology, , Volume: 67, Issue:6, 1992
Altered Expression of Ganglioside Metabolizing Enzymes Results in GM3 Ganglioside Accumulation in Cerebellar Cells of a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis.International journal of molecular sciences, , Feb-22, Volume: 19, Issue:2, 2018
Altered levels of α-synuclein and sphingolipids in Batten disease lymphoblast cells.Gene, , Apr-15, Volume: 539, Issue:2, 2014
In vitro transformation of human congenital naevus to malignant melanoma.Melanoma research, , Volume: 12, Issue:1, 2002
Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.International journal of cancer, , Mar-15, Volume: 41, Issue:3, 1988
Depletion of Gangliosides Enhances Articular Cartilage Repair in Mice.Scientific reports, , 03-02, Volume: 7, 2017
Ganglioside GM3 has an essential role in the pathogenesis and progression of rheumatoid arthritis.PloS one, , Volume: 7, Issue:6, 2012
Gangliosides from normal and osteoarthritic joints.The Journal of rheumatology. Supplement, , Volume: 43, 1995
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.Frontiers in immunology, , Volume: 13, 2022
Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing β3Gn-T5 knockout mice.Scientific reports, , 02-07, Volume: 8, Issue:1, 2018
Inhibition of EGF-mediated receptor activity and cell proliferation by HK1-ceramide, a stable analog of the ganglioside GM3-lactone.Glycobiology, , Volume: 12, Issue:8, 2002
Ganglioside shedding and changes in ceramide biosynthesis in human ovarian tumors.Biochemistry. Biokhimiia, , Volume: 62, Issue:5, 1997
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor.The Journal of biological chemistry, , Feb-15, Volume: 261, Issue:5, 1986
Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with predominant bulbar palsy and anti-GM3 IgG antibodies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 39, Issue:7, 2018
Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(alpha2-3)Gal.Journal of neurology, neurosurgery, and psychiatry, , Volume: 81, Issue:6, 2010
A novel antiganglioside specificity against terminal NeuNAc(alfa 2-3)Gal in acute bulbar palsy.Journal of neuroimmunology, , Volume: 176, Issue:1-2, 2006
Ganglioside GM3 stimulates lipid-protein co-assembly in α-synuclein amyloid formation.Biophysical chemistry, , Volume: 293, 2023
Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis.PloS one, , Volume: 12, Issue:2, 2017
Acceleration of α-synuclein aggregation by exosomes.The Journal of biological chemistry, , Jan-30, Volume: 290, Issue:5, 2015
Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.Journal of molecular biology, , Mar-19, Volume: 397, Issue:1, 2010
Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma.Biochimica et biophysica acta. General subjects, , Volume: 1864, Issue:12, 2020
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.Cancer research, , Nov-15, Volume: 69, Issue:22, 2009
Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 13, Issue:9, 2007
Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.Biochemical and biophysical research communications, , May-04, Volume: 356, Issue:2, 2007
Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.The Journal of investigative dermatology, , Volume: 124, Issue:4, 2005
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.Cancer immunology, immunotherapy : CII, , Volume: 53, Issue:2, 2004
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.Human & experimental toxicology, , Volume: 21, Issue:5, 2002
Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins.The journal of investigative dermatology. Symposium proceedings, , Volume: 4, Issue:2, 1999
Ganglioside profiles of experimental melanomas and of their melanosomal fractions.Melanoma research, , Volume: 5, Issue:2, 1995
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.Cancer research, , Nov-01, Volume: 53, Issue:21, 1993
Alteration in keratinocyte ganglioside content in basal cell carcinomas.The Journal of investigative dermatology, , Volume: 98, Issue:2, 1992
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.Japanese journal of clinical oncology, , Volume: 22, Issue:5, 1992
Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells.Journal of cellular physiology, , Volume: 141, Issue:3, 1989
Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.International journal of cancer, , Mar-15, Volume: 41, Issue:3, 1988
Tissue accumulation of sulfatide and GM3 ganglioside in a patient with variant Farber disease.Clinica chimica acta; international journal of clinical chemistry, , Jan-31, Volume: 234, Issue:1-2, 1995
Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.Human genetics, , Volume: 89, Issue:5, 1992
GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy.Biochemistry, , May-29, Volume: 40, Issue:21, 2001
[Ganglioside lactones in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 58, Issue:10, 1993
[Gangliosides GM3 and GD3 in human stomach and breast tumors].Biokhimiia (Moscow, Russia), , Volume: 56, Issue:3, 1991
Survey of Hanganutziu and Deicher antibodies in operated patients.International archives of allergy and applied immunology, , Volume: 95, Issue:2-3, 1991
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.Nature genetics, , Volume: 36, Issue:11, 2004
[Insulin resistance in type 2 diabetes as a microdomain syndrome].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, , Volume: 48, Issue:8 Suppl, 2003
Polyphenol from millet bran increases the sensitivity of colorectal cancer cells to oxaliplatin by blocking the ganglioside GM3 catabolism.Food & function, , Jan-07, Volume: 12, Issue:1, 2021
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.Glycobiology, , Volume: 16, Issue:7, 2006
Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.Oncology research, , Volume: 11, Issue:1, 1999
Ganglioside GM3 as a modulator of differentiation of mouse myeloid leukemia cells (M1-T22).Cell structure and function, , Volume: 13, Issue:2, 1988
Activation of CMP-N-acetylneuraminic acid:lactosylceramide sialyltransferase during the differentiation of HL-60 cells induced by 12-O-tetradecanoylphorbol-13-acetate.The Journal of biological chemistry, , Dec-05, Volume: 261, Issue:34, 1986
Ganglioside GM3: an acidic membrane component that increases during macrophage-like cell differentiation can induce monocytic differentiation of human myeloid and monocytoid leukemic cell lines HL-60 and U937.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 83, Issue:3, 1986
The differentiation of HL-60 cells in the synthetic medium induced by GM3 ganglioside.Bioscience reports, , Volume: 5, Issue:6, 1985
An acidic glycosphingolipid, monosialo-ganglioside GM3, is a potent physiological inducer for monocytic differentiation of human promyelocytic leukemia cell line HL-60 cells.Biochemical and biophysical research communications, , Oct-15, Volume: 132, Issue:1, 1985
Glycosphingolipid patterns in human promyelocytic HL-60 leukemia cells susceptible or resistant to differentiation induction by phorbol 12-myristate 13-acetate.Biochimica et biophysica acta, , Mar-10, Volume: 1176, Issue:1-2, 1993
Differential effects of long-chain (sphingoid) bases on the monocytic differentiation of human leukemia (HL-60) cells induced by phorbol esters, 1 alpha, 25-dihydroxyvitamin D3, or ganglioside GM3.Cancer research, , Jun-15, Volume: 49, Issue:12, 1989
Effect of a cell differentiation inducer, ganglioside GM3, on the neutral glycosphingolipid composition and cell membrane fluidity of a human promyelocytic leukemia cell line HL-60.In vivo (Athens, Greece), , Volume: 4, Issue:3
Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169.PLoS pathogens, , Volume: 9, Issue:4, 2013
HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection.Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, , Nov-01, Volume: 19, Issue:3, 1998
Overexpression of monosialoganglioside GM3 on lymphocyte plasma membrane in patients with HIV infection.Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, , Jun-01, Volume: 12, Issue:2, 1996
Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion.Glycoconjugate journal, , Volume: 17, Issue:3 -4
Common and uncommon pathogenic cascades in lysosomal storage diseases.The Journal of biological chemistry, , Jul-02, Volume: 285, Issue:27, 2010
Metabolic processing of gangliosides by normal and Salla human fibroblasts in culture. A study performed by administering radioactive GM3 ganglioside.The Journal of biological chemistry, , Sep-06, Volume: 271, Issue:36, 1996
Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.Human genetics, , Volume: 89, Issue:5, 1992
Use of isotopically radiolabelled GM3 ganglioside to study metabolic alterations in Salla disease.Indian journal of biochemistry & biophysics, , Volume: 34, Issue:1-2
Safety/Toxicity (6)
Article | Year |
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. Cancer immunology, immunotherapy : CII, , Volume: 67, Issue:8 | 2018 |
Increased Expression of Simple Ganglioside Species GM2 and GM3 Detected by MALDI Imaging Mass Spectrometry in a Combined Rat Model of Aβ Toxicity and Stroke. PloS one, , Volume: 10, Issue:6 | 2015 |
Synthesis and cytotoxicity assay of four ganglioside GM3 analogues. European journal of medicinal chemistry, , Mar-21, Volume: 75 | 2014 |
Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. Molecular immunology, , Volume: 48, Issue:8 | 2011 |
Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study. Human & experimental toxicology, , Volume: 21, Issue:5 | 2002 |
Induction of nitric oxide production by ganglioside GM3 in murine peritoneal macrophages activated for tumor cytotoxicity. In vivo (Athens, Greece), , Volume: 12, Issue:3 | |
Pharmacokinetics (2)
Dosage (2)
Interactions (1)